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ACTIONABLE BIOLOGY AND PROGNOSTIC BIOMARKERS IN BREAST CANCER
PATIENTS OF AFRICAN DESCENT

by

NIKITA WRIGHT

Under the Direction of Ritu Aneja, PhD

ABSTRACT

Women of African descent are disproportionately affected by breast cancer relative to European
women. Africans and African-Americans are more likely to acquire aggressive breast cancer
phenotypes such as triple negative breast cancer (TNBC), which lacks expression of
pharmacologically-targetable targets such as estrogen receptor (ER), progesterone receptor (PR),
and human epidermal growth factor receptor 2 (HER2). Given breast cancer patients of African
descent are predominantly triple negative, they are often refractory to hormone and HER2targeted systemic therapies in the clinic, underlying their more aggressive disease course and
poorer prognosis relative to women of other ethnic backgrounds. My work seeks to identify
actionable biomarkers in patients of African descent, who are predominantly triple-negative and
thus lack targeted treatment options and robust risk-predictive biomarkers. Herein, I present a
three-pronged approach to examine inherent differences in tumor biology among racially-distinct

breast tumors. I have examined surrogates of intratumor heterogeneity (mitotic propensity and
centrosome amplification), the tumor immune microenvironment (tumor-infiltrating
lymphocytes), and drivers of cell proliferation (human epidermal growth factor receptor family)
among racially-distinct breast cancer patients and their potential as risk-prognostic biomarkers
and alternative therapeutic targets. These facets of aggressive tumor biology have been linked to
the acquisition of aggressive cellular phenotypes and drug resistance/relapse in breast cancer
suggesting racial disparities in these biomarkers could perhaps be underlying the divergence in
mortality rates. Furthermore, these key aspects of aggressive tumor biology (drivers of
intratumor heterogeneity, tumor-infiltrating lymphocytes, and drivers of cell proliferation) can be
evaluated in clinical samples using techniques such as immunohistochemistry and H&E staining
as well as therapeutically targeted through rationally-designed agents such as putative
centrosome declustering agents, immunotherapeutic intervention, monoclonal antibodies, and
receptor agonists. Hence, my work suggests clinically-facile risk-prognostic and actionable
biomarkers for patients of African descent, which may aid in reducing the global racial disparity
in breast cancer. Furthermore, this work has broader clinical implications by extending
prognostic biomarkers and actionable targets for aggressive breast cancer patients, irrespective of
ethnicity, as well as paves the path for alternative avenues of addressing the global racially
disparate burden in breast cancer such as metabolic, epigenetic, and proteomic approaches.
Moreover, our work may further encourage the implementation of personalized treatment in the
clinic based on each patient’s distinct tumor molecular profile.

INDEX WORDS: Triple negative breast cancer, African, Risk-prognostic, Biomarkers,
Intratumor heterogeneity, Tumor immune microenvironment
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1.1

INTRODUCTION

The racially disparate burden in breast cancer
At least 1 in 8 women in the United States (US) will acquire breast cancer (BC) in their

lifetime(1). BC reigns as the number one form of invasive cancer diagnosed among women in
the United States (US) and ranks second place, behind lung cancer, among the leading causes of
death from cancer among women today(1). Women of African descent are disproportionately
afflicted and affected by BC compared to women of European descent in the US. AfricanAmerican (2) women exhibit significantly higher BC incidence rates than European-American
(3) women before the age of 40(4). However, among all ages, AA women are more likely to die
from BC than EA, Hispanic, and Native American women with death rates as much as 60%
higher in some states such as Louisiana and Mississippi(4, 5). Furthermore, AA women tend to
be diagnosed and die from BC at a much younger age compared to their EA counterparts(4).
Moreover, BC patients of African ancestry experience a more aggressive clinical disease course
as AAs exhibit lower proportions of localized BC and higher proportions of regional and distantstage BC than EAs and other ethnic groups(4). Hence, AAs are more likely to be diagnosed with
advanced staged BC than EAs among BC patients(6, 7). The prevalence of more aggressive BC
subtypes is higher among AA compared to EA patients. Estrogen receptor-negative,
progesterone receptor (PR)-negative, and triple negative BC (TNBC) have been reported to be
more prevalent among AA compared to EA patients(8). TNBC, defined by a lack of ER, PR, and
human epidermal growth factor receptor 2 (HER2), was recently reported to be twice as high
among AA (24 per 100,000) compared to EA (12 per 100,000) women leaving AA patients with
a lack of pharmacologically-targetable treatment options(4). Racial disparity in clinical outcomes
persists within BC subtypes. Chen and colleagues observed that AA women exhibit a 40-70%
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higher risk of developing stage IV disease than EA women across all BC subtypes(9). Among
luminal-A like and luminal-B like BC patients, AAs were found to exhibit a 76% and 56%
higher mortality rates than EAs, respectively(9). Black women were reported to exhibit
significantly worse overall survival (OS) and progression-free survival (PFS) than white women
among ER-positive BC patients(10). Although controversial, some studies have reported a more
aggressive disease course and a poorer prognosis in AAs compared to EAs among TNBC
patients(11-13).
Distinctions in inherent tumor biology have been suspected to underlie the racial
disparate burden in BC. Thus, cancer health disparity research has largely focused on identifying
pharmacologically-targetable biomarkers differentially-expressed among racially-distinct BC
patients or strongly associated with African ancestry that can enhance risk-prognostication and
reduce the disproportionately higher mortality rates observed among patients of African descent.
However, many of the targeted therapeutics rationally designed for these biomarkers may
perform well in preclinical studies but often perform dismally once they reach advanced clinical
trials or elicit a significant response in only a small percentage of BC patients(14). One of the
primary factors underlying this poor performance is the high interpatient and intratumoral
heterogeneity rampant among the BC landscape, which interferes with the efficacy of these
targeted agents(14-17). These novel agents are also often accompanied by toxic, harmful side
effects that exacerbate the patient’s previously compromised health(18-20). Moreover, validating
detection methods with high specificity and sensitivity, identifying appropriate cut-offs, lack of
robust drug response biomarkers, limited understanding of drug mechanism of action, lack of
pharmokinetic/pharmocodynamic studies, high costs of drug development, interobserver
discordance, and variability in tissue fixation, sample procuring methods, antibodies,
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immunohistochemical (IHC) staining methods, and resources all present significant challenges in
successfully integrating targeted therapeutics into the clinic(14, 19-28). Furthermore, the time
consuming, costly, and inefficient preclinical and clinical trial process presents further
challenges in clinical implementation. Thus, AA BC patients are left with limited effective
treatment options.
1.2

Triple negative breast cancer
The clinical management of TNBC continues to confound clinicians. Accounting for a

small subset (10-20%) of all BC cases, TNBC patients experience notably lower survival rates
than non-TNBC patients(11, 29, 30). The defining feature of this subtype is its lack of ER, PR,
and HER2 overexpression(31); therefore, the only treatment options for TNBC are conventional
chemotherapy, surgery and radiation therapy. TNBC is notorious for its extensive interpatient
heterogeneity and intratumoral heterogeneity (32) that collude to produce poor clinical
outcomes(33). In fact, TNBC is renowned for its aggressive clinical disease course and its higher
prevalence among women of younger age and African descent(29, 34-36). Higher visceral and
cerebral metastasis and local relapse rates typify their clinical course(37, 38). Furthermore,
TNBC tumors display more unfavorable clinico-pathological features upon presentation such as
larger tumor size, higher nuclear grade, higher stage, higher mitotic index, higher Ki67
proliferation index, and lymph node involvement compared to other breast cancer subtypes(34,
39, 40). These tumors also possess a higher likelihood of exhibiting distant recurrence within the
first five years of diagnosis(34). These statistics have highlighted the need for finding new
treatment modalities to improve TNBC outcomes. However, these efforts have been met with a
stalemate in the clinic owing to the heterogeneous nature of the disease. Neoadjuvant
chemotherapy is the first-line treatment choice for TNBCs due to their relatively higher
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chemosensitivity and pathological complete response (pCR) rates compared to non-TNBC
patients(35). Despite reportedly higher pCR rates, TNBC patients tend to experience
significantly reduced progression-free survival (PFS) and lower overall survival (OS) within 3
years post-treatment compared to non-TNBC patients(41). This contradiction, often termed by
clinicians and researchers as “the triple-negative paradox”, may in part be explained by the small
percentage of TNBC patients that actually fall into the pCR group(34, 41). Only 30% of TNBC
patients that undergo anthracycline and taxane-based cytotoxic chemotherapy prior to surgery
achieve pCR and experience improved DFS rates(42). In addition, among patients with residual
disease, TNBC patients experience higher relapse and death rates than non-TNBC patients
within the first three years of follow-up(43-45). This outcome may partially be reflected by the
high administration of adjuvant endocrine therapy for patients with luminal tumors. Thus, there
is an urgent need for alternative targeted treatment options for this subset of BC patients. Despite
a surge of preclinical and clinical studies investigating promising therapeutic targets for TNBC
patients over the past decades, as of date, none have been approved.
1.2.1 Heterogeneous landscape of triple negative breast cancer
Perhaps the most groundbreaking attempt to subcatergorize TNBCs according to
common molecular features was undertaken by Lehmann and colleagues(46). Lehmann and his
colleagues analyzed gene expression profiles of human TNBC tumor samples and conducted
consensus clustering on the most differentially expressed genes to segment the subtype into
seven unique clusters sharing common gene expression profiles. Six stable clusters and one
unstable cluster was classified by Lehmann et. al as seven distinct TNBC subtypes characterized
by shared gene ontologies and unique enriched canonical pathways. These seven molecular
TNBC subtypes were labeled basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory,
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mesenchymal (M), mesenchymal stem-like (MSL), luminal androgen receptor (LAR), and
unstable (UNS). The basal-like 1 (BL1) and basal-like 2 (BL2) subtypes stratify the intrinsic
basal-like BC molecular subtype. These subgroups of basal-like BCs were found to be enriched
in components of the cell cycle, DNA replication pathways, DNA damage response, and exhibit
upregulation of genes associated with proliferation such as Ki67. The BL2 subtype is particularly
enriched in growth factor receptor expression such as EGFR, Insulin-like growth factor (IGFR),
and hepatocyte growth factor (MET). The IM subgroup is enriched for gene ontologies involved
in fundamental signaling immune pathways such as T cell and B cell receptor signaling, natural
killer cell pathway, and cytokine signaling. Additionally, this group has been observed to display
increased antigen processing and presentation (46). The M and MSL subtypes are both enriched
in genes that regulate cell motility, extracellular matrix receptor interaction, and cell
differentiation including enhanced Wnt/β-catenin and TGF-β signaling. However, the MSL
subtype differentiates itself from the M subtype with increased expression of genes in pathways
that promote growth factor (i.e. EGFR, platelet-derived growth factor (PDGF)), calcium, and
extracellular signal-regulated kinase signaling. In addition, MSL exhibits high activity of genes
involved in angiogenesis and epithelial-mesenchymal transition. Perhaps the most distinguishing
feature of the MSL subtype from the M subtype is a reduced expression levels of markers
associated with cell proliferation along with elevated expression of stem cell and mesenchymal
stem cell genes. Although ER negative, LAR subtype gene expression analysis revealed
enhanced androgen and estrogen metabolic pathways. Particularly, increased expression of
androgen receptor and its downstream targets was observed and further supported by enhanced
nuclear AR immunohistochemical staining. Additionally, hierarchical clustering revealed that the
LAR subtype exhibit a luminal-like gene signature making them resemble luminal ER positive
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breast cancer. Lehmann and colleagues also uncovered subtype-specific sensitivities among the
TNBCs to conventional therapeutic agents(46). They identified TNBC cell lines that share
homogenous gene ontologies with each of the major TNBC subtypes through conducting gene
expression profiling and clustering analysis. Their work yielded a comprehensive panel of TNBC
cell lines representative of the six identified molecular TNBC subtypes. They utilized the panel
to analyze differential drug response between the subtypes to traditional therapeutic agents
administered in clinics. Cell viability assays revealed that the cell lines characterized as basallike displayed significantly higher sensitivity to cisplatin compared to mesenchymal- and LARlike lines likely due to their enrichment in DNA damage response markers. As one may suspect,
the AR-dependent LAR-like cell lines displayed significantly higher sensitivity to the AR
antagonist, bicalutamide, than the basal-like lines. These results suggest that the increased AR
signaling present in LAR tumors permit this subgroup of TNBC patients to be selectively
susceptible to anti-androgen targeted therapy. This clinically translatable information is valuable
and warrants further investigation to discriminate TNBC subtypes according to their favorable
therapeutic response to guide clinical decision-making.
Androgen receptor is expressed in approximately 10-43% of TNBCs depending on the
cutoff of positivity used and thus, has emerged as a promising therapeutic target for TNBC
patients(47). AR knockdown and inhibition with enzalutamide among AR-expressing TNBCs
has resulted in reduced proliferation, migration, invasion and increased apoptosis in vitro and in
vivo(48-50). Traina and colleagues also observed that enzalutamide elicited a clinical benefit rate
(CBR) of 25% at 24 weeks and a median progression-free survival (PFS) of 14.7 weeks among
advanced AR-positive TNBC patients in a nonrandomized phase II clinical trial as opposed to
patients exhibiting less AR expression, who exhibited a CBR of only 20% at 24 weeks and a
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median PFS of 12.6 weeks (unpublished data). Another phase II clinical trial using the AR
antagonist, bicalutamide, elicited a CBR rate of 19% at 24 weeks and a median PFS of 12 weeks
among AR-positive TNBC patients(51). However, the remaining roughly 67-90% of TNBCs
lack AR expression deeming the disease a “quadruple threat” and is often referred to as
quadruple negative breast cancer (QNBC). Thus, this subgroup of TNBCs are more immune to
novel AR-targeted therapeutic agents compared to AR-expressing TNBCs and some studies have
reported a worse prognosis among QNBCs compared to TNBCs(52-57). Hence, some QNBCs
exhibit even more of a dire need for alternative therapeutic options and risk-predictive
biomarkers than AR-positive TNBCs. TNBC has been a hot topic of cutting-edge research over
the past decade in which a plethora of ongoing preclinical and clinical trials have yielded
promising biomarkers and therapeutic targets. However, recent evidence suggests genetic
differences between TNBC and QNBC tumors and although the prognostic role of AR in TNBC
remains controversial, many studies have revealed that a lack of AR expression confers a more
aggressive disease course. However, leading-edge research on alternative biomarkers and
treatment strategies for QNBC patients remain scarce. Thus, there is an urgent need for increased
preclinical and clinical QNBC research to uncover novel actionable molecular targets for this
unique group of TNBC patients.
1.2.2 The racially disparate burden in triple negative breast cancer
Intriguingly, racial disparities exist within the inherently aggressive TNBC subtype. As
previously mentioned, pre-menopausal African-American (2) women are overwhelmingly more
afflicted with TNBC compared to women of other ethnicities, which is primarily underlying their
substantially lower survival rates and poorer clinical outcomes(41, 58). Moreover, studies show
higher incidence rates and earlier age of onset of TNBC in native African women compared to
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AA women(12, 59). Moreover, accumulating evidence suggests that even among TNBCs, AAs
experience poorer clinical outcomes such as lower OS and PFS than EAs owing to more
unfavorable clinico-pathological features such as larger tumor size, higher proliferation, more
extensive lymph node involvement, and presentation at a younger age(12, 13, 60). In addition,
ITH was recently found to be greater in AA compared to European-American (3) TNBC
tumors(61). Further evidence has uncovered that AA TNBCs harbor more aggressive TNBC
subtypes such as BL1 and MSL while EA TNBCs harbor more favorable TNBC subtypes such
as LAR(60, 61). Interestingly, Gasparini and colleagues observed that loss of AR was more
prevalent among AA compared to EA TNBC patients as well as associated with more
unfavorable clinico-pathological features and a poorer prognosis(62). Furthermore, Davis et. al
discovered that AR loss was more associated with AA compared to EA TNBC tumors(63).
These findings are consistent with reports of a greater prevalence of basal-like TNBC, which
lacks AR expression and reduced sensitivity to AR antagonists, among AA compared to EA
TNBCs (46). These unsettling statistics necessitate further investigation into the potential
molecular drivers underpinning disparities in tumor biology between AA and EA TNBCs.
Several studies are addressing inherent biological differences between AA and EA
TNBCs. A comparative analysis revealed higher Ki-67 and c-Kit expression and lower CK5,
CK8, CK19, CD44 and AR expression in AA than EA TNBC patients(60). Linder et al.,
transcriptionally profiled AA and EA TNBC samples and observed increased loss of BRCA1
expression and upregulation of IGFR and VEGF in AA compared to EA tumors(64). The group
also found higher IGF-1 and VEGF activity and tumor vascularization in AAs compared to EAs
among TNBC tumors. Gene-expression studies have uncovered considerably more upregulation
of Wnt-β-catenin signaling in TNBC patients of African descent compared to TNBC patients of
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European descent(12). Nalwoga et al., detected notably more enrichment of aldehyde
dehydrogenase 1 (ALDH1), a cell surface marker associated with cancer stem cells, in TNBC
tumors of African origin compared to TNBC tumors of non-African origin(65). Therapies
targeting the previously mentioned inherent molecular differences distinguishing AA from EA
TNBCs, such as PARP, IGFR, VEGF, and Wnt inhibitors, may potentially aid in attenuating the
ethnic disparity in TNBC. However, these rationally-designed agents have yet been shown to
perform robustly in TNBC patients or have been approved for targeted TNBC treatment. Thus,
further investigation is warranted to uncover robust therapeutic targets and risk-prognostic and/or
predictive biomarkers for AA TNBC patients.
1.3

Intratumoral heterogeneity
ITH has indisputably become one of the chief culprits underlying challenges in

successfully treating and managing BC. Wang and colleagues claim that “no two cancer cells
within the same cancer have the same genome”(66). Thus, BC cells are able to resist or become
immune to conventional treatment strategies, such as chemotherapy, as well as rationally
designed novel targeted therapies. Thus, intratumor diversity may underlie therapeutic resistance,
metastasis, and relapse, which all characterize BC aggressiveness(67). Keenan and colleagues
reported that AAs exhibit greater intratumor heterogeneity than EAs among both BC and TNBC
tumors, which may be underlying the racial disparate burden in these diseases(61). Hence, it
may be worthy to investigate disparities in drivers of ITH between AA and EA breast tumors or
target the “root” of racial disparities in BC as a promising alternative strategy to alleviating the
burden. Centrosome amplification (CA) and mitotic propensity (MP) have been considered to be
two key drivers of ITH as they collectively foster chromosomal instability (CIN), which
promotes ITH(67). Herein, my research proposes to investigate differences in these two drivers
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of ITH between AA and EA BCs to rationalize the racial disparate burden in BC and uncover
their potential as robust prognostic biomarkers and/or therapeutic targets in AA BC patients.
1.3.1 Centrosome amplification: Driver of intramoral heterogeneity
The centrosome is the microtubule-organizing center of the cell and plays a key role in
cell shape, cell polarity, cell motility, cell adhesion, organelle transport, and assembly of the
mitotic spindle to ensure normal bipolar cell or genome division(68, 69). Normal cells harbor 12 centrosomes depending on the phase of the cell cycle it is in. However, cancer cells typically
exhibit CA or an increase in the number (numerical CA) or size (structural CA) of centrosomes
which can sporadically occur as a result of dyregulation of the centrosome duplication pathway,
de novo centrosome biogenesis, and/or cytokinesis failure(70). Thus, supernumerary
centrosomes can compromise mitotic fidelity and interfere with proper segregation of
chromosomes into daughter cells. As a result, aneuploidy or chromosomal instability arises
which can pave the path for the generation of clonal diversity and aggressive karyotypes(71, 72).
Centrosomal aberrations have been shown to positively correlate with ploidy and chromosomal
instability(71, 72). Cells burdened with extra centrosomes often cluster their centrosomes at
opposite poles of the cell to form a “pseudo biopolar spindle” in lieu of a lethal multi-polar
spindle in order to ensure cell survival and allow genomically unstable cells to successfully
replicate and thrive(73). Centrosome clustering has been significantly associated with worse OS
and recurrence-free survival (RFS)(71). Excess centrosomes can also interfere with cell polarity
and thus, enhance cell migration and progression(74, 75). Thus, CA has been linked to breast
tumorigenesis and aggressiveness. Approximately, 80% of breast carcinomas have been reported
to display CA(72). Centrosomal aberrations in breast tumors have been significantly associated
with high grade and stage, lymph node metastasis, TNBC phenotype, and poor clinical outcomes
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such as overall survival (OS) and progression-free survival (PFS) (71, 72, 76, 77). As previously
mentioned, these aggressive characteristics are associated with BC patients of African ancestry.
Thus, it may be worthy to investigate differences in centrosomal profiles between AA and EA
breast tumors as a suspect in the racial disparate burden in BC. Establishing differences in the
incidence and severity of CA between AA and EA TNBC patients may provide compelling
evidence for rationalizing differences in tumor progression and the divergence in clinical
outcomes between the ethnic groups. Furthermore, uncovering this inherent tumor biological
disparity between the racially-distinct patients may establish CA as a novel racial disparity
biomarker in BC and a promising target for therapeutic intervention. CA is a cancer-cell specific
trait that distinguishes them from normal, healthy cells. Thus, targeting CA offers a minimally
cytotoxic therapeutic strategy that selectivity targets cancer cells burdened with severe
centrosomal aberrations. Conveniently, there are already rationally designed drugs that
selectively kill cancer cells harboring CA and are currently under clinical evaluation as
promising anti-cancer therapeutics. These novel agents include putative centrosome declustering
drugs such as griseofulvin and noscapine, commercially available HSET inhibitors such as
CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as GF-15(2, 78-81).
Furthermore, non-invasive methods that can detect centrosomal status (i.e. fine-needle aspirate
cytology, immunohistochemistry) may demonstrate feasibility in the clinic for selecting patients
that will exhibit susceptibility to these agents(77, 82). Validating associations between the
severity level of CA with tumor growth, metastasis, and chemoresistance in preclinical and
clinical BC models may illuminate upstream or downstream targets of CA that may be driving
more aggressive BCs and variances in tumor progression between racially-distinct patients.
Moreover, this elucidation may lay the groundwork for future studies to investigate differences
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in molecular signaling pathways preceding the onset of CA or the mechanisms extra centrosomes
exploit to drive more aggressive tumor behavior in AA compared to EA TNBC patients.
Furthermore, CA exists in precancerous lesions and has been demonstrated to act as a precursor
to breast tumorigenesis(83). Thus, evaluating centrosomal profiles among early-stage AA BC
patients may serve as a risk-predictive biomarker for aggressive disease.
1.3.2 Mitotic propensity: Engine of intratumoral heterogeneity
MP, or turnover rate of proliferating cells in a tumor, is another important component
fueling ITH(67). Tumors with a high propensity are more prone to erroneous mitoses and
consequently chromosomal instability. As a result, increased clonal diversity and the generation
of aggressive cellular phenotypes can arise. Indices routinely utilized in the clinic to measure
tumor proliferation include mitotic index (MI) and Ki-67 proliferation index (84). MI and KI
have proven to be useful as autonomous indices in the clinic as a high MI and KI among early
stage tumors have been reported to be synonymous with a poor patient prognosis in BC(85, 86).
However, both indices are gleaned from separate fields and thus the precise propensity of a
tumor cell to double among the proliferating cell population remains elusive. MI is deduced by
computing the quantity of mitotic (M phase) cells per 10 high-powered microscopic fields
whereas, KI is determined as the percentage of positive Ki-67 nuclear stained proliferating (G1,
S, G2, and M phases) carcinoma cells in low-powered microscopic fields. A higher MI and KI
have been reported among AA compared to EA breast tumors(87). Furthermore, extraneous
factors often interfere with accurately quantitating mitotic figures in patient tumor samples and a
lack of consensus on an appropriate cut-off and discrepancies in Ki-67 immunohistochemical
(IHC) staining still persists(32, 88, 89). Thus, our group recently proposed a novel metric that
rationalized the inconsistencies and limitations of MI and KI as autonomous prognosticators. The
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metric cleverly integrates MI and KI onto the same measurement scale to ascertain the frequency
of mitotic cells among Ki-67 positive cycling cells or mitotic propensity, termed mitosis:
proliferation (M:P ratio). Hence, our metric provides an additional layer of risk-predictive
information than MI and KI alone. My research proposes to investigate differences in M:P ratio
or cycling kinetics between AA and EA breast tumors to (i) rationalize their differences in ITH
and metastatic propensity and (ii) determine if M:P ratio can enhance risk-prognostication for
AA BC patients at risk for faster tumor kinetic progression.
1.4

Tumor immune microenvironment
Accumulating evidence suggest that the interplay between the breast tumor and its

microenvironment plays a critical role in tumor progression and therapeutic responses. The
breast microenvironment provides a supportive niche for tumor growth and is composed of the
extracellular matrix, stromal cells, fibroblasts, adipocytes, endothelial cells, and immune
cells(90). Immune cells infiltrate the tumor upon neoplastic transformation to elicit an
antitumoral or protumoral inflammatory response. Primarily lymphocytes, macrophages, mast
cells, and neutrophils comprise the inflammatory defense army that infiltrate the incipient tumor
to mount an attack or facilitate tumor progression(91). Thus, these inflammatory cells harbor
dual roles in BC initiation and progression by secreting cytokines, growth factors, chemokines,
oxygen intermediates to stimulate proliferation, apoptotic prevention or promotion factors,
morphogenesis factors, and inducing mutagenic changes that promote DNA damage in tumor
cells(91). Tumor associated macrophages (TAMs), neutrophils, T, and B lymphocytes harbor
both pro-tumorigenic and tumoricidal properties however, natural killer (NK) lymphocytes are
the only tumor infiltrating immune cells that harbor solely anti-tumorigenic properties. Tumor
infiltrating lymphocytes (TILs) have been recognized as a bonified biomarker of the anti-tumoral

14

immune response, have been proven to harbor both prognostic and predictive value in BC and
TNBC, and have become one of the primary targets of cancer immunotherapy today. Thus, TILs
will be the primary focus of my dissertation.
1.4.1 Tumor infiltrating lymphocytes: Critical mediators of the antitumoral immune
response
TILs are white blood cells or T, B, and NK lymphocytes that migrate to the tumor stroma
or within the tumor upon neoplastic transformation to eradicate tumor cells and control tumor
progression. In BC, TILs primarily consists of T cells (~75%) and specifically CD8+ cytotoxic T
cells, CD4+ helper T cells, and CD4+ regulatory T cells (T regs)(92, 93). Cytotoxic T
lymphocytes kill tumor cells by inducing apoptosis. T cells express T cell receptors (TCRs) that
recognize neoantigens on cancer cells and induce programmed cell death by (i) releasing the
cytotoxin perforin to inject granzymes into the cytoplasm and trigger the caspase cascade
pathway through their serine protease function and by (ii) expressing their surface protein, FAS
ligand, which can bind to Fas on the cancer cell and recruit the death-induced signaling complex
and Fas-associated death domain to activate the caspase cascade reaction. TILs are associated
with more aggressive BC such as high grade, high stage, high Ki-67, lymph node metastasis, and
younger age at diagnosis(93). Furthermore, TIL infiltration is significantly more observed in
TNBC compared to non-TNBCs(92). Particularly, CD8+ T lymphocytes inversely correlates
with ER and PR expression and their density is significantly higher in TNBCs compared to nonTNBCs(94, 95). However, a presence of TILs have been associated with a significantly better
prognosis in BC and TNBC. TILs have been shown to be an independent predictor of improved
pathological complete response (pCR) following neoadjuvant chemotherapy (NAC) in both BC
and TNBC as well as better OS and disease-free survival (DFS) among non-NAC treated TNBC
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patients(96, 97). High TIL levels have also been significantly associated with improved overall
survival (OS), increased metastasis-free survival (MFS), and reduced distance recurrence in
TNBC(96). Hence, the presence of TILs plays a critical role in disease course and survival
outcomes among BC and TNBC patients.
1.4.2 Racial disparities in the tumor microenvironment: Suspect in the racially disparate
burden in BC
Emerging evidence suggest disparities in the breast tumor immune microenvironment
exists between AA and EA breast tumors, which has been suspected to be contributing to the
racial disparate burden in BC. Tumor stromal genes such as PSPHL, CXCL10, and CXCL11
have been reported to be significantly higher in AA compared to EA BC patients(98). Multiple
groups have revealed significantly higher levels of pro-inflammatory cytokines such as resistin,
leptin, interleukin 6 (IL-6) as well as the resistin receptor, CAP1, in AA compared to EA
patients(99-103). Martin and colleagues also observed significantly higher expression levels of
vascular endothelial growth factor (VEGF) and syndecan-1 (known inducers of angiogenesis) in
AA compared to EA BC patients(98). In addition, Martin et. al observed greater microvessel
density in AA compared to EA BC patients(98). TAMs have also been reported by several
groups to be significantly higher in AA compared to EA BC patients(98, 104, 105). Tripathi and
colleagues also discovered an enriched immune gene signature in the T and B cell response
pathways among AA QNBC tumors suggesting increased anti-tumor immunity among AA
QNBC patients (unpublished data). Hence, this evidence suggests disparities between AAs and
EAs exists in the breast tumor microenvironment, which may be underlying the racial disparity
in BC. However, the role of racial disparities in the tumor microenvironment in the racial
disparate burden in BC, and especially in TNBC, remains poorly explored. Particularly, racial
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disparities in TIL levels between AA and EA breast tumors remain elusive. In this dissertation, I
investigate differences in TILs between AA and EA TNBC patients and their potential as robust
risk-prognostic/predictive biomarker and therapeutic target for AA patients at risk for a poorer
prognosis.
1.5

Tumor cell proliferation
Aggressive BC is often characterized by what it lacks such as the absence of the hormone

and growth receptors, ER, PR, AR, and HER2 that promote BC proliferation and consequently a
lack of risk-prognostic and targeted treatment options. Furthermore, as previously discussed, BC
patients of African descent tend to lack expression of these tumor proliferation markers,
exempting them from being eligible to receive conventional treatments targeting these
biomarkers, which is a major underlying factor in their observed disparate clinical outcomes
compared to patients of other ethnicities. Hence, it may be advantageous to investigate the role
of other growth receptors in aggressive BC subtypes that lack expression of these traditional
proliferation biomarkers such as TNBC and QNBC among AA BC patients as alternative riskprognostic and/or targeted treatment options.
1.5.1 Human epidermal growth factor receptor family
The human epidermal growth factor receptor (EGFR) family consists of four structurally
related tyrosine kinase receptors (EGFR/HER1, HER2, HER3, and HER4) that collectively
stimulate growth factor signaling pathways that play critical roles in cell proliferation, growth,
survival, and differentiation, such the PI3 kinase, Ras-Raf-MAPK, JNK, and PLCg
pathways(106-108). Aberrant expression of these receptors can also promote loss of cell
adhesion and polarity and initiate invasion and angiogenesis and has been associated with human
malignancies(109-111). Activation of these receptors and their signaling pathway via ligand
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binding is mediated through hetero- or homo- dimerization of these receptors followed by
subsequent phosphorylation of tyrosine residues on the intracellular tyrosine kinase
domain(112). HER2 preferentially dimerizes with EGFR(113). HER2 is overexpressed in
approximately 20-25% of all BCs and is a well-established predictive biomarker and therapeutic
target in BC(107). However, owing to the lack of HER2 amplification in TNBCs and QNBCs it
may be advantageous to investigate other members of the EGFR family as viable risk-predictive
biomarkers or therapeutic targets for TNBC patients and patients of African ancestry. In this
dissertation, I will investigate the role of the other three EGFR family members (EGFR, HER3,
and HER4) in the global racial disparate burden and their potential as risk-prognostic/predictive
biomarkers and/or therapeutic targets among ethnically-distinct TNBC patient populations.
1.5.1.1 EGFR
EGFR is overexpressed in at least 50% of TNBCs, which is notably higher compared to
other BC subtypes(107). Ligands for EGFR include EGF, ampiregulin, transforming growth
factor (TGF)-α, betacellulin, heparin-binding EGF, and epiregulin(114). EGFR expression is
significantly more associated with young age, lower hormone receptor expression levels, high
grade, high proliferation, genomic instability, and lymphocytic infiltration(115, 116). EGFR has
expression has also correlated with higher risk of relapse among adjuvant treated BC
patients(116). Moreover, high EGFR copy number, immunoreactivity and expression have been
shown to be independent prognostic indicators of poorer overall survival (OS) and disease-free
survival (DFS) in TNBC, suggesting EGFR to be a potentially targetable and risk-prognostic
biomarker in TNBC (117-120). Researchers at Caris Research Institute recently reported that
EGFR IHC expression was higher among AR-negative compared to AR-positive TNBCs
suggesting increased cellular growth and proliferation in QNBCs compared to TNBCs as well.
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Anti-EGFR agents such as tyrosine kinase inhibitors (i.e. gefitinib and erlotinib) and anti-EGFR
monoclonal antibodies (i.e. cetuximab) are currently being tested in TNBC patients in phase I/II
clinical trials as monotherapy and in combination with chemotherapy and have elicited improved
response in some patients(121). Thus, EGFR may serve as a promising risk-prognostic
biomarker and therapeutic target for TNBC and QNBC patients as well as patients of African
ancestry who exhibit a high prevalence of these diseases.
1.5.1.2 HER3
HER3 is unique in that it is the only receptor in the family that is catalytically inactive
and requires dimerization with other members in order to be active(122). The receptor
heterodimerizes with EGFR to stimulate the PI3K signaling pathway(122). Its overexpression
has been reported in approximately 20-30% of invasive breast carcinomas(123). Yamaguchi and
colleagues recently observed that HER3 signaling promotes upregulation or programmed cell
death ligand 1 (PD-L1) which plays a critical role in suppression of anti-tumor immunity
(unpublished data). HER3 has also been reported to limit patient sensitivity to EGFR-targeted
agents such as cetuximab by increasing EGFR-HER3 heterodimerization and activating
downstream signaling pathways in BC(124). Reports on the prognostic role of HER3 in BC
remain conflicted however, it has been associated with poorer overall survival (OS) and DFS in
TNBC according to one study (122, 125). Our group also recently reported that combined
EGFR-HER3 score predicts worse BC-specific survival (BCSS) and increased distant metastasis
after adjusting for age and stage among TNBC patients (unpublished data). A high EGFR-HER3
score among chemotherapy-treated patients in this cohort was associated with high IHC
expression of luminal cytokeratins, DNA damage response proteins, and P-cadherin. Hence, it
may be worthy to investigate the role of HER3 in the racial disparate burden in TNBC.
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1.5.1.3 HER4
HER4 is detected in less than half of BCs and generally characterized by antiproliferative
and pro-apoptotic activity(126). This EGFR family member has been reported to be
downregulated in 18-75% of BCs and upregulated in 7-29% of cases(127). It is also unique in
that it is the only member of the family that exist in four juxtamembrane (JM) and cytoplasmic
(CYT) isoforms (JM-a/CYT1, JM-a/CYT2, JM-b/CYT1, and JM-b/CYT2) due to alternative
mRNA splicing and one of these isoforms (JM-a) can be cleaved by tumor necrosis factor
(TNF)-α converting enzyme (TACE) and γ-secretase and released into the cytoplasm as a soluble
HER4 intracellular domain (4ICD) that can translocate to the nucleus(128-130). Ligands for
HER4 include the neuregulins, epiregulin, betacellulin, and heparin-binding EGF(114). The
receptor displays a diverse range of roles including modulating cell proliferation, cell cycle
arrest, and pro-apoptotic pathways(131, 132). The 4ICD of HER4 promotes proliferation of ERα positive BC cells and apoptosis of BC cells through the cell-killing BH3 domain(133). Thus,
HER4 is often associated with a favorable prognosis in BC and specifically prolonged event-free
survival and OS among TNBCs(122, 134, 135). However, Kim et. al recently reported that high
HER4 levels are significantly associated with poor 5-year disease relapse free survival in
TNBC(84). HER4 has been reported to positively correlate with ER-positive BC and be
associated with less recurrence and mortality among ER-positive patients(131, 136).
Upregulation of HER4 gene expression has even been shown to predict response to neoadjuvant
chemotherapy (NAC) in BC(137). In addition, HER4 has been associated with low proliferative
indices, cell growth inhibition, and low histological grade as well as been observed to antagonize
the influence of HER2 on clinical outcome(127). HER4 mRNA expression levels were found to
be significantly lower among AR-negative compared to AR-positive TNBC cases(62). Hence,
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lack of HER4 expression may be a marker of aggressive BC and serve as a novel prognostic
biomarker this patient population.
1.5.1.4 Retinoic acid receptor-α
Retinoic acid (RA), a derivative of retinol of vitamin A, influence cell growth,
differentiation, and death through binding to members of the retinoic acid receptor (124)
subfamily comprised of RARa, RARb, and RARg, which belong to the nuclear receptor
superfamily of transcription factors(138). RARs heterodimerize to members of the retinoic X
receptor (RXR) subfamily to initiate RA-mediated signaling. RAR is activated by both all-trans
and 9-cis RA, whereas RXR can only be activated by 9-cis RA(139). The RAR-RXR dimer
translocates to the nucleus and regulates transcription of target genes by binding to specific RA
response elements (RAREs) on the gene promoter. Unlike the EGFR family, RA signaling
through RARs has been reported to elicit differentiation as well as antiproliferative, proapoptotic, and anti-oxidant activity(138). Thus, aberrant RA signaling has been linked to breast
tumorigenesis and RA and its derivatives (retinoids) are often exploited as potential
chemotherapeutic or chemopreventative agents. However, ER-negative BCs and TNBCs have
been reported to express lower levels of RARa compared to non-TNBCs which may reflect their
enhanced proliferative activity(140). The role of RARa in TNBC and particularly in the racially
disparate burden remains elusive. Hence, my dissertation work explores the potential role of this
biomarker as a driver of the racial disparity in TNBC incidence and mortality between patients of
African and European descent.
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2

DISTINCTIONS IN BREAST TUMOR RECURRENCE PATTERNS POSTTHERAPY AMONG RACIALLY-DISTINCT POPULATIONS

2.1

Abstract
Clinical studies have revealed a higher risk of breast tumor recurrence in African-American

(2) patients compared to European-American (EA) patients, contributing to the alarming inequality
in clinical outcomes among the ethnic groups. However, distinctions in recurrence patterns upon
receiving hormone, radiation, and/or chemotherapy between the races remain poorly characterized.
We compared patterns and rates (per 1000 cancer patients per 1 year) of recurrence following each
form of treatment between AA (n=1850) and EA breast cancer patients (n=7931) from a cohort of
patients (n=10504) treated between 2005-2015 at Northside Hospital in Atlanta, GA. Among
patients who received any combination of adjuvant therapy, AA displayed higher overall rates of
recurrence than EA (p=0.015; HR: 1.699; CI: 1.108-2.606). Furthermore, recurrence rates were
higher in AA than EA among stage I (p=0.031; HR: 1.736; CI: 1.052-2.864) and T1 classified
patients (p=0.003; HR: 2.009; CI: 1.263-3.197). Interestingly, among patients who received
neoadjuvant chemotherapy, AA displayed higher rates of local recurrence than EA (p=0.024; HR:
7.134; CI: 1.295-39.313). Our analysis revealed higher incidence rates of recurrence in AA
compared to EA among patients that received any combination of adjuvant therapy. Moreover, our
data demonstrates an increased risk of tumor recurrence in AA than EA among patients diagnosed
with minimally invasive disease. This is the first clinical study to suggest that neoadjuvant
chemotherapy improves breast cancer recurrence rates and patterns in AA.
2.2

Introduction
The significant divide in breast cancer mortality between African-American (2) and

European-American (EA) patients remains a challenge for clinicians. Despite a similar number of
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reported incidences of breast cancer among AA and EA women, AAs experience notably higher
severity in clinical outcomes and exhibit a 40% higher death rate than EAs among premenopausal
and menopausal breast cancer patients (1-3). Recurrent breast cancer has impeded successful
management of the disease for decades and is one of the primary factors for this racial division in
prognosis (4). Statistics demonstrate that approximately 40% of all breast cancer survivors will
experience a recurrence episode during their lifetime, which has been suggested to play a principal
role in breast cancer mortality (4, 5). Clinical studies have revealed a higher risk of recurrence in
AA compared to EA, presumably contributing to the inequality in clinical outcomes among the
ethnic groups (1). This statistic has provided an impetus for clinicians to devise and implement
robust prognosticative measures to preclude recurrence in AA breast cancer patients. However,
distinctions in recurrence rates and patterns following various forms of treatment between the races
have not been thoroughly evaluated. This warrants more investigation to potentially attenuate the
observed racial disparity in recurrence in the clinic. Hence, we conducted a large institutional study
based in Atlanta, Georgia, in which we analyzed rates and patterns of tumor recurrence post
hormone, radiation, and chemotherapy among AA and EA breast cancer patients. This
retrospective clinical study uncovered previously unrecognized distinctions in recurrence patterns
following each conventional form of treatment among racially distinct breast populations and may
impart valuable clinical insight into preclusive measures for mitigating the ethnic disparity in
breast tumor recurrence.
2.3

Results

2.3.1 Clinico-pathological characteristics of patients
The demographics, breast clinico-pathological characteristics, therapies administered and
patterns of recurrence among the patients in the cohort are illustrated in Fig 1. From this cohort of
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10,504 NH patients, 225 were recorded as having experienced a recurrence episode and 6,009 were
determined as displaying no breast tumor recurrence. The remaining patients did not have recorded
data indicating presence of recurrence or lack thereof. Among patients displaying recurrence,
higher risk of recurrence was more prevalent among younger patients (p<0.0001) (Fig 1A). Among
patients with no missing recurrence data, approximately 61% of patients who experienced
recurrence were under the age of 48, compared to only 39% who did not experience any recurrence.
Among breast clinico-pathological characteristics, recurrence was significantly more associated
with higher nuclear grade, NGH grade, stage, as well as T, N, and M classifications (p<0.0001)
(Fig 1B). Moreover, recurrence was weakly associated with lymph node metastasis with roughly
35% of patients with recurrence displaying a positive nodal status compared to only 15% of nonrecurrence patients (p=0.121). Regarding treatment, there were statistical significant differences
in the distribution of recurrence and non-recurrence patients who were administered neoadjuvant
and adjuvant chemotherapy, hormone therapy, and a combination of adjuvant therapies (p<0.0001)
(Fig 1C). There was a weak statistical significant difference between the proportion of recurrence
and non-recurrence patients that received radiation therapy (p=0.065). Please visit Supplementary
Table 1 for details.
2.3.2 Clinico-pathological characteristics among racially distinct patients
Among the NH patients exhibiting recurrence, the demographics, breast clinicopathological features, and therapies administered were compared between AA (n=49) and EA
(n=166) as shown in Fig 2. Regarding patient demographic characteristics, a test of hypothesis for
population differences revealed a weak statistical significant difference in age at diagnosis between
the races (p=0.145) (Fig 2A). Approximately 51% of AA were diagnosed under the age of 48,
compared to only 35% of EA. No significant differences in either clinico-pathological
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characteristics or treatments between the races were observed, likely owing to a significant
reduction in patient numbers after stratification of recurrence patients by race (Fig 2B, C). Please
visit Supplementary Table 2 for details.
2.3.3 Recurrence patterns among racially distinct patients
Recurrence rates and patterns, expressed in terms of incidence rates, were compared
broadly between AA and EA patients (Table 1); the analysis indicated that AA exhibited higher
overall tumor recurrence rates than EA (p=0.002; HR: 1.676; CI: 1.210-2.323). AA also displayed
higher rates of distant recurrence than EA (p=0.023; HR: 1.699; CI: 1.075-2.684); however, these
differences did not remain statistically significant after controlling for age, grade, and stage, likely
owing to low patient numbers. Additionally, AA experienced higher rates of single tumor
recurrence episodes than EA (p=0.003; HR: 1.758; CI: 1.208-2.557) and higher rates of distant
recurrence to a single site than EA breast cancer patients (p=0.012; HR: 1.742; CI: 1.130-2.684),
although statistical significance was not maintained after adjusting for age, grade, and stage.
2.3.4 Recurrence patterns among racially distinct patients following each form of treatment
Incidence rates and patterns of recurrence were compared between AA and EA after they
received hormone, radiation, chemotherapy, and/or any combination of adjuvant therapy (Table
2). AA exhibited unadjusted higher rates of recurrence (p=0.041; HR: 1.612; CI: 1.021-2.545) and
a trend towards higher incidence of distant tumor recurrence than EA post radiation therapy
(p=0.065; HR: 1.732; CI: 0.967-3.100). However, statistical significance was lost after controlling
for age, grade, and stage. The same trend of higher overall and distant recurrent was observed
among recurrent patients who received hormone therapy and any combination of adjuvant
therapies. Among patients who underwent hormone therapy, AA displayed stronger overall
tendencies than EA to suffer from recurrence (p=0.112; HR: 1.541; CI: 0.906-2.623) and distant
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recurrence (p=0.123; HR: 1.692; CI: 0.868-3.301). Following any combination of adjuvant
therapy, AA displayed higher recurrence rates than EA after adjusting for age, grade, and stage
(p=0.015; HR: 1.699; CI: 1.108-2.606). Moreover, AA displayed higher rates of distant recurrence
than EA (p=0.003; HR: 2.164; 1.290-3.629) before adjusting for age, grade, and stage, as well as
stronger tendencies toward regional recurrence (p=0.104; HR: 2.043; CI: 0.863-4.837) after
receiving any combination of adjuvant therapy.
Quite interestingly however, among patients with recurrence that received neoadjuvant
chemotherapy, this trend was reversed. AA displayed lower tendencies toward recurrence than EA
patients; however, statistical significance was unable to be achieved owing to a low number of
patients (n=40) recorded as receiving neoadjuvant chemotherapy and exhibiting recurrence.
Furthermore, AA displayed lower tendencies toward regional and distant tumor recurrence
(p=0.112; HR: 0.310; CI: 0.073-1.315) than EA patients. Moreover, AA displayed higher rates of
local recurrence than EA after controlling for age, grade, and stage (p=0.024; HR: 7.134; CI:
1.295-39.313). These results suggest that aggressive recurrence rates and patterns may be
attenuated in AA patients who received neoadjuvant chemotherapy. Additional studies with larger
numbers of patients with recurrence that received neoadjuvant chemotherapy could further clarify
the significance of this trend.
2.3.5 Recurrence rates among racially distinct breast cancer patients in different stages
Overall incidence rates of recurrence were compared between AA and EA in both early (I–
II) and late stage (III-IV) breast cancer patients (Table 3). Our data revealed that AA displayed
higher recurrence rates than EA among stage I patients (p=0.001; HR: 2.165; CI: 1.348-3.476),
even after adjusting for age, grade, and stage (p=0.031; HR: 1.736; CI: 1.052-2.864). Among early
stage (I-II) patients, AA also exhibited higher recurrence rates than EA (p=0.002; HR: 1.793; CI:

36

1.252-2.567), although statistical significance was only weakly maintained after controlling for
age, grade, and stage (p=0.131; HR: 1.339; CI: 0.917-1.956). Furthermore, AA displayed higher
recurrence rates than EA among T1 classified patients, irrespective of age, grade, and stage
(p=0.003; HR: 2.009; CI: 1.263-3.197). Moreover, unadjusted models reveal that AA displayed
higher rates of recurrence than EA among N0 (p=0.005; HR: 1.777; CI: 1.186-2.661) and M0
(p=0.002; HR: 1.682; CI: 1.210-2.338) classified patients. However, rates of recurrence were not
significantly higher in AA as compared to EA among late stage patients. Thus, these results suggest
that AA are at higher risk than EA for tumor recurrence among patients with non-invasive or
minimally invasive breast cancer.
2.3.6 Survival outcomes among racially distinct patients displaying recurrence
Survival duration after initial recorded recurrence was compared between the racial groups
(Fig 3). AA exhibited a non-statistically significant trend toward shorter survival time than EA
after experiencing their first episode of recurrence (p=0.231) (Fig 3A). The average time until
death was compared between EA and AA patients who experienced distant recurrences (Fig 3B).
Interestingly, AA and EA patients exhibiting distant recurrence were comprised of similar
percentages of alive patients, however AA (n=26) died considerably sooner than EA (n=80)
(p=0.015). More precisely, AA patients who experienced distant recurrences died approximately
one year earlier than EA distant recurrent patients. However patient numbers were too low to
control for variables of age, grade, and stage.
2.4

Discussion
This clinical study is the first extensive investigation into the rates and patterns of tumor

recurrence in breast cancer patients following conventional treatments among racially distinct
populations. Our study has revealed notable distinctions in recurrence patterns among EA and AA
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patients. First, AA displayed considerably higher rates of recurrence than EA (Table 1 and 2).
Second, we observed higher severity in recurrence patterns displayed by AA for whom we
discerned stronger trends in AA of tumor recurrence to regional and distant sites (Table 1 and 2).
This trend was evident after patients received radiation, hormone, and any combination of adjuvant
therapies. Overall, these observed trends were quite significant since local recurrence tends to elicit
a more favorable clinical prognosis compared to distant recurrence, while the latter trends type
precedes a poorer clinical prognosis. Triple negative breast cancer (TNBC) patients have been
shown to display an increased risk for recurrence and particularly for recurrence to distant sites,
while non-TNBC patients exhibit higher trends of recurrence to local sites (1,8). These findings
parallel our observations of an increased risk of overall and especially distant recurrence in AA,
as well as an increased risk of local recurrences in EA. This tendency reflects the well-reported
higher incidence of TNBC phenotypes in AA patients and a higher prevalence of non-TNBC
subtypes in EA patients (8,9). Furthermore, we observed a trend of a higher number of recurrence
episodes in AA compared to EA. Additionally, we discerned stronger inclinations of distant
recurrence to multiple organs in AA compared to EA. These observed aggressive recurrence
patterns reveal that AA patients exhibit an increased prospect of a poor clinical prognosis,
theoretically contributing to their higher mortality rates than EA patients. Recurrence rates were
also found to be higher in AA than EA among early stage, minimally invasive breast cancer
patients (Table 3). This data presents an intriguing paradox as advanced stage upon diagnosis is
typically associated with increased risk for recurrence (10-13). Thus, these findings suggest that
AA patients of all clinical stages should be closely evaluated for the prospect of tumor recurrence.
Neoadjuvant chemotherapy seemed to reverse these observed recurrence trends (Table 2). Among
patients who received neoadjuvant chemotherapy, AA displayed a lower rate of recurrence than
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EA; however due to a low number of recorded patients that received neoadjuvant chemotherapy,
statistical significance was diminished. In addition, higher incidences of aggressive recurrence
patterns in AA were notably attenuated after these patients underwent neoadjuvant chemotherapy.
This data suggest preoperative chemotherapy may reduce the severity of recurrence rates and
patterns in AA patients. This study suggests that neoadjuvant chemotherapy should be
recommended for AA patients who are at higher risk for developing recurrence. A recent clinical
study reported that in fact, neoadjuvant chemotherapy is administered more frequently to AA than
EA patients likely as a result of their higher prevalence of advanced stage, grade, and triple
negative receptor status upon presentation (14). Owing to their robust prognostic value, the extent
of lymph node involvement and tumor size warrant stringent evaluation upon diagnosis and serve
as principal prognostic factors in assessing breast cancer recurrence proclivities in AA patients (1).
Established supplementary prognostic factors often considered by clinicians, such as higher stage
and grade upon initial diagnosis, lymphatic and vascular invasion, premenopausal status, and a
TNBC phenotype, also merit thorough scrutiny for AA breast cancer patients (9,10-13,15-17).
Hence, rigorous supervision of the prospect of recurrence is conceivably compulsory to palliate
the elevated risk of recurrent breast cancer demonstrated by AA patients.
Although prior clinical studies have exposed disparities in recurrence risk among EA and
AA, this study is one of the first to uncover distinctions in rates and patterns of tumor recurrences
following conventional forms of breast cancer treatments among the racial groups, and thus
highlights the need for further investigation and surveillance. Our comprehensive analysis has also
illuminated previously unrecognized differences in the rates and patterns of recurrence postchemotherapy among racially distinct populations by suggesting that AA respond better to
neoadjuvant chemotherapy. Additionally, no study has yet elucidated the significantly higher risk

39

for recurrence among early stage AA patients. Overall, this study further advocates that race should
be considered among the potential decisive risk factors in the clinic for recurrence. Awareness of
the higher rate of recurrence in AA may compel clinicians to consider race as a critical factor in
evaluating the prospect of the cancer returning after patients enter remission, and allow this factor
to play a major role in treatment decisions. Hereinafter, enriched comprehensive screening
programs and tailored treatment plans may be imperative to impede augmented risk of tumor
recurrence and aggressive recurrence patterns in AA patients that may be reinforcing their poor
clinical outcomes.
2.5

Methods

2.5.1 Study cohort
In this study, a large cohort of breast cancer patients treated at Northside Hospital (NH)
in Atlanta, Georgia from 2005 to 2015, were examined. We received approval and permission by
the institutional review board at Northside Hospital to access patient clinico-pathological
information used in this study and have a written human subjects assurance on file. The
demographics and clinico-pathological characteristics of each patient were recorded to generate a
database of 10,504 patients. Patient demographic information recorded in the database included
age at time of diagnosis and ethnicity. Age at diagnosis among patients was divided into three
subgroups, comprised of patients below the age of 48 (premenopausal), over the age of 55
(postmenopausal), and in between (perimenopausal), to precisely describe menopausal status.
The races of patients in the database were primarily comprised of African-Americans (2) and
European-Americans (EA). The “unknown/others” subcategory denote patients of all other
ethnicities (excluding AA and EA) and patients lacking race information. Breast tumor
characteristics that were recorded for each patient consisted of nuclear grade, Nottingham (NGH)
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grade, stage, nodal status, T (primary tumor), N (lymph node metastasis) and M (distant
metastasis) classifications. American Joint Committee on Cancer (AJCC)/Union for International
Cancer Control (UICC) TNM Classification and Stage groupings for breast carcinoma will be
used in this article. All patient treatments were recorded, including chemotherapy, hormone, and
radiation therapy. Patients that underwent chemotherapy were subcategorized into neoadjuvant
and adjuvant depending on the timing of treatment. Additionally, any combination of hormone,
radiation, and chemotherapy that patients received was labeled as a combination of adjuvant
therapies. Follow up data was collected to determine breast cancer recurrence episodes, as well
as the site of recurrence, such as local, regional or distant sites. Local recurrences comprise
recurrence of the tumor in the primary site. Regional recurrence encompasses recurrence of the
breast cancer in adjacent lymph nodes. Distant recurrences involve metastatic breast cancer in
remote organs such as distant lymph nodes, bone, liver or others.
2.5.2 Follow-up
Both follow-up of patients and initial diagnosis occurred between the years of 2005 and
2015. Initial diagnosis dates as well as treatment start and completion dates for any therapies were
documented. Dates of last contact for all patients were recorded. Survival status (alive/dead) was
reported for each patient along with survival time. Dates of first recurrence were noted. February
19, 2015 was the final follow-up for the last patient seen.
2.5.3 Statistical analysis
A significance level of 0.05 and 95% confidence intervals were selected for all analyses.
Sample sizes were based on the available patients that comprised each category in the NH database
and not power analysis. Chi-square tests were performed to examine significant differences in
clinico-pathological characteristics, therapy administration, and recurrence characteristics
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between recurrence and non-recurrence patients as well as between AA and EA breast cancer
patients. Recurrence rates were calculated as per 1000 person-years. Test statistics were computed
using MATLAB (MATLAB and Statistics Toolbox Release 2015a, The MathWorks, Inc., Natick,
Massachusetts, United States) program and 1-tailed univariate p-values were reported. One-tailed
analysis was preferred over two-tailed for this particular study to adequately reflect the
presumption that treatment is expected to improve patient outcome. Multivariate Cox proportional
hazard models were computed to determine significant differences in recurrence rates and patterns
between the racial groups (6, 7). These statistical models were additionally modified to control for
variables of age, grade, and stage. The Kaplan Meier analysis was conducted in SAS 9.4 program
to estimate survival function for AA and EA with recurrent disease over a 10-year period. A logrank test was conducted to evaluate significance level for between-race differences in survival.
Finally, a t-test was used to compare mean time from first recorded recurrence event until death
among patients with distant recurrence.
2.6

Tables and Figures

Table 2.1 Broad-spectrum recurrence patterns among racially distinct populations.
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EA

AA

n

IR

n

IR

166

13.44

49

21.77

Local

48

3.89

12

5.33

Regional

27

2.19

10

4.44

Distant

84

6.8

27

12

Overall

p value; HR (95%
CI)
Unadjusted Model
0.002; 1.676 (1.210,
2.323)

p value; HR (95%
CI)
Adjusted Model
0.319; 1.192 (0.844,
1.683)

0.373; 1.349 (0.698,
2.606)
0.188; 1.701 (0.772,
3.747)
0.023; 1.699 (1.075,
2.684)

0.665; 0.857 (0.428,
1.718)
0.151; 1.749 (0.815,
3.752)
0.280; 1.299 (0.809,
2.085)

0.003; 1.758 (1.208,
2.557)
0.754; 1.139 (0.505,
2.573)

0.218; 1.287 (0.861,
1.923)
0.315; 0.652 (0.283,
1.503)

Recurrence site

Number of recurrences
Single

131

10.6

41

18.21

Multiple

35

2.83

8

3.55

Distant recurrence
0.012; 1.742 (1.130,
0.451; 1.220 (0.728,
2.684)
2.043)
0.492; 1.566 (0.436,
0.617; 0.672 (0.142,
Multiple sites 11
0.89
3
1.33
5.625)
3.187)
Abbreviation: IR, incidence rate (1000 person-years).
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.
Single site

73

5.91

24

10.66
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Table 2.2 Recurrence rates and patterns after receiving any form of treatment among racially
distinct populations.
EA
Treatment

AA

p value; HR (95%
CI)

p value; HR (95%
CI)

n

IR

n

IR

Unadjusted model

Adjusted model

Overall

85

22.73

23

26.66

0.466; 1.181 (0.755,
1.846)

0.807; 0.943 (0.587,
1.514)

Local

13

3.48

7

7.46

Regional

20

5.35

6

6.4

Distant

50

13.37

12

12.79

0.125; 2.053 (0.818,
5.151)
0.594; 1.284 (0.512,
3.219)
0.832; 0.934 (0.498,
1.751)

0.394; 1.548 (0.567,
4.226)
0.749; 1.169 (0.450,
3.041)
0.613; 0.840
(0.426,1.653)

0.373; 0.673 (0.281,
1.609)
0.026; 6.857 (1.256,
37.447)

0.409; 0.690 (0.286,
1.664)
0.024; 7.134 (1.295,
39.313)

Chemotherapy

Neoadjuvant chemotherapy
Overall

32

28.95

6

19.77

Local

2

1.81

4

13.18

Regional

7

6.33

0

0

N/A

N/A

Distant

23

20.81

2

6.59

0.112; 0.310 (0.073,
1.315)

0.136; 0.332 (0.078,
1.417)

0.405; 1.253 (0.737,
2.130)
0.865; 0.897 (0.255,
3.153)
0.333; 1.598 (0.619,
4.125)
0.664; 1.179 (0.561,
2.480)

0.891; 1.039 (0.603,
1.788)
0.500; 0.645 (0.181,
2.303)
0.843; 1.102 (0.421,
2.885)
0.100; 1.000 (0.463,
2.159)

0.112; 1.541 (0.906,
2.623)
0.676; 0.731 (0.169,
3.172)
0.369; 1.654 (0.552,
4.959)
0.123; 1.692 (0.868,
3.301)

0.949; 1.020 (0.568,
1.830)
0.290; 0.332 (0.043,
2.558)
0.580; 1.380 (0.442,
4.305)
0.482; 1.307 (0.619,
2.757)

0.041; 1.612 (1.021,
2.545)
0.450; 1.414 (0.575,
3.475)
0.532; 1.503 (0.419,
5.392)
0.065; 1.732 (0.967,
3.100)

0.986; 1.004 (0.609,
1.658)
0.689; 0.816 (0.302,
2.205)
0.736; 1.264 (0.324,
4.490)
0.810; 1.083 (0.568,
2.063)

Adjuvant chemotherapy
Overall

57

20.96

18

26.16

Local

12

4.41

3

4.36

Regional

15

5.52

6

8.72

Distant

30

11.03

9

13.08

Hormone therapy
Overall

69

10.45

17

15.94

Local

15

2.27

2

1.87

Regional

14

2.12

4

3.75

Distant

40

6.06

11

10.31

Radiation therapy
Overall

79

12.62

23

19.34

Local

22

3.52

6

5.04

Regional

10

1.6

3

2.52

Distant

47

7.51

15

12.61

Adjuvant radiation, hormone, and chemotherapy
0.013; 1.678 (1.115,
0.015; 1.699 (1.108,
2.524)
2.606)
0.279; 0.520 (0.159,
0.145; 0.405 (0.121,
Local
31
3.66
3
1.96
1.698)
1.364)
0.104; 2.043 (0.863,
0.558; 1.310 (0.531,
Regional
19
2.25
7
4.58
4.837)
3.230)
0.003; 2.164 (1.290,
0.101; 1.607 (0.912,
Distant
51
6.03
20
13.09
3.629)
2.833)
Abbreviation: IR, incidence rate (1000 person-years).
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.
Overall

101

11.94

30

19.63
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Table 2.3 Overall recurrence rates among racially distinct staged breast cancer patients.
EA

AA

n

IR

n

IR

Early (I-II)

130

11.14

39

19.08

Late (III-IV)

31

55.17

9

50.65

p value; HR (95%
CI)
Unadjusted Model

p value; HR (95%
CI)
Adjusted Model

0.002; 1.793 (1.252,
2.567)
0.857; 0.934 (0.445,
1.962)

0.131; 1.339 (0.917,
1.956)
0.637; 0.823 (0.366,
1.850)

0.001; 2.165 (1.348,
3.476)
0.447; 1.239 (0.713,
2.154)
0.902; 0.949 (0.410,
2.195)
0.822; 0.832 (0.167,
4.152)

0.031; 1.736 (1.052,
2.864)
0.823; 0.936 (0.523,
1.674)
0.590; 0.774 (0.306,
1.959)
0.967; 0.964 (0.168,
5.518)

N/A
<0.0001; 2.776
(1.781, 4.326)
0.504; 0.801 (0.419,
1.534)
0.215; 0.275 (0.035,
2.115)
0.680; 1.282 (0.394,
4.173)

N/A
0.003; 2.009 (1.263,
3.197)
0.215; 0.647 (0.325,
1.287)
0.161; 0.228 (0.029,
1.796)
0.983; 1.015 (0.241,
4.270)

0.005; 1.777 (1.186,
2.661)
0.201; 1.518 (0.801,
2.877)
0.744; 1.207 (0.391,
3.719)
0.742; 0.697 (0.081,
5.970)

0.211; 1.319 (0.854,
2.037)
0.828; 1.079 (0.545,
2.136)
0.965; 0.970 (0.258,
3.646)
0.974; 0.962 (0.095,
9.711)

Grouped stage

Individual Stage
I

70

7.76

23

15.84

II

60

22.67

16

27.02

III

25

48.01

7

45.01

IV

6

145.8

2

90.29

T0

2

130.83

0

N/A

T1

67

9.75

28

25.63

T2

54

28.48

11

22.3

T3

12

49.67

1

13.31

T4

9

106.73

4

121.36

N0

101

9.81

31

16.89

N1

44

27.05

12

39.2

N2

13

46.45

4

53.23

N3

5

55.06

1

43.27

TNM Staging
T

N

M
0.002; 1.682 (1.210,
0.288; 1.210 (0.851,
2.338)
1.721)
0.822; 0.832 (0.167,
0.967; 0.964 (0.168,
M1
6
145.8
2
90.29
4.152)
5.518)
Abbreviation: IR, incidence rate (1000 person-years).
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.
M0

157

12.82

46

20.8

45

Figure 2.1 NH demographics, breast clinico-pathological characteristics, and treatment
compared between patients with or without tumor recurrence.
(A) The numbers and percentages of patients displaying demographic and (B) breast clinicopathological characteristics were compared for patients with (n=225) and without recurrence
(n=6009). (C) The numbers and percentages of recurrence for both recurrence and non-recurrence
patients that underwent each form of conventional breast cancer treatment were also compared.
Significant differences were observed between recurrence and non-recurrence patients displaying
all clinico-pathological characteristics (p<0.0001), with the exception of nodal status (p=0.012).
Significant differences were also observed between recurrence and non-recurrence patients
receiving each form of treatment (p<0.0001), except for radiation therapy (p=0.065). A chi-square
statistical analysis was used to generate p-values in order to determine significant differences in
the proportion of patients exhibiting or not exhibiting recurrence in each category. For example,
regarding grade, a p value of 0.02 represents a significant difference for the distribution of
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recurrence and non-recurrence patients across all grades. Please refer to Supplementary Table 1
for details.

Figure 2.2 NH demographics, breast, clinico-pathological and treatment compared between
AA and EA with tumor recurrence.
(A) The demographic and (B) clinico-pathological characteristics of AA (n=49) and EA (n=166)
patients with recurrence in the NH cohort were compared. (C) Treatment administration was also
compared between AA and EA recurrent breast cancer patients. A chi-square statistical analysis
was used to generate p-values in order to determine significant differences in the proportion of AA
and EA patients exhibiting each characteristic and undergoing each form of treatment. No
statistical significant differences were observed. Please refer to Supplementary Table 2 for details.
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Figure 2.3 AA exhibit lower survival duration than EA among recurrent breast cancer
patients.
(A) Survival time from first recurrence episode until death was compared between AA and
EA breast cancer patients. Log-rank analysis was conducted to determine statistical
differences between the racial groups. AA exhibited a non-significant lower survival time
than EA (p=0.231). (B) The mean time (days) until death was compared between AA and
EA breast cancer patients displaying distant recurrence. AA died notably sooner than EA
patients (p=0.015). A t-test was performed to determine significant differences between the
racial groups.
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3

A NOVEL METRIC ILLUMINATES DISTINCTIONS IN CYCLING KINETICS
AMONG RACIALLY-DISTINCT BREAST TUMORS

3.1

Abstract
Breast tumors in African-Americans (AAs) exhibit higher recurrence rates and faster

kinetic progression to metastasis than those in European-Americans (EAs). This results in a stark
ethnic disparity in breast cancer outcomes. Hence, enhancing understanding of cell cycle kinetics
within breast tumors may illuminate motives underpinning racial differences in metastatic
propensities. Current clinico-pathological prognostic markers that evaluate cell proliferation in
breast carcinomas include mitotic index (MI) and Ki-67 index (KI). However, as autonomous
prognosticators measured on distinct scales, MI and KI lack the ability to convey the proportion
of mitotic cells among cycling cells, undermining their prognostic value. We performed a threecolor immunofluorescence staining on paraffin-embedded AA (n=81) and EA (n=124) breast
tumor tissue specimens from Northside Hospital to integrate mitotic cells and cycling cells into
the same measurement scale. Phospho-histone H3 was used as a mitotic marker and Ki-67 as a
cell proliferation marker. Stained samples were examined with confocal microscopy to determine
the proportion of mitotic cells to Ki-67 positive cycling cells to yield a Mitosis: Proliferation
(M:P ratio). We observed higher M:P ratio in AA compared to EA breast tumor tissue specimens
(p=0.002). We also observed higher M:P ratio in AA compared to grade-matched and stagematched EA patients. AA displayed significantly higher M:P ratio than EA among early stage
breast tumors (p=0.015). Furthermore, among the clinico-pathological parameters, age, race,
grade, stage, and receptor status, multivariate analysis revealed that race was the only variable
that exhibited a significant confounding influence on M:P ratio (p=0.042). Conclusion: A
higher M:P Ratio likely reflects an increased risk of developing intratumoral heterogeneity and
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producing aggressive clones; thus, a higher M:P ratio may provide an explanation for the
observed greater metastatic propensity exhibited in AA compared to EA patients. Thus, our
novel metric provides new insights into the KI-MI relationship in tumors, exposes previously
unrecognized differences in cycling kinetics among early stage AA and EA breast tumors, and
proffers additional metastatic risk predictive information currently unavailable in the clinic.
3.2

Introduction
Despite the vast array of cliniopathological prognostic markers available in clinics today,

African Americans (AAs) exhibit a 39% higher mortality rate than EA breast cancer patients(4).
This stark disparity is explicated by increased tumor metastasis and tumor infiltration among AA
breast cancer patients (Yancy, et al., 2007). These circumstances underscore the urgent need for
deeper insight into the biological properties of early stage and low-grade breast tumors. Faster
tumor kinetic progression underlie the more aggressive behavior exhibited by AA compared to
EA breast tumors (Yancy, et al., 2007). Thus, procurement of improved perceptions of cell cycle
kinetics may be beneficial in discerning motives for enhanced metastatic risk in AA breast
tumors. Previous studies have reported that early stage tumors demonstrate high mitotic turnover
and this surge in mitotic events promotes an increase in erroneous cell divisions (Laroye and
Minkin, 1991). Consequently, genomic integrity is compromised, fostering karyotypic diversity
and spawning the emergence of aggressive clones harboring superior metastatic proficiency
(Hanahan and Weinberg, et al., 2011). Thus, advanced insight into cell proliferation may be
critical to disentangling the enigma of varying metastatic propensities among racially-distinct
breast tumors. With a present lack of markers that can adequately assess risk for tumor
metastasis, further examination of cell cycle mechanics may generate a promising new direction
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in enhancing efficacy of existing prognostic markers and illuminate differences among racially
distinct breast tumors.
Existing cliniopathological prognosticators that elucidate cell cycle dynamics in breast
carcinomas include mitotic index (MI) and Ki-67 proliferation index (KI). MI, a component of
histological grade, signifies actively dividing cells or cells in M phase, thus capturing the
frequency of mitotic occurrences within a tumor (Reyal, et al., 2012). KI, an independent
prognostic marker, ascertains cells merely in the cell cycle (G1, S, G2, and M phases), thus
capturing a holistic view of cell proliferation within lesions (Reyal, et al., 2012). Both indices
proffer valuable information in stratifying patients into high-risk and low-risk groups for tumor
metastasis and fatal outcomes. A high MI has been linked to an increased risk of death and
recurrence irrespective of tumor size and lymph node metastasis and high Ki-67 has been
associated with worse disease-free survival (DFS) and overall survival (OS) in breast cancer(85,
141-144). Illumination of mitotic frequency within early stage breast tumors may reflect the
predisposition of incipient breast lesions acquiring aggressive traits, and thus offers vital
metastatic risk-predictive information. Evaluation of cell proliferation within a tumor may
expose inclinations of a tumor to spread and infiltrate distant sites within a patient. A high KI
and MI among early stage breast tumors has been reported to be synonymous with a poor patient
prognosis (Azambuja, et al., 2007, Laroye and Minkin, 1991, Medri, et al., 2003). Additionally,
clinical studies have observed notably higher MI and KI-67 expression in AA in comparison to
EA primary breast tumors (Porter, et al., 2004). This knowledge may rationalize the considerably
higher aggressive behavior exhibited by AA breast tumors than EA breast tumors, thus MI and
KI serve as useful metastatic risk-predictive markers.
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Despite the prognostic advantages of these independent parameters and the valuable role
they play in metastatic risk assessment, MI and KI possess unsettling limitations that spark
reservations in their ability to accurately assess metastatic dispositions of breast tumors. With
both indices functioning autonomously, KI and MI portray an incomplete picture of the precise
relationship of mitotic cells amongst proliferative cells by proffering information on distinct
aspects of cell cycle progression within a tumor. KI is quantified as a percentage of nuclear Ki67 stained invasive carcinoma cells observed in low-power microscopic fields (Reyal, et al.,
2012). In contrast, MI is quantified as the number of mitotic cells per 10 high-power microscopic
fields within the periphery of the tumor (Elston and Ellis, et al, 1991, Haapasalo, et al., 1989,
Reyal, et al., 2012). The substantial variations in acquirement of these indices and the vastly
different fields in which they are perceived deems it difficult to decipher the frequency of
dividing cells among proliferating cells within breast tumors. This lack of depth poses a limited
view of cell cycle dynamics within lesions and thus restricts the predictive power of these
prognosticators for metastatic risk. Furthermore, discordancy between MI and KI scores has been
observed in some studies. Fluctuations in cell cycle duration during M-phase can influence the
number of mitoses visualized at different times within the same tumor. Hence, shorter cell cycle
durations or a large fraction of growing cells may contribute to a faster tumor-doubling time
thus, the correlation between the number of mitotic events and proliferation rate may be not be
exactly linear(145). Lee and colleagues recently observed a poor correlation between MIB-1
(antibody against Ki-67 antigen) and mitotic and phosphorylated histone H3 (pHH3) scores
among breast adenocarcinomas after adjusting for intratumoral heterogeneity(146). Factors such
as differences in the proportion of time that a cell spends between the mitotic phase and
interphase as well as variability in cell cycle time among different tissue and tumor types have
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been suspected to underlie the discordance(146) Rossi and colleagues also observed a lack of
correlation between MI and KI among breast cancer patients(147). In their study, patients with
discrepancies between MI and KI exhibited a worse prognosis than patients with low MI and KI
and a better prognosis than patients with high MI and KI. Thus, these findings stress the need for
joint analyzation of these markers in order to improve risk-prognostication.

In addition to this narrow understanding of the MI and KI relationship in tumors, there
exist many glitches in MI and KI as independent prognostic markers and illuminators of cell
proliferation. The accuracy of quantifying mitotic figures within a patient tumor sample is
consistently jeopardized by extraneous factors present within the tumor microenvironment such
as, apoptotic bodies and piknotic nuclei, that create an impediment in distinguishing mitotic
nuclei (Veras, et al., 2009). Delays in fixation of tumor tissue samples can attribute to a
diminution in accuracy and reproducibility of mitotic counts (Cross, et al., 1990, Diest, et al.,
2004). Furthermore, mitotic counts are often miscalculated owing to exclusion of prophase cells
during acquirement of mitotic figures (Elston and Ellis, et al, 1991). Despite Ki-67 proliferation
expression as an acceptable measure of breast cancer outcomes, uncertainties remain in its
competence as an efficacious prognostic tool in the clinical arena. Ki-67 proliferation index lacks
dependability with poorly defined and established cut-offs that can effectively stratify breast
cancer patients into high and low risk groups for tumor proliferation, undermining its strength in
clinical prognostication (Reyal, et al., 2012, Dowsett, et al., 2011). Moreover, there remains
ample room for improvement in the acquisition of Ki-67 index owing to discrepancies in
interpretation of Ki-67 immunohistochemical staining (Dowsett, et al., 2011). These
shortcomings threaten the ability of the two indices to precisely assess cell cycle progression
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within breast tumors, thus impeding accurate evaluation of metastatic risk in breast cancer
patients. Hence, this imprecision presents an obstacle in comprehending inconsistencies in
metastatic rate among AA and EA breast tumors.
We have developed a novel metric that rationalizes the inconsistencies and limitations of
MI and KI as autonomous prognosticators and the lack of depth these indices convey in
elucidating cell cycle mechanics. The metric cleverly integrates MI and KI onto the same
measurement scale to ascertain the frequency of mitotic cells among Ki-67 positive cycling cells,
in which we have termed mitosis to proliferation (M:P) ratio. Hence, this novel metric allows
clinicians to conveniently visualize and assess proliferation and mitotic counts in the same
microscopic field simultaneously, increasing efficiency and rapidness of evaluating cell cycle
kinetics among breast cancer patients. Thus, combining their measurement scales may
significantly strengthen the correlation between MI and KI in the clinic. Furthermore, this
improved index derives an opportunity to deduce the relationship between mitotic cells and
proliferating cells within low grade breast tumors, providing an additional layer of predictive
information that was previously unavailable. Thus, this clinically translatable prognostic tool
may infer enhanced interpretations of cell cycle kinetics within early stage breast tumors and
augment clinical inferences of metastatic predispositions of early stage breast lesions. This
heightened comprehension of metastatic inclinations of incipient breast tumors may improve
understanding of the perplexing dissimilar metastatic proclivities among AA and EA breast
tumors. We analyzed differences in M:P ratio between AA and EA breast tumor tissue
specimens from Northside Hospital (NH) in Atlanta, GA and patient-derived TNBC cell lines to
evaluate the prognostic ability of M:P ratio among racially-distinct breast tumors. We postulate
that M:P ratio may reveal notable variations in mitotic tendencies within AA and EA breast
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tumors and consequently serve as a tool to enhance profiling of metastatic risk among racially
distinct breast tumors. This enhanced scope of understanding of cell cycle kinetics within breast
tumors, may aid in unraveling the mystery still puzzling pathologists today that of the
substantially higher migratory potential harbored by AA breast tumors in comparison to EA
breast tumors.
3.3

Results

3.3.1 Demographic and clinico-pathological variables among racially-distinct breast cancer
patients
Descriptive characteristics of the NH patient cohort are provided in Table 1. We
examined differences in clinico-pathological characteristics between AA (n=81) and EA (n=124)
breast cancer patients observed at NH. We observed significant differences in nuclear grade
between the races as 53.1% of AA and 37.1% of EA patients presented as grade 2 and 23.5% of
AA and 42% of EA patients as grade 3 (p=0.02). We also observed significant differences in
mitotic index in which 45.7% of AA and 31.45% of EA patients presented with a score of 2 and
8.6% of AA and 36.3% of EA patients with a score of 3 (p<0.0001). Furthermore, we observed
weakly significant differences in stage in which 24.7% of AAs presented at late stage (III-IV)
compared to 21% of EAs (p=0.09).
3.3.2 A novel metric may predict patient survival
We derived a novel metric that integrates MI and KI onto the same measurement scale to
enhance our understanding of cycling kinetics and mitotic propensity among breast tumors. In
order to combine the two indices into the same field, we performed a 3 color
immunofluorescence staining on formalin-fixed paraffin-embedded (FFPE) AA and EA breast
tumor tissue sections from Northside Hospital (NH) in Atlanta, GA as shown in Figure 1A.
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Histone H3 is a nuclear core histone on DNA chromatin and its serine residues are
phosphorylated during mitosis to facilitate chromosome condensation hence, metaphase
chromosomes are heavily phosphorylated as opposed to interphase chromosomes(148, 149).
Thus, the antibody against pHH3, has been show to strongly correlate with mitotic counts and
mitotic activity index (MAI)(146, 150). Recently, pHH3 was shown to have significantly better
reproducibility, predictability and better represent proliferation than Ki-67 and has better
sensitivity for detecting mitosis than MAI among invasive breast carcinomas(151). Thus, pHH3
was used as a mitotic marker and Ki-67 as a proliferation marker. The nuclei were stained with
propidium iodide. The stained samples were imaged using immunofluorescence confocal
microscopy and approximately 10-12 fields were captured per specimen. The number of mitotic
and proliferative cells were quantitated and integrated into our proposed mitosis: proliferation
(M:P) ratio formula, which is the proportion of mitotic cells per field to the total number of Ki67 positive cycling cells in the same field (Figure 1B).
3.3.3 M:P ratio differentiates racially-distinct breast tumors
M:P ratios were computed in AA (n=81) and EA (n=124) breast cancer patient specimens
and compared between the racial groups . Interestingly, we observed that M:P ratio was
significantly higher among AA compared to EA breast cancer patients (p=0.002) (Figure 2A).
We also observed a trend of higher M:P ratio in AA compared to nuclear grade-matched EA
breast cancer patients (Figure 2B). M:P ratio was weakly higher in AA compared to EA among
grade 1 (p=0.1), grade 2 (p=0.08) and grade 3 (p=0.1) breast cancer patients. Furthermore, we
observed significantly higher M:P ratio in AA compared to EA among early stage (I-IIa) breast
cancer patients (p=0.015) but not among late stage (IIb-IV) patients (p=0.2) (Figure 2C). We
performed a multivariate linear regression analysis to determine if demographic and clinico-
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pathological variables such as age, race, nuclear grade, stage, and receptor status have a
confounding influence on M:P ratio. Interestingly, we observed that race was the only covariate
that exhibited a significant confounding influence on M:P ratio (p=0.042) (Table 2).
3.4

Discussion
The vast differences in tumor kinetic progression between breast cancer patients of

African and European ancestry continue to challenge clinicians. Evaluating risk of metastatic
progression among a heterogeneous breast cancer patient population remains imprecise with
current clinico-pathological parameters measuring cell proliferation unable to provide an
accurate assessment of the mitotic propensity of breast tumors. Our study proposes a novel
metric termed M:P ratio that is able to glean an additional layer of risk-predictive information by
capturing the frequency of actively dividing cells among the proliferative cell population, which
has not yet been achieved in the clinic today. Our innovative metric combines the more widely
accepted marker of mitosis, pHH3, and the most robust marker of proliferation today, Ki-67,
onto the same uniform measurement scale to discern the cycling kinetics of breast tumors. To
investigate the clinical utility of our novel metric among breast cancer patients of varying kinetic
progression, we analyzed differences in M:P ratio between AA and EA breast cancer patients as
they posit the ideal model system to assess cycling kinetics between aggressive and less
aggressive breast tumors.
We observed that M:P ratio differentiates racially-distinct breast cancer patients and AA
and EA TNBC patient-derived cell lines with a trend of higher M:P ratio among patients of
African ancestry. M:P ratio was significantly higher in AA compared to EA among early-stage
breast cancer patients suggesting that AAs may be exhibiting faster cycling kinetics during the
early stages of the disease, which may be predisposing them to a poorer patient prognosis.
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Interestingly, our multivariate regression analyses revealed that race was the only variable that
exhibited a significant confounding influence on M:P ratio. Furthermore, M:P ratio may be able
to predict a poorer patient prognosis among early-stage breast cancer patients as we found that
M:P ratio negatively correlated with a poorer overall survival among low grade patients. Thus,
M:P ratio may be able to serve as a risk-prognostic marker in the clinic and stratify early-stage
patients into high- and low- risk groups to guide clinical-decision making and optimize treatment
paths, especially for patients of African ancestry.
Hence, our study proposes a hitherto untapped parameter of cycling kinetics that may
transform clinical oncology by refining measurement of cell proliferation in the clinic. MI and
KI serve as conventional clinical measures of cell proliferation in the clinic today but present
with many shortcomings prompting the urgent need for more robust clinically-applicable
parameters that reconcile their weaknesses. M:P ratio serves as an innovative metric that
successfully rationalizes the limitations of MI and KI as independent parameters and provides an
additional layer of valuable risk-prognostic information currently unavailable in the clinic today.
This novel metric is clinically-applicable as it can be measured through conventional
immunohistochemical staining methods. Moreover, the unique index proffers clinicians a more
efficient and less time consuming method to successfully assess cell proliferation among breast
cancer patients by allowing visibility of mitotic and proliferating cell counts in one microscopic
field. Hence, this novel methodology of employing one measurement scale may strengthen the
correlation between mitotic and proliferating cell counts, reduce inter- and intra- observer
variability and refine risk-prognostication. As mentioned earlier, recent studies have suggested
that pHH3 marker is a more accurate assessment of mitosis in tumors compared to mitotic
activity index and is more reproducible than Ki-67 alone thus, our novel index may glean a more
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accurate assessment of the actively dividing cell population(151, 152). Furthermore, our study
utilized the ideal model to investigate differences in cycling kinetics between aggressive and less
aggressive breast tumors by examining disparities in M:P ratio between AA and EA breast
cancer patients. Thus, our investigation further rationalizes the poorer clinical outcomes
observed among AA patients and uncovers a novel risk-predictive metric that may enhance
prognostication among patients of varying tumor kinetic progression. However, validation of the
prognostic and predictive power of M:P ratio among additional cohorts will be necessary to
implementing the metric into the clinic as standard routine assessment of cycling kinetics among
breast cancer patients.
3.5

Methods

3.5.1 Breast tumor tissue specimens
Clinical data on breast cancer patients treated at Northside Hospital (NH) from 20052015 in Atlanta, Georgia was extensively mined from pathology reports. A plethora of breast
clinico-pathological information and outcome data were extracted from pathology reports on
10,504 patients evaluated at NH. Demographic characteristics documented include race, gender,
and age. Breast tumor clinico-pathological variables extracted include nuclear grade, mitotic
score, stage, Nottingham grade, and Ki-67 percentage. The outcome data acquired include OS.
Archival formalin-fixed, paraffin-embedded tissue specimens were provided by NH to
accompany clinical patient data. Research Collaborative Agreements were instituted with NH
who consented to supplementing our mined clinical patient data with tumor tissue specimens.
Among these samples, 205 AA and EA breast cancer patient samples were isolated to conduct
our study
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3.5.2 Immunofluorescence tissue staining and confocal microscopy
Formalin-fixed, paraffin-embedded tissue sections were incubated at 60°C-70°C for 2h,
followed by 2 xylene washes (5 min each) and sequential ethanol washes (100%, 95%, 70% and
50%). Antigen retrieval was carried out in citric acid buffer (pH 6.0) at 98°C for 20 min. Slides
were allowed to cool down and blocked in 5% BSA/PBS (30 min). Tissue sections were then
incubated for 1h with a cocktail of rat anti-human pHH3 antibody (1:500) (Abcam, Cambridge,
UK) and mouse anti-human DM1A (α-tubulin, 1:1000) (Sigma-Aldrich, MO, USA) followed by
donkey anti-rat Alexa 488 (1:2000) and goat anti-mouse Cy5 (1:2000) (Invitrogen, Grand Island,
NY) secondary antibody incubation for 1h at room temperature. Slides were then washed 3 times
in PBS followed by 1h incubation with rabbit anti-human Ki67 (1:1000) (Abcam, Cambridge, UK)
and goat anti-rabbit Alexa 405 (Invitrogen, 1:2000) secondary antibody incubation for 1h at room
temperature. Slides were again washed 3 times in PBS followed by incubation with Propidium
Iodide (0.1ug/ml) for 15 min at room temperature and washing in PBS. Finally, coverslips were
mounted on the slides using Prolong Antifade mounting medium (Invitrogen, Grand Island, NY).
Zeiss LSM 700 confocal microscope was used to capture immunofluorescence images at 63X
objective magnification. Approximately, 10-12 randomly selected fields were captured per sample.
3.5.3 Cell lines
All cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-236, HCC1143, HCC1937,
HCC1187, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) were procured from
American Type Cell Culture (ATCC) and cultured according to ATCC recommendations.
3.5.4 Cell lysates preparation and immunoblotting
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis
buffer (Cell Signaling) as previously described(153). Protein concentration in cell lysates was
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determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved
in 10% SDS-PAGE gels as previously described(154). SuperSignal West Pico Chemiluminescent
Substrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin,
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary
antibodies were obtained from Abcam. Protein expression was semi-quantitated using
densitometry with the ImageJ Software and normalized to β-actin.
3.5.5 Cell viability assay
All cell lines were treated with gefitinib (LC Laboratories) and carboplatin (Abcam).
Sensitivities of cell lines to these drugs were assessed by performing MTT assay as previously
described(155). IC50 values were computed using GraphPad Prism Software Inc.
3.5.6 Immunocytochemistry staining and FACS
AA and EA TNBC cell lines were seeded into triplicates and fixed in 70% ethanol once
cells reached ~80% confluence. Cells were blocked with 2% bovine serum albumin (BSA) in 1x
PBS and 0.05% Triton X-100 at room temperature for 1 h. Cells were then incubated in the
antibodies anti-Ki-67 PE (BioLegend) and anti-pHH3 conjugated to AlexaFluor488 (Sigma)
diluted in blocking buffer at 1:1000 for 45min in 37°C. Antibodies were rinsed from cells with
1x PBS 5 times and then cells were incubated in 7-Aminoactinomycin D (7-AAD) (BioLegend)
(0.25µg/ml) for 10 min at room temperature to stain DNA. The stained cells were subjected to
FACS to isolate the populations of pHH3 and Ki-67 positively stained cells for each cell line.
The single cell population was first gated for the total number of 7-AAD positive cells. The
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population of 7-AAD positive cells was then gated for the number of cells positive for Ki-67 and
the percentage of cells positive for Ki-67 was determined. The cells positive for Ki-67 were then
gated for cells positive for pHH3 and the percentage of cells positive for pHH3 was determined.
FlowJo V10 software was used to analyze the data. Dot plots of side scatter area (SSC-A) were
plotted.
3.5.7 Statistical Analyses
Chi-square tests were performed to analyze differences in breast clinico-pathological
variables, biomarkers, and treatment information between AA and EA breast cancer patients. A
one-tailed student t-test was performed to analyze significant differences in M:P ratios, protein
expression, and drug sensitivities between 2 groups. A multivariate regression analysis was
performed to evaluate potential confounding influences of demographic and clinico-pathological
variables on M:P ratio. A linear regression plot was constructed to determine association of M:P
ratio with overall survival (OS). SAS 9.4 program was used to perform hierarchical clustering to
stratify TNBC cell lines into high and low M:P ratio subgroups by using Ward’s method to
identify an ideal threshold value of 2.02. Results with p<0.05 were considered statistically
significant.
3.6

Tables and Figures
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Table 3.1 Clinico-pathological characteristics of AA and EA breast cancer patients
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Table 3.2 Multivariate regression analysis of demographic and clinico-pathological
variables on M:P ratio

Figure 3.1 Quantitation of M:P ratio among breast tumors. Confocal micrographs of positive
staining for pHH3 (mitotic marker), Ki-67 (proliferation marker) and propodium iodide (PI) in
breast tumor tissue specimens in same field from NH (A). M:P ratio equation integrating the
number of mitotic and proliferating cells in same field to yield the proportion of mitotic cells
among the proliferating cell population (B).
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Figure 3.2 Comparison of M:P ratio among racially-distinct breast tumors. Comparison of
M:P ratio among all (A), grade-matched (B) and stage-matched (C) AA and EA breast tumor
tissue specimens. *p<0.05. **p<0.01.
3.7
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4

CENTROSOME AMPLIFICATION IN BREAST CANCER: A BIOMARKER OF
AGGRESSIVE DISEASE FEATURES AND RACIAL DISPARITIES

4.1

Abstract
Centrosome amplification (CA), a key property of malignant tumor cells, has emerged as

a marker of breast cancer (BC) aggressiveness that is highly associated with triple-negative BC
(TNBC). TNBC is a BC subtype that disproportionately afflicts African American (AA) women.
However, the association of CA with TNBC molecular subtypes and self-reported race, the value
of CA as an independent risk-predictive biomarker in early-stage TNBC, and the mechanisms by
which CA may drive aggressive TNBC behavior remains under-studied. Using confocal
microscopy, we quantitatively compared numerical CA profiles in a panel of race-annotated nonTNBC and TNBC cell lines of different subtypes based on AR expression and TNBC molecular
subtypes. We then compared race-annotated patient non-TNBCs and TNBCs of different AR
expression levels and molecular subtypes in terms of their CA20 - an established signature of 20
genes implicated in CA - and evaluated the prognostic value of CA20 in multivariate Cox models
of disease-free survival (DFS) using public gene expression data. To discern mechanisms by which
CA may fuel aggressive TNBC behavior, we induced CA in TNBC cell lines with aphidicolin and
assessed expression of protein biomarkers of BC aggressiveness. Numerical CA was higher in
TNBC than non-TNBC in vitro analyses and CA20 was higher among AA compared to EA BCs.
Furthermore, high CA20 as a continuous variable predicted worse DFS in early-stage TNBC
patients in adjusted analysis (p=0.03, hazard ratio=1.20). Induction of CA in TNBC cell lines
upregulated expression of markers of angiogenesis and epithelial-mesenchymal transition (EMT)
suggesting that CA may promote TNBC aggressiveness through these mechanisms. Collectively,
these findings support an association between numerical CA and more aggressive TNBC features,
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poorer DFS among early-stage BC patients and AA race. Our study also reveals novel mechanisms
by which CA may promote aggressive TNBC behavior. Hence, our work suggests CA as a riskpredictive biomarker for TNBC patients that may also represent a viable therapeutic target.
4.2

Introduction
TNBC accounts for approximately 10-30% of invasive BC cases in the U.S. It is a unique

BC subtype that lacks expression of the estrogen and progesterone receptors and amplification of
the human epidermal growth factor receptor 2 (HER2/neu). The absence of these targets
eliminates conventional endocrine therapy and HER2-targeted systemic treatments as therapeutic
options and traditional chemotherapy is unable to eradicate most TNBCs. The disease is
characterized by an aggressive clinical course, evidenced by its greater metastatic propensity,
more unfavorable clinico-pathological characteristics upon presentation, and higher inter-patient
and intratumor heterogeneity compared with non-TNBCs [1-3]. The disease is significantly more
prevalent among premenopausal women and predominantly afflicts women of African ancestry,
who experience poorer clinical outcomes than EA TNBCs. Currently, no reliable biomarkers or
effective targeted treatments exist for TNBC patients; thus, AA TNBC patients often suffer
abysmal outcomes. Novel biomarkers to risk-stratify TNBC patients, ideally ones that also
represent possible therapeutic targets, are urgently needed to identify patients requiring more
aggressive treatment regimens so that mortality rates can be reduced in these patients. CA is a
hallmark of BC that causes ITH by fostering erroneous mitoses, which drive genetic instability
and the generation of diverse karyotypes [4, 5]. It is well established that CA is associated with
BC progression and imparts aggressive phenotypes, thus representing a possible anti-cancer
target [6-11]. Furthermore, TNBCs harbor greater incidence and severity of CA than non-TNBCs
[12, 13], although the potential prognostic and therapeutic value of CA in TNBC is unclear. The
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goal of the present study was to shed light on the potential of CA as a biomarker of aggressive
TNBC features and poor DFS, and mechanisms by which CA may promote TNBC progression,
which could be exploited therapeutically.
4.3

Results

4.3.1 TNBC cell lines exhibit higher numerical CA than non-TNBC cell lines
Our group recently uncovered more extensive numerical CA and more severe structural
centrosomal aberrations in several TNBC compared to non-TNBC cell lines [12]. In this study, we
quantitated numerical centrosomal profiles in a more extensive panel of established cell lines
derived from TNBCs (n=10) and non-TNBCs (n=2). We found a non-significant trend towards
higher numerical CA in TNBC compared with non-TNBC cell lines (p=0.10) (Figures 1A and
B). We also assessed the severity of numerical CA in each cell line (i.e., the percentage of cells
with 3, 4, or 5+ centrosomes) and discovered that TNBC cell lines exhibit a non-significant trend
towards more severe numerical CA, with a higher percentage of cells with 4 centrosomes
(p=0.056) and ≥5 centrosomes (p=0.07) (Figure 1C). We immunoblotted TNBC and non-TNBC
cell lines for expression of centrosomal proteins and CA markers. We observed significantly
higher expression of γ-tubulin (p=0.049) and Cyclin-E (p=0.034) in TNBC compared to nonTNBC cell lines (Figure 1D). We also observed a trend of higher pericentrin expression in TNBC
compared to non-TNBC cell lines (p=0.08). Furthermore, we assessed whether there were
differences in expression of KIFC1, a minus-end directed microtubule binding protein that
participates in centrosome clustering [23], between TNBC and non-TNBC cell lines. Interestingly,
we observed a trend of higher KIFC1 expression in TNBC compared to non-TNBC cell lines
(p=0.1).
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4.3.2 Aggressive TNBC subtypes exhibit higher numerical CA than less aggressive TNBC
subtypes
Accumulating evidence has exposed the vastly heterogeneous landscape of TNBC.
Lehmann and colleagues uncovered six distinct intrinsic molecular subtypes in the disease based
on shared gene ontologies (“TNBCtype”), including basal-like 1 (BL1), basal-like 2 (BL2),
mesenchymal stem cell-like (MSL), mesenchymal (M), immunomodulatory (IM), and luminal
androgen receptor (LAR) subtypes [24]. The IM and MSL subtypes in patient TNBCs may reflect
gene expression profiles of substantial infiltrating lymphocytes and stromal cells, respectively
[19], which led to refinement of the classification scheme (“TNBCtype-4”) [19]. We compared
centrosomal profiles between TNBC cell lines of different molecular subtypes (representative
micrographs in Figure 2A). Interestingly, we observed that BL1 and MSL TNBC cell lines
exhibited higher numerical CA than BL2, M, and LAR TNBC cell lines, with the exception of
MDA-MB-438 cell line (p=0.016) (Figure 2B). BL1 and MSL TNBC cell lines also exhibited
more severe numerical CA than BL2, MSL, M, and LAR TNBC cell lines, specifically, exhibiting
a greater percentage of cells with ≥5 centrosomes (p=0.01) (Figure 2C). We also found that BL1
TNBC cell lines exhibited significantly higher numerical CA than BL2, MSL, M and LAR TNBC
cell lines, with the exception of MDA-MB-468 cell line (p=0.036) (Figure 2D) and BL1 TNBC
cell lines exhibited a trend towards a greater proportion of cells with 4 or ≥5 centrosomes (p=0.089
and 0.10, respectively) (Figure 2E). Furthermore, western blot analyses revealed a weakly
significant trend of higher g-tubulin expression in BL1 and MSL compared to BL1, MSL, M, LAR,
and IM TNBC cell lines (p=0.059) (Figure 2F) and significantly higher g-tubulin expression in
BL1 compared to BL2, MSL, M, LAR, and IM TNBC cell lines (p=0.015) (Figure 2G). These
results suggest that CA may be more extensive and severe in BL1 and/or MSL TNBCs.
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4.3.3 Racial disparities in numerical CA exist between AA and EA TNBC cell lines
Women of African ancestry are 2-3 times more likely to develop TNBC than women of
European ancestry [1]. Distinctions in inherent tumor biology between the races have been
suggested to underlie this disparate burden; however, there is a limited understanding of the
biological factors contributing to the racial disparity in TNBC. Thus, we were interested to see if
disparities in centrosomal profiles exist between AA and EA TNBCs (representative
micrographs in Figure 3A). Interestingly, we found that EA TNBC cell lines exhibited a greater
percentage of cells with numerical CA than AA TNBC cell lines (p=0.01) (Figure 3B).
Furthermore, EA TNBC cell lines exhibited more severe CA, with a greater percentage of cells
with 4 (p=0.007) or ≥5 (p=0.029) centrosomes than AA TNBC cell lines (Figure 3C). However,
immunoblotting for centrosome structural proteins and markers of CA revealed that AA TNBC
cell lines exhibited higher expression of pericentrin (p=0.027) and Cyclin-E (p=0.024) (Figure
3D). Furthermore, we assessed whether there were differences in expression of KIFC1 between
AA and EA TNBC cell lines. Interestingly, we found higher expression of this marker in AA
than EA TNBC cell lines (p=0.05) (Figure 3D). This finding suggests that centrosome clustering
may be more robust in AA than EA TNBC cell lines cells. Thus, we investigated the sensitivity
of AA and EA TNBC cell lines to the centrosome declustering agent, griseofulvin (Figure 4).
We observed that AA TNBC cell lines exhibited significantly lower IC50 values to griseofulvin
than EA TNBC cell lines (79.5 vs. 105.7) (p=0.04), suggesting greater sensitivity to centrosome
declustering agents among AA TNBCs and corroborating our findings of higher KIFC1
expression and increased centrosome clustering among AA compared to EA TNBC cell lines.
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4.3.4 CA20 is higher in more aggressive BC subtypes
Previoulsy, our group developed a transcriptional signature that may reflect CA and
correlates with chromosomal instability and worse prognosis in multivariable models, referred to
as the CA20 score, which is the sum of the normalized expression of 20 genes whose dysregulation
causes CA [1]. To confirm our in vitro findings, we used publicly available microarray data to
compute CA20 scores and determine differences between AA and EA BCs, TNBCs and nonTNBCs, and among TNBC subtypes. TCGA Breast dataset includes annotation about the variables
of interest; thus, we queried it using Oncomine [2] to obtain normalized expression values for the
CA20 genes, which were summed as previously described to derive CA20 scores [1]. CA20 was
higher for AAs than EAs among all BC patients (p=0.008) (Figure 5A). However, AAs are
predisposed to TNBC, which exhibits higher CA20 than non-TNBC [2]. CA20 is also associated
with more aggressive disease features, such as higher tumor grade [18]. As a result, TNBC status
and other aggressive disease features like TNBC status, higher tumor stage (for both TNBCs and
non-TNBCs), HER2+ status (for non-TNBCs), low AR expression (for both TNBCs and nonTNBCs), and TNBC molecular subtype (for TNBCs) could confound analyses. Due to nonhomogeneity of variances between BC subtypes, we only explored differences in CA20 within BC
subtypes. We found a non-significant trend towards different mean CA20 by AJCC stage within
non-TNBCs, which exhibited higher mean CA20 in higher-stage cases (p=0.095), and within
TNBCs, which exhibited higher CA20 in lower-stage cases (p=0.063) (Figure 5Bi,ii). CA20 was
also higher in HER2+ than HER2- non-TNBCs (p=0.004) (Figure 5C). Thus, amongst nonTNBCs, CA20 is higher in more aggressive subtypes.
We were interested to compare mean CA20 between racially distinct non-TNBCs and
TNBCs after adjusting for potentially confounding factors. As CA20 was found to differ
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significantly based on HER2 and AR statuses among non-TNBCs, and a non-significant trend was
also noted for AJCC stage, we included these factors along with self-reported race in a generalized
linear model to predict CA20. Tests of between-subjects effects revealed that AJCC stage was not
a significant predictor (p=0.37), whereas all other factors exhibited p<0.10. Considering this
finding and that CA20 did not significantly differ by stage in unadjusted models, were removed
stage from the model and refit it. Among non-TNBCs, we found that CA20 was higher in AA than
EA tumors (p=0.054, adjusted mean=26.41 vs. 22.65) and HER2+ than HER2- tumors (p=0.001,
adjusted mean=26.68 vs. 22.37) (Table 1). Although the difference in the adjusted mean CA20 by
race did not reach the threshold for significance, the observed power was low (0.49), likely due to
the small number of AA TNBCs (n=11). By contrast, the observed powers for other factors and
the corrected model were ≥0.89. In addition, full-factorial models did not reveal any interactions
among factors (p>0.20 for all). Thus, among non-TNBCs, CA may be higher in breast tumors from
AA patients and in the setting of HER2 positivity. When these factors are considered, CA20 does
not differ by AJCC stage.
We also fit generalized linear models to predict CA20 among TNBCs adjusting for race
and stage. Among TNBCs, AJCC stage did not significantly predict CA20 although a nonsignificant trend was noted (p=0.075, with the trend in the same direction as noted in unadjusted
analyses). By contrast, CA20 did not differ by race according in the adjusted model (p=0.92), but
the analysis was severely underpowered to detect a racial difference (observed power=0.051).
Thus, we sought a different dataset to explore racial differences, the Yale TNBC dataset. The
CA20 distribution was approximately normal for EA patients, whereas it was non-normal for AA
patients (p=0.013), exhibiting two distinct peaks, which we suspected existed due to some
underlying grouping, such as lymph node status. Indeed, a trend towards different nodal status by
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race was found (p=0.092), with AAs exhibiting a higher frequency of node-positive disease. In
addition, CA20 was higher in node-positive than node-negative TNBCs from AA patients
(p=0.016) (Figure 5D), suggesting it could be a confounding factor in analyses of racial
differences. Because only 2 node-positive EA TNBCs were present in the dataset, we decided to
focus exclusively on node-negative disease in exploring racial differences in CA20 using this
dataset. Among node-negative TNBCs, we found that CA20 was higher in EA than AA cases
(p=0.034, mean rank=22.00 vs. 14.63) (Figure 5E). Thus, in the case of node-negativity, EA
TNBCs may exhibit higher CA20 than AA TNBCs, which supports our in vitro results of higher
numerical CA in EA compared with AA among TNBC cell lines.
Unlike the TCGA data, the Yale data showed that mean CA20 may differ by TNBCType6
(p<10-6). Specifically, the MSL and LAR subtypes exhibited lower CA20 than the other TNBC
subtypes (p<0.05 for all per Tukey’s HSD post-hoc testing, Figure 5F; Table 2). These results
support our in vitro finding of higher numerical CA among BL1 TNBCs. Lower CA20 among
LAR TNBCs also corroborates our in vitro results of higher CA being associated with TNBCs
lacking AR expression. We compared mean CA20 between node-negative AA and EA TNBCs
after adjusting for TNBCType and did not detect a significant difference (p=0.21), although the
mean was higher in EA than AA TNBCs; however, the analysis was underpowered to detect a
difference (observed power=0.24).
4.3.5 High CA20 predicts poorer survival among early stage BC patients
Finally, we were interested to test the ability of CA20 to stratify early-stage BCs regardless
of subtype in terms of DFS. In univariate Cox models, higher CA20 score (continuous and
categorical) predicted significantly worse DFS (p=0.026, HR=1.047, and p=0.013, HR=2.85,
respectively) (Table 3). In multivariate Cox models, only CA20 (continuous or dichotomized by
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the mean) was a significant predictor, with all other covariates eliminated from the final model.
This finding suggests that higher CA20, rather than the other covariates considered, uniquely
confers poor DFS among early-stage BC patients.
4.3.6 CA promotes aggressiveness in TNBC in vitro
CA has long been associated with chromosomal instability, aneuploidy, and mitotic spindle
abnormalities [31]. Greater centrosomal aberrations has recently been associated with enhanced
cell migration in BC patient specimens as well as in cultured cell lines [32]. However, the precise
role of CA in TNBC remains elusive. We induced CA in TNBC cell lines, MDA-MB-468 and
MDA-MB-231, and immunoblotted cells for markers of angiogenesis and EMT to investigate the
role of CA in TNBC (Figure 6). Upregulation of CA was confirmed through immunoblotting for
centrosome structural proteins and CA markers for which we observed ≥4-fold increased
expression. Interestingly, in the MDA-MB-468 cell line there was ~2.7-fold increase in expression
of angiogenesis markers (Fig 6A) and ~2.1-fold increase in expression of EMT markers with the
exception of E-cadherin, which exhibited an ~1.5 fold decrease in expression (Fig 6B). Our results
also suggest more robust upregulation of angiogenesis and metastasis markers upon induction of
CA in the AA TNBC cell line, MDA-MB-468, compared with the EA TNBC cell line, MDA-MB231. These observations suggest that CA may be promoting disease progression in AA and EA
TNBCs via different mechanisms.
4.4

Discussion
The limited availability of prognostic biomarkers and therapeutic strategies for TNBC

contributes to the significant disparity in outcomes between TNBC and non-TNBC patients and
underscores the need for (a) novel, alternative biomarkers that can predict the risk of a more
aggressive disease course in patients, and (b) new and robust therapeutic targets to slow or prevent
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disease progression in TNBC patients. Our study investigated the role of CA in TNBC to support
the viability of CA as a potential risk-predictive biomarker in TNBC. A strength of our study is
that a variety of TNBC cell lines of different molecular subtypes and derived from racially-distinct
patients was used, although a limitation of any study of cell lines is generalizability to patient
populations. Indeed, our group recently reported discordance in CA between patient tumors and
patient-derived cancer cell lines [15]. Thus, to corroborate our in vitro work, we analyzed patient
tumor data as well, another strength of our study, although it may have been underpowered to
detect racial differences among TNBCs. At present, we are not aware of any publicly available
microarray datasets with a large sample of race-annotated TNBCs, for which there is an urgent
unmet need.
Our study is the first study to compare CA between molecular TNBC subtypes, uncovering
more extensive and severe numerical CA among BL1 and MSL TNBC cell lines, which was
corroborated by analysis of patient TNBCs. Our results are consistent with previous studies
reporting the BL1 TNBC subtype to be associated with AA race [22, 33]. Keenan and colleagues
found that BL1 and MSL tumors were more present among AA compared to EA TNBCs. Lindner’s
group reported that transcriptional features of BL1 subtype correspond to AA TNBC tumors and
transcriptional features of MSL and LAR correspond to EA TNBC tumors. AA TNBC cell lines
also exhibited evidence of enhanced clustering, which may empower cancer cells with enhanced
migratory ability and foster the acquisition of more aggressive cellular phenotypes [28, 34-36].
Given the literature detailing the role of CA and clustering in promoting aggressive behavior of
TNBC cells and our finding that higher CA20 is an independent predictor of poor DFS in earlystage TNBC, targeting TNBCs with numerical CA and centrosome clustering may be a promising
therapeutic strategy. Collectively, our findings suggest that AA TNBCs may be more susceptible
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to centrosome declustering drugs than EA TNBCs, and it is imperative that preclinical models
testing declustering drugs consider race.
The precise mechanisms in which CA may be promoting aggressive TNBC remain under
investigation. To gain deeper insights into how CA may be contributing to rapid progression in
TNBC, we induced CA in TNBC cell lines and evaluated the effect on various markers of BC
aggressiveness. Interestingly, upon induction of CA we observed a significant upregulation of
angiogenesis and EMT markers, suggesting a role of CA in upregulating these processes in TNBC.
Our results corroborate our recent findings revealing that CA strongly correlates with expression
of the metastasis marker, vimentin, in breast tumor tissue samples, as well as with enhanced
migration and invasion in TNBC in vitro [30]. Our work is also the first to provide evidence of a
direct association of CA and key angiogenesis molecules in TNBC cells suggesting novel
mechanisms excessive centrosomes may be employing to promote tumor progression in TNBC.
Interestingly, we also observed racial differences in these markers following induction of CA, with
BC angiogenesis and EMT markers significantly more upregulated in the AA TNBC cell line. Our
study lays the foundation for larger studies investigating whether mechanisms by which CA may
promote TNBC progression differ based on race. Future studies evaluating the role of CA in TNBC
patient specimens with accompanying patient clinico-pathological variables and clinical outcomes
would be necessary to establish CA as a robust risk-predictive and prognostic biomarker for TNBC
patients.
CA is a cancer-cell specific trait that distinguishes them from normal, healthy cells [46].
Thus, targeting CA offers a minimally cytotoxic therapeutic strategy that selectivity targets cancer
cells burdened with severe centrosomal aberrations. Conveniently, there are already rationally
designed drugs that selectively kill cancer cells harboring CA and are currently under clinical

80

evaluation as promising anti-cancer therapeutics. These novel agents include putative centrosome
declustering drugs such as griseofulvin and noscapine, commercially available HSET inhibitors
such as CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as PJ34 and GF-15
[28, 47-51]. Hence, these agents may aid in abrogating an aggressive disease course in TNBC
patients, perhaps in particular AA TNBC patients. Furthermore, non-invasive methods that can
detect centrosomal status (i.e. fine-needle aspirate cytology, immunohistochemistry) may
demonstrate feasibility in the clinic for selecting TNBC patients that will exhibit susceptibility to
these agents. Thus, assessing CA in the clinic may provide a novel strategy to stratify TNBC
patients into high- and low- risk groups for an aggressive disease course and allow for optimization
of treatment plans. According to our results, CA-targeting agents may be particularly promising
therapeutic options for QNBC and BL1 TNBC patients. These agents may serve as a novel
alternative therapeutic target for TNBC patients exempt from receiving AR-targeted therapy as
well as potentially attenuate racial disparities in BC and TNBC.
4.5

Methods

4.5.1 BC cell lines
All cell lines, including TNBC cell lines (MDA-MB-231, MDA-MB-468, HCC1143,
HCC1937, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) and non-TNBC
(MCF-7, T47D) cell lines, were procured from American Type Cell Culture (ATCC) and cultured
according to ATCC recommendations.
4.5.2 Cell lysate preparation and immunoblotting
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis
buffer (Cell Signaling) as previously described [14]. Protein concentration in cell lysates was
determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved
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in 10% SDS-PAGE gels as previously described [15]. SuperSignal West Pico Chemiluminescent
Subtrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin,
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary
antibodies were obtained from Abcam. Protein expression was semi-quantitated using
densitometry with the ImageJ Software and normalized to β-actin.
4.5.3 Immunoflourescence staining
Cells were seeded onto glass coverslips. After reaching ~80% confluence, cells were fixed
in ice-cold methanol. Coverslips were blocked in 2% bovine serum albumin (BSA) in 1x PBS and
0.05% Triton X-100 at room temperature for 1 h. Coverslips were incubated in primary antibodies
for g-tubulin (Abcam) and a-tubulin (Sigma-Aldrich) diluted in blocking buffer at 1:1000 for
45min in 37°C. Coverslips were incubated in Alexa Fluor 488 goat anti-rabbit and Alexa Fluor
555 goat anti-mouse secondary antibodies (Invitrogen) diluted in blocking buffer at 1:3000 for
40min in 37°C. Primary and secondary antibodies were washed from cover slips with 1x PBS.
Cover slips were incubated in Hoechst (Life Technologies) at room temperature for 10 min and
mounted with Prolong Gold Antifade Reagent (Invitrogen). DU4475 is a suspension cell line and
thus, was not assessed for numerical CA in this study.
4.5.4 Numerical CA Quantitation
Cells were imaged with the Zeiss LSC 700 confocal microscope using 63x objective
(Oberkochen, Germany). All images were processed with Zen software (Oberkochen, Germany).
Approximately 250-300 randomly selected cells were counted per cell line. The percentage of cells
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exhibiting numerical CA (i.e., >2 centrosomes) and multipolar mitoses (i.e., mitotic spindles with
>2 poles) were quantitated in each cell line. In addition, the severity of CA was assessed by
quantitating the percentage of cells with 3, 4, or ³5 centrosomes in each cell line.
4.5.5 Induction of CA
Each cell line was seeded in duplicate. After reaching ~70% confluence, cells were treated
with 25 µM aphidicolin from Nigrospora sphaerica (Sigma-Aldrich) for 72 h to induce CA
through S-phase arrest. Cells treated with solvent containing no drug were used as a negative
control. Cell lysates were collected after 24-36 h. Induction of CA was confirmed through
immunoblotting for centrosomal proteins (g-tubulin, centrin-2, and pericentrin) and CA markers
(Cyclin-E, PLK4).
4.5.6 Cell viability assay
AA (MDA-MB-468 and HCC1806) and EA (BT-20, HCC1143, and MDA-MB-231)
TNBC cell lines were treated with griseofulvin (Sigma-Aldrich). Sensitivities of cell lines to
griseofulvin were assessed through MTT assay as previously described[30]. IC50 values were
computed using GraphPad Prism Software Inc. Griseofulvin concentrations versus percentage of
cell survival was plotted for each cell line using GraphPad Prism Software, Inc.
4.5.7 Statistical analysis of in vitro data
A one-tailed student t-test or one-way ANOVA was performed for analyses comparing 2
or >2 groups, respectively. Results with p<0.05 were considered statistically significant.
4.5.7 CA20 analyses
Datasets: To determine whether CA20 differs between breast cancers from AAs and EAs,
we queried the Cancer Genome Atlas (TCGA) breast dataset [16] using Oncomine [17] to obtain
normalized expression values of CA20 genes, which were summed as previously described to
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derive CA20 scores [18]. Metastases, normal breast samples, male breast cancers, and ductal
carcinomas in situ were excluded, resulting in n=524 cases. Annotation about TNBC status, TNBC
subtype, PAM50, and PAM50lite data were obtained from Lehmann et al. [19], except for one
missing case (TCGA-E2-A14W), the annotation for which was obtained from cBioPortal [20, 21].
All other demographic and clinical annotation was obtained from cBioPortal. Publically available
ER/PR/HER2 IHC data was used to determine TNBC status. HER2 status was determined by IHC
results, but for cases with equivocal or indeterminate IHC values, FISH was used instead. The
Yale TNBC dataset [22] was downloaded from GEO (accession GSE46581), and TNBCType6
values for this dataset were obtained using the TNBCtype tool [20].
Statistical analysis: Levene’s test was used to assess equality of variances between groups.
The Shapiro-Wilk test was used to assess whether samples derived from normally distributed
populations. Exploratory analysis of TCGA breast data revealed the CA20 distribution for EA
TNBCs was non-normal, exhibiting negative skew and leptokurtosis; however, after trimming the
bottom 5% of CA20 values (n=3 cases), the distribution was approximately normal, and so this
5% trimmed dataset was used for all subsequent analyses. Exploratory analysis of the Yale TNBC
data revealed a single outlier in the BL1 TNBC subtype, so the outlier-trimmed dataset was used
for all subsequent analyses. CA20 was compared between groups using parametric (independentsamples, 2-tailed t-test or one-way ANOVA) or non-parametric (Mann-Whitney or KruskallWallis tests) depending on satisfaction of test assumptions. For significant ANOVA tests, Tukey’s
HSD post-hoc testing was performed. The association between categorical variables (race, nodal
status, and TNBC) was assessed using Fisher’s exact test due to the small sample size of TNBCs.
The relationship between CA20 and AR expression was found to be non-monotonic based on
examination of scatterplots; thus, AR groups were defined based on expression levels. To obtain
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adjusted mean CA20 values for non-TNBCs, generalized linear models of main effects were fit
after ensuring satisfaction of assumptions, with CA20 as the dependent variable and including
potentially confounding factors (i.e., with p<0.10). DFS was computed as the time in months from
initial treatment to the event (recurrence or progression) or last follow-up for censored cases. We
tested the impact of high CA20 (continuous or categorized based on the mean) on DFS among
early-stage (i.e., AJCC stage I/II) BC patients in univariate and multivariate Cox models adjusted
for self-reported race and other potentially confounding factors, first ensuring non-violation of the
proportional hazards assumption for all covariates by entering each one as a time-dependent
covariate in univariate Cox models. Kaplan-Meier product-limit DFS estimates were plotted for
categorical CA20 groups, and differences in DFS times were tested using the log-rank test.
Univariate Cox models of DFS were fit including CA20 (continuous) or CA20 (mean as a cutpoint)
for early-stage BC patients of all subtypes. In addition, multivariate Cox models were fit entering
relevant clinicopathologic and demographic covariates, including ER, PR, and HER2 statuses;
nodal status (+/-); tumor size (2 cm cutpoint); PAM50 type (Normal-Like, Luminal A, Luminal B,
HER2-enriched, or Basal-Like); AR status (10th percentile cutpoint); race (AA or EA); and age at
diagnosis (continuous), subject to backward stepwise elimination if p≥0.10. In addition, we tested
the impact of CA20 score on DFS among early-stage TNBCs using Kaplan-Meier analysis with
the log-rank test and univariate and Cox regression. Covariates with p<0.10 in univariate Cox
models were entered into multivariate models. Observed power was computed using α=0.05. IBM
SPSS v. 21 was used and results with p<0.05 were considered statistically significant.
4.6

Tables and Figures
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Table 4.1 Adjusted mean difference in CA20 scores among non-TNBCs based on race and

Table
mean difference in CA20 scores among non-TNBCs based on the race and
HER2 4.1
andAdjusted
AR statuses
HER2 and AR statuses
95% Confidence
Interval
Adjusted mean

Standard

Lower

Upper

difference

Error

Bound

Bound

p-value

Power

AA

3.76

1.95

-0.07

7.59

0.054

0.49

HER2+

4.31

1.28

-6.82

-1.80

0.001

0.92

Factor

Observed

Table 4.2 Turkey post-hoc testing of mean CA20 scores by TNBC subtypes.
CI=Confidence Interval; SE=Standard Error
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95% CI
Mean
TNBCType
BL1

BL2

SE

p

Bound

Bound

BL2

4.7499

3.4768

.747

-5.455

14.955

M

5.7671

2.8709

.349

-2.659

MSL

19.6127

.000

10.336

28.890

IM

3.9741

.714

-4.231

12.179

LAR

19.7339*

4.0870

.000

7.738

31.730

-4.7499

3.4768

.747

-14.955

5.455

1.0172

3.3969

1.000

-8.953

10.987

14.8628*

3.6451

.002

4.164

25.562

IM

-.7758

3.3334

1.000

-10.560

9.008

LAR

14.9840*

4.4722

.016

1.858

28.110

BL1

-5.7671

2.8709

.349

-14.193

2.659

BL2

-1.0172

3.3969

1.000

-10.987

8.953

MSL

13.8456

3.0726

.000

4.827

22.864

IM

-1.7930

2.6954

.985

-9.704

6.118

LAR

13.9667*

4.0192

.011

2.170

25.764

BL1

-19.6127*

3.1607

.000

-28.890

-10.336

BL2

-14.8628*

3.6451

.002

-25.562

-4.164

BL1

MSL

MSL

Upper

Difference

M

M

Lower

*

3.1607
2.7954

*

14.193

Table 4.3 Univariate and multivariate Cox models of disease-free survival based on CA20
score.
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Only final model covariates are given. BC=Breast Cancer; CI=Confidence Interval; HR=Hazard
Ratio; MV=Multivariate; UV=Univariate
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Figure 4.1 Quantitation of numerical CA in TNBC and non-TNBC cell lines.
A. Representative immunofluorescent confocal micrographs of TNBC and non-TNBC cell lines
stained for centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and nuclei (using
Hoechst, blue). B. Comparison of the prevalence of numerical CA in TNBC and non-TNBC cell
lines. C. Comparison of the severity of numerical CA between TNBC and non-TNBC cell lines.
250-300 cells were counted per cell line. D. Western blots comparing centrosomal protein and CA
marker expression between TNBC and non-TNBC cell lines. Scale bar represents 5 µM.
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Figure 4.2 Quantitation of numerical CA in TNBC cell lines of different molecular subtypes.
A. Representative immunofluorescent confocal micrographs of TNBC cell lines stained for
centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and DNA (Hoechst, blue). B.
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Quantitation of the extent of numerical CA in BL1 and MSL cell lines compared to that in BL2,
M, and LAR TNBC cell lines. C. Quantitation of the severity of CA (i.e., the percentage of cells
with 3, 4, or 5+ centrosomes) in BL1 and MSL cell lines compared to that in BL2, M, and LAR
TNBC cell lines. D. Quantitation of the prevalence of numerical CA in BL1 cell lines compared
to its prevalence in cell lines from all other TNBC molecular subtypes. E. Quantitation of the
severity of CA (i.e., the percentage of cells with 3, 4, or 5+ centrosomes) in BL1 cell lines and its
comparison with that in all other TNBC subtypes. F. Western blots comparing g-tubulin expression
between BL1 and MSL and BL2, M, LAR, and IM TNBC cell lines. G. Western blots comparing
g-tubulin expression between BL1 and MSL, BL2, M, LAR, and IM TNBC cell lines. *p<0.05,
**p£0.01. Scale bar represents 5 µM.

Figure 4.3 Quantitation of numerical CA in AA and EA TNBC cell lines.
A. Representative immunofluorescent confocal micrographs of EA and AA TNBC cell lines
stained for centrosomes (g-tubulin, green), microtubules (a-tubulin, red), and DNA (Hoechst,
blue). B. Quantitative comparison of the percentage of cells with numerical CA between EA and
AA TNBC cell lines. C. Quantitative comparison of the severity of CA (i.e., the percentage of
cells with 3, 4, or 5+ centrosomes) between EA and AA TNBC cell lines. D. Western blots in EA
and AA TNBC cell lines of i. pericentrin, KIFC1, and Cyclin-E. *p<0.05, **p£0.01.
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Figure 4.4 Sensitivity of AA and EA TNBC cell lines to griseofulvin.
MTT assays were performed on AA and EA TNBC cell lines and IC50 values were compared
between the racially-distinct cell lines. i. Comparison of IC50 values from griseofulvin treatment
between AA and EA TNBC cell lines. ii. Plot of percent cell survival vs concentration (uM) in
AA and EA TNBC cell lines. *p<0.05.
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Figure 4.5 Differences in CA20 scores between groups of BC patients.
A-C: TCGA data, D-F: Yale data. A. Boxplots of CA20 by race among all breast cancer subtypes
(Mann-Whitney test p=0.008, mean rank=244.55 vs. 193.90; median=27.22 vs. 23.36; in AAs and
EAs, respectively); B. Bar graphs of mean CA20 by AJCC stage in (i) non-TNBCs (ANOVA
p=0.095, means=19.01, 21.60, 22.37, and 23.39, respectively, for stages I-IV, respectively) and
(ii) TNBCs (ANOVA p=0.063, means=31.59, 32.63, 28.84, and 26.11, for stages I-IV,
respectively). C. Boxplots of CA20 by HER2 status in non-TNBCs (Mann-Whitney test p=0.004,
mean rank=160.1 vs 126.7; median =20.64 vs. 24.40, in HER- vs. HER2+ cases). D. Boxplots of
CA20 by lymph node (LN) status in AA TNBCs (Mann-Whitney test p=0.016, mean rank=20.55
vs. 12.58; median=192.45 vs. 209.81; for LN- and LN+ cases, respectively). E. Boxplots of CA20
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by race among LN- TNBCs (Man-Whitney test p=0.034, mean rank=14.63 vs. 22.00;
median=192.45 vs. 203.10, for AAs and EAs, respectively). F. Means plot from ANOVA of CA20
by TNBCType. For all bar graphs, error bars reflect +/- 2X standard error. Open circles in boxplots
represent outliers with >1.5X of the interquartile range.

Figure 4.6 Induction of CA in TNBC in vitro and expression of proteins involved in disease
progression.
Western blots using MDA-MB-468 and MDA-MB-231 TNBC cell lines of proteins associated
with A. angiogenesis and B. EMT. “C” denotes untreated cells (controls) and “T” denotes cells
treated with aphidocolin for 72 h at 25 µM.
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5

CENTROSOME AMPLIFICATION AS A NOVEL BIOMARKER OF QUADRUPLE
NEGATIVE BREAST CANCER DISEASE

5.1

Abstract
Centrosome amplification (CA), a key property of malignant tumor cells, has emerged as

a marker of breast cancer (BC) aggressiveness that is highly associated with triple-negative BC
(TNBC). Although controversial, the absence of androgen receptor (AR) expression in TNBC, or
quadruple negative breast cancer (QNBC), has been reported to confer a more aggressive disease
course. However, the role of CA in QNBC and the mechanisms by which CA may be driving
aggressive QNBC behavior remains under-studied. Using confocal microscopy, we quantitatively
compared numerical CA profiles in a panel of AR-positive and AR-negative TNBC cell lines. We
then compared CA20 - an established signature of 20 genes implicated in CA – between QNBC
and TNBC patients and evaluated the prognostic value of CA20 in multivariate Cox models of
disease-free survival (DFS) using public gene expression data. To discern mechanisms by which
CA may fuel aggressive QNBC behavior, we induced CA in a QNBC and TNBC cell line with
aphidicolin and assessed aggressive BC biomarkers. Numerical CA was higher in AR-negative
than AR-positive TNBC in in vitro analyses, findings that were substantiated by gene expression
studies of CA20 in patient BCs. Furthermore, high CA20 as a continuous variable predicted worse
DFS in early-stage TNBC patients in adjusted analysis (p=0.03, hazard ratio=1.20). Induction of
CA in TNBC cell lines upregulated expression of markers of BC stem cells and the DNA damage
response, suggesting that CA may promote TNBC aggressiveness through these mechanisms.
Collectively, these findings support an association between numerical CA and QNBC disease and
poorer DFS among early-stage TNBC patients. Our study also reveals novel mechanisms by which
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CA may promote aggressive QNBC behavior. Hence, our work suggests CA as a potential riskpredictive biomarker for QNBC patients that may also represent a viable therapeutic target.
5.2

Introduction
TNBC accounts for approximately 10-30% of invasive BC cases in the U.S. It is a unique

BC subtype that lacks expression of the estrogen and progesterone receptors and amplification of
the human epidermal growth factor receptor 2 (HER2/neu). The absence of these targets eliminates
conventional endocrine therapy and HER2-targeted systemic treatments as therapeutic options and
traditional chemotherapy is unable to eradicate most TNBCs. The disease is characterized by an
aggressive clinical course, evidenced by its greater metastatic propensity, more unfavorable
clinico-pathological characteristics upon presentation, and higher inter-patient and intratumor
heterogeneity compared with non-TNBCs [1-3]. The disease is significantly more prevalent among
premenopausal women and predominantly afflicts women of African ancestry who, according to
some studies, experience a more aggressive disease course and poorer clinical outcomes than EA
TNBCs [1, 4, 5]. Currently, no reliable biomarkers or effective targeted treatments exist for TNBC
thus, patients often suffer abysmal outcomes. Thus, alternative risk-prognostic and therapeutic
targets are urgently needed to successfully manage the disease.
Androgen receptor (AR) has recently emerged as a promising alternative therapeutic target
for TNBC patients. AR is expressed in approximately 10-43% of TNBCs depending on the
threshold of positivity used[6]. Knockdown and inhibition of AR with enzalutamide among ARexpressing TNBCs resulted in a reduction in proliferation, migration, invasion and an increase in
apoptosis[7-9]. Also, Traina and colleagues observed that enzaluatmide elicited a clinical benefit
rate (CBR) of 25% at 24 weeks and a median progression-free survival (PFS) of 14.7 weeks among
AR-positive TNBC patients but a CBR of only 20% at 24 weeks and a median PFS of 12.6 weeks
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among patients with less AR expression in a nonrandomized phase II clinical trial (unpublished
data). The AR antagonist, bicalutamide, also performed well in a phase II clinical trial as the drug
elicited a CBR of 19% at 24 weeks and a median PFS of 12 weeks among AR-positive TNBC
patients[10]. However, the remaining 76-90% of TNBCs that lack expression of AR, often referred
to as quadruple negative breast cancer (QNBC), may not be as sensitive to these novel AR-targeted
agents. Furthermore, some studies have reported that a lack of AR expression in TNBC confers a
more aggressive disease course[11-16]. Moreover, a lack of AR expression has been observed to
be more prevalent among TNBC patients of African compared to European ancestry[17]. Thus,
this subgroup of TNBC patients are even more at a disadvantage than AR-positive TNBC patients
and are in urgent need for alternative biomarkers and treatment options.
CA is a hallmark of BC that causes ITH by fostering erroneous mitoses, which drive genetic
instability and the generation of diverse karyotypes [18, 19]. It is well established that CA is
associated with BC progression and imparts aggressive phenotypes, thus representing a possible
anti-cancer target [20-25]. Emerging evidence suggest that TNBCs harbor greater incidence and
severity of CA than non-TNBCs and that CA underlies an aggressive disease course among
TNBCs [26, 27]. However, the role of CA in QNBC and it’s a potential as an alternative biomarker
and therapeutic target in the disease remains elusive. In this study, we investigate the potential
prognostic and therapeutic value of CA in QNBC and mechanisms by which CA may promote
QNBC progression, which could be exploited therapeutically. ‘
5.3

Results

5.3.1 Numerical CA is higher in AR-negative compared to AR-positive TNBC cell lines
As previously mentioned, a subset of TNBCs lack expression of AR and are classified as
AR-negative or QNBCs, which exhibit a more basal-like molecular subtype, are more common
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among individuals of African ancestry, are not susceptible to AR-targeted therapy, and are
characterized by poor DFS [41-43]. Hence, we were interested to determine if QNBCs exhibit
more numerical CA than TNBCs (representative micrographs in Figure 1A). We compared
numerical CA between QNBC and TNBC cell lines and found that numerical CA was higher in
QNBC cell lines (p=0.050) (Figure 1B). We also found that QNBC cell lines exhibited a greater
proportion of cells with ≥5 centrosomes than TNBC cell lines (p=0.037) (Figure 1C). We also
tested whether numerical CA differs between QNBCs, TNBCs, and non-TNBCs and uncovered a
non-significant trend towards increasing numerical CA with decreasing hormone receptor
expression (p=0.10) (Figure 1D). We found that the percentage of cells with or ≥5 centrosomes
increased with decreasing hormone receptor expression as well (p=0.039) (Figure 1E). The effects
of AR signaling on centrosome homeostasis in BC are unknown, but our study suggests AR loss
is associated with CA in TNBC.
5.3.2 CA20 is higher in AR-low compared to AR-high expressing TNBCs
Previoulsy, our group developed a transcriptional signature that may reflect CA and
correlates with chromosomal instability and worse prognosis in multivariable models, referred to
as the CA20 score, which is the sum of the normalized expression of 20 genes whose dysregulation
causes CA [1]. To confirm our in vitro findings, we used publicly available microarray data to
compute CA20 scores. TCGA breast dataset includes annotation about the variables of interest;
thus, we queried it using Oncomine [2] to obtain normalized expression values for the CA20 genes,
which were summed as previously described to derive CA20 scores [1].
CA20 was higher in AR-low than AR-high non-TNBC cases (p=0.002) (Figure 3A; Table
1). Thus, amongst non-TNBCs, CA20 is higher in more aggressive subtypes. We also discovered
that CA20 was higher in the AR-low group among TNBCs when the 10th percentile was used
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(p=0.013, mean rank=56.88 vs. 36.32) (Figure 3B). This finding supports our in vitro results of
higher CA being associated with QNBC.
5.3.3 High CA20 predicts poorer survival among early stage TNBC patients
Finally, we were interested in testing the ability of CA20 to stratify early-stage TNBCs
regardless of subtype in terms of DFS. Among early-stage TNBCs, higher CA20 score
(continuous) was associated with worse DFS in univariate analysis (p=0.040, HR=1.16) and
multivariate analysis (p=0.013, HR=1.23) (Table 2) with the exception of age at diagnosis
(p=0.11). The QNBC patient sample size was too small to analyze for survival. Thus, higher CA20
score (continuous) may offer reliable prognostic information among early-stage TNBC patients
regardless of commonly considered clinicopathologic and demographic information. We
suspected categorizing based on mean CA20 score among early-stage TNBCs was not ideal
because TNBCs have very high CA20 scores (relative to non-TNBCs), and the threshold at which
these high levels confer poor prognosis may be lower than the mean value among TNBCs.
5.3.4 CA promotes aggressiveness in QNBC in vitro
CA has long been associated with chromosomal instability, aneuploidy, and mitotic spindle
abnormalities [45]. Greater centrosomal aberrations have recently been associated with enhanced
cell migration in BC patient specimens as well as in cultured cell lines [46]. However, the precise
role of CA in TNBC and QNBC remains elusive. We induced CA in the TNBC cell line, MDAMB-468, and the QNBC cell line, MDA-MB-231, by arresting the cells in S-phase with
aphidocolin treatment and immunoblotted each cell line for markers of stem cells (i.e. CD44,
ALDHA1, Integrin-α) and DNA damage (PARP, p53, RAD51, p21) to investigate the role of CA
in AR-low and AR-high expressing TNBC cell lines (Figure 4). Upregulation of CA was
confirmed through immunoblotting for centrosome structural proteins and CA markers for which
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we observed ≥4-fold increased expression. Interestingly, in the MDA-MB-468 cell line there was
~2-fold increase in expression of stem cell markers (Fig 4A) and ~2.3 fold increase in expression
of DNA damage markers (Fig 4B). In MDA-MD-231 cells there was a ~4-fold increase in DNA
damage markers. The results suggest a potential role of CA in TNBC aggressiveness via this
mechanism. Our results also suggest more robust upregulation of stem cell, angiogenesis, and
metastasis markers upon induction of CA in the TNBC cell line, MDA-MB-468, compared with
the QNBC cell line, MDA-MB-231. Conversely, there was notably more upregulation of DNA
damage markers observed in the QNBC compared to the TNBC cell line.
5.4

Discussion
The recent emergence of QNBC disease has left this novel subgroup of TNBCs with an

even more limited availability of prognostic biomarkers and therapeutic strategies than ARpositive TNBC. Although, controversial, some studies suggest that lack of AR expression confers
a more aggressive disease course which underscores the need for (a) novel, alternative biomarkers
that can predict the risk of a more aggressive disease course and (b) new and robust therapeutic
targets to slow or prevent disease progression in QNBC patients. Our study investigated the role
of CA in QNBC to support the viability of CA as a potential risk-predictive biomarker and
therapeutic target in QNBC. Indeed, our group recently reported discordance in CA between
patient tumors and patient-derived cancer cell lines [29]. Thus, to corroborate our in vitro work,
we analyzed patient tumor data as well.
Our study is the first to compare centrosome profiles in TNBCs based on AR status,
uncovering more extensive and severe CA in the AR-negative subgroup.
The precise mechanisms in which CA may be promoting aggressiveness in QNBC remain
elusive. To gain deeper insights into how CA may be contributing aggressive disease in QNBC,

104

we induced CA in MDA-MB-231 and MDA-MB-468 QNBC and TNBC cell lines, respectively
and evaluated the effect on various markers of BC aggressiveness. Interestingly, upon induction
of CA we observed a significant upregulation of stem cell, angiogenesis, DNA damage, and EMT
markers in both cell lines, suggesting a role of CA in upregulating these processes in TNBC. Our
work is consistent with previous literature reporting a link between CA and DNA damage in BC.
As previously mentioned, several studies have suggested that CA drives chromosomal instability
to foster tumor progression [45, 48, 49]. Aberrant function of tumor suppressor genes involved in
the DNA repair pathway, such as p53 and BRCA1/2, have been associated with amplified
centrosomes and subsequent erroneous cell division in BC cell lines [18, 19, 45]. Our results also
corroborate our recent findings revealing that CA strongly correlates with expression of the
metastasis marker, vimentin, in breast tumor tissue samples, as well as with enhanced migration
and invasion in TNBC in vitro [30]. Denu et. al recently observed a decrease in CD24 expression
and increase in CD44 expression upon induction of CA in normal breast epithelial cells by PLK4
overexpression[27]. However, our work is also the first to provide evidence of a direct association
of CA and key stem cell and angiogenesis molecules in TNBC cells suggesting novel mechanisms
excessive centrosomes may be employing to promote tumor progression in TNBC. Approximately
30% of TNBCs are chemosensitive and achieve a complete pathological response to neoadjuvant
chemotherapy, however the remaining 70% of TNBC patients often succumb to residual disease
and relapse, which underlies their poorer clinical outcomes compared with other subtypes of BC
patients [50, 51]. Cancer stem cells have been implicated in drug resistance and relapse from
chemotherapy in BC [52-56]; thus, upregulation of stem cell markers upon induction of CA in
TNBC cell lines may reveal a potential role of CA in chemoresistance in TNBC. Further validation
of a link between CA and stem cell generation may support screening of early-stage TNBC patients

105

for centrosomal status to allow for early risk-prediction of patient response to chemotherapy. An
early detection of an unfavorable response to chemotherapy may prompt clinicians to recommend
the addition of CA-targeting agents to chemotherapy regimens to elicit a more robust response and
prevent TNBC patients from experiencing relapse. However, DNA damage markers were notably
more regulated in the QNBC compared to the TNBC cell line suggesting the DNA damage
response pathway may be particularly more active in QNBC tumors.
CA is a cancer-cell specific trait that distinguishes them from normal, healthy cells [57].
Thus, targeting CA offers a minimally cytotoxic therapeutic strategy that selectivity targets cancer
cells burdened with severe centrosomal aberrations. Conveniently, there are already rationally
designed drugs that selectively kill cancer cells harboring CA and are currently under clinical
evaluation as promising anti-cancer therapeutics. These novel agents include putative centrosome
declustering drugs such as griseofulvin and noscapine, commercially available HSET inhibitors
such as CW069 and AZ82, and poly-ADP ribose polymerase inhibitors such as PJ34 and GF-15
[58-63]. Hence, these agents may aid in abrogating an aggressive disease course in QNBC and
BL1 TNBC patients in addition to platinum-based drugs. Furthermore, non-invasive methods that
can detect centrosomal status (i.e. fine-needle aspirate cytology, immunohistochemistry) may
demonstrate feasibility in the clinic for selecting QNBC patients that will exhibit susceptibility to
these agents. Thus, assessing CA in the clinic may provide a novel strategy to stratify QNBC
patients into high- and low- risk groups for an aggressive disease course and allow for optimization
of treatment plans. Thus, these agents may serve as a novel alternative therapeutic target for TNBC
patients exempt from receiving AR-targeted therapy. However, future studies evaluating the role
of CA in QNBC patient specimens with accompanying patient clinico-pathological variables and
clinical outcomes would be critical to establishing CA as a robust risk-predictive and prognostic
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biomarker for QNBC patients.
5.5

Methods

5.5.1 BC cell lines
All cell lines, including TNBC cell lines (MDA-MB-231, MDA-MB-468, HCC1143,
HCC1937, HCC38, HCC70, HCC1806, DU4475, MFM-223, BT-549, BT-20) and non-TNBC
(MCF-7, T47D) cell lines, were procured from American Type Cell Culture (ATCC) and cultured
according to ATCC recommendations.
5.5.2 Cell lysate preparation and immunoblotting
Cell lysates were collected after cells reached ~80% confluence and lysed with 1x lysis
buffer (Cell Signaling) as previously described [28]. Protein concentration in cell lysates was
determined using Bradford Protein Assay (BioRad) and spectrometry. Cell lysates were resolved
in 10% SDS-PAGE gels as previously described [29]. SuperSignal West Pico Chemiluminescent
Subtrate (ThermoScientific) was used to visualize the bands. PARP, Hif-1a, and E-cadherin
primary antibodies were obtained from BD Biosciences. Cyclin-E, Centrin-2, VEGF, Vimentin,
uPAR, RAD51, MMP9, p53, and β-actin primary antibodies were obtained from Santa Cruz
Biotech. γ-tubulin, PLK4, pericentrin, integrin-α2, MMP2, and ALDHA1 primary antibodies were
obtained from Abcam. p21 and CD44 antibodies were obtained from Cell Signaling. Secondary
antibodies were obtained from Abcam. Protein expression was semi-quantitated using
densitometry with the ImageJ Software and normalized to β-actin.
5.5.3 Immunoflourescence staining
Cells were seeded onto glass coverslips. After reaching ~80% confluence, cells were fixed
in ice-cold methanol. Coverslips were blocked in 2% bovine serum albumin (BSA) in 1x PBS and
0.05% Triton X-100 at room temperature for 1 h. Coverslips were incubated in primary antibodies
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for g-tubulin (Abcam) and a-tubulin (Sigma-Aldrich) diluted in blocking buffer at 1:1000 for
45min in 37°C. Coverslips were incubated in Alexa Fluor 488 goat anti-rabbit and Alexa Fluor
555 goat anti-mouse secondary antibodies (Invitrogen) diluted in blocking buffer at 1:3000 for
40min in 37°C. Primary and secondary antibodies were washed from cover slips with 1x PBS.
Cover slips were incubated in Hoechst (Life Technologies) at room temperature for 10 min and
mounted with Prolong Gold Antifade Reagent (Invitrogen). DU4475 is a suspension cell line and
thus, was not assessed for numerical CA in this study.
5.5.4 Numerical CA Quantitation
Cells were imaged with the Zeiss LSC 700 confocal microscope using 63x objective
(Oberkochen, Germany). All images were processed with Zen software (Oberkochen, Germany).
Approximately 250-300 randomly selected cells were counted per cell line. The percentage of cells
exhibiting numerical CA (i.e., >2 centrosomes) and multipolar mitoses (i.e., mitotic spindles with
>2 poles) were quantitated in each cell line. In addition, the severity of CA was assessed by
quantitating the percentage of cells with 3, 4, or ³5 centrosomes in each cell line.
5.5.5 Cell viability assay
QNBC and TNBC cell lines were treated with griseofulvin (Sigma-Aldrich). Sensitivities
of cell lines to griseofulvin were assessed through MTT assay as previously described[30]. IC50
values were computed using GraphPad Prism Software Inc. Griseofulvin concentrations versus
percentage of cell survival was plotted for each cell line using GraphPad Prism Software, Inc.
5.5.6 Induction of CA
Each cell line was seeded in duplicate. After reaching ~70% confluence, cells were treated
with 25 µM aphidicolin from Nigrospora sphaerica (Sigma-Aldrich) for 72 h to induce CA
through S-phase arrest. Cells treated with solvent containing no drug were used as a negative
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control. Cell lysates were collected after 24-36 h. Induction of CA was confirmed through
immunoblotting for centrosomal proteins (g-tubulin, centrin-2, and pericentrin) and CA markers
(Cyclin-E, PLK4).
5.5.7 Statistical analysis of in vitro data
A one-tailed student t-test or one-way ANOVA was performed for analyses comparing 2
or >2 groups, respectively. Results with p<0.05 were considered statistically significant.
5.5.8 CA20 analyses
Datasets: To determine whether CA20 differs between QNBC and TNBC patients, we
queried the Cancer Genome Atlas (TCGA) breast dataset [31] using Oncomine [32] to obtain
normalized expression values of CA20 genes, which were summed as previously described to
derive CA20 scores [33]. Metastases, normal breast samples, male breast cancers, and ductal
carcinomas in situ were excluded, resulting in n=524 cases. Publically available ER/PR/HER2/AR
IHC data was used to determine TNBC status. The Yale TNBC dataset [37] was downloaded from
GEO (accession GSE46581) [35].
Statistical analysis: Levene’s test was used to assess equality of variances between groups.
The Shapiro-Wilk test was used to assess whether samples derived from normally distributed
populations. CA20 was compared between groups using parametric (independent-samples, 2tailed t-test or one-way ANOVA) or non-parametric (Mann-Whitney or Kruskall-Wallis tests)
depending on satisfaction of test assumptions. For significant ANOVA tests, Tukey’s HSD posthoc testing was performed. The association between categorical variables (race, nodal status, and
TNBC) was assessed using Fisher’s exact test due to the small sample size of TNBCs. The
relationship between CA20 and AR expression was found to be non-monotonic based on
examination of scatterplots; thus, AR groups were defined based on expression levels. DFS was
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computed as the time in months from initial treatment to the event (recurrence or progression) or
last follow-up for censored cases. We tested the impact of high CA20 (continuous or categorized
based on the mean) on DFS among early-stage (i.e., AJCC stage I/II) TNBC patients in univariate
and multivariate Cox models adjusted for self-reported race and other potentially confounding
factors, first ensuring non-violation of the proportional hazards assumption for all covariates by
entering each one as a time-dependent covariate in univariate Cox models. Univariate Cox models
of DFS were fit including CA20 (continuous) or CA20 (mean as a cutpoint) for early-stage BC
patients of all subtypes. In addition, multivariate Cox models were fit entering relevant
clinicopathologic and demographic covariates, including ER, PR, and HER2 statuses; nodal status
(+/-); tumor size (2 cm cutpoint); PAM50 type (Normal-Like, Luminal A, Luminal B, HER2enriched, or Basal-Like); AR status (10th percentile cutpoint); and age at diagnosis (continuous),
subject to backward stepwise elimination if p≥0.10. Covariates with p<0.10 in univariate Cox
models were entered into multivariate models. Observed power was computed using α=0.05. IBM
SPSS v. 21 was used and results with p<0.05 were considered statistically significant.
5.6

References
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6

TUMOR-INFILTRATING LYMPHOCYTES AS RISK-PROGNOSTIC
BIOMARKER AMONG EARLY-STAGE AFRICAN-AMERICAN TRIPLE
NEGATIVE BREAST CANCER PATIENTS

6.1

Abstract
Triple negative breast cancer (TNBC) is defined by a lack of pharmacologically-targetable

breast cancer biomarkers and disproportionately afflicts and affects African-American (AA)
women. Tumor-infiltrating lymphocytes (TILs) have been associated with better clinical
outcomes, response to neoadjuvant chemotherapy (NAC) but more aggressive breast tumor
features. Among formalin-fixed, paraffin-embedded resection samples, we compared stromal and
peripheral TILs between early-stage AA and EA TNBC patients at Emory University Hospital in
Atlanta, GA. We also compared proportions of infiltrating immune subsets and performed
differential gene expression analyses between AA and EA TNBC patients in a publically available
gene expression dataset. Among early-stage (I-II) patients (N=103), we observed more stromal
TILs among AAs (N=71) compared to EAs (N=32) (p=0.02). Among early-stage AA patients,
stromal TILs correlated negatively with age at diagnosis (ρ=-0.25; p=0.03) and androgen receptor
expression (ρ=-0.26; p=0.04) and positively with BRCA1-associated protein (ρ=0.30; p=0.02) and
programmed cell death protein 1 (ρ=0.56; p<0.0001). High peripheral TIL count predicted better
10-year overall survival (p=0.045; hazard ratio (HR): 0.27; 95% CI:0.08-0.97) and 10-year
disease-free survival (p=0.027; HR:0.30; 95% CI:0.10-0.87) among early-stage AA patients in
multivariate analyses. In silico analyses revealed greater proportions of T regulatory cells
(p=0.046) among AA compared to EA TNBC samples as well as more upregulation of
proinflammatory genes, gene ontologies, and biological pathways reflecting cytokine activity,
lymphocyte differentiation, and immune effector processes among AA patients. Our findings
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uncover previously unrecognized racial disparities in the tumor immune microenvironment among
triple negative breast tumors and suggests that TILs may serve as a promising risk-prognostic
biomarker for early-stage AA TNBC patients.
6.2

Introduction
Triple negative breast cancer (TNBC) is a highly aggressive breast cancer (BC) subtype

that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2/neu) (1). Therefore, TNBC patients do not benefit from
conventional endocrine and HER2-targeted systemic treatments leaving chemotherapy and
radiation as the mainstay of treatments (2, 3). African-American (AA) women are 2-3 times more
prone to developing TNBC and experiencing onset of the disease at a younger age compared to
European-American (EA) women (4, 5). TNBC patients of African descent also exhibit more
unfavorable clinico-pathological tumor characteristics, acquire more aggressive TNBC subtypes,
and display poorer clinical outcomes compared to TNBC patients of European descent (2, 5-11).
Novel, alternative biomarkers are urgently needed to manage an aggressive disease course and
reduce mortality rates among this patient population.
Neoplastic transformation induces tumor-infiltrating lymphocytes (TILs) to migrate to the
tumor site and control progression (12, 13). TILs that migrate to the tumor stroma are considered
stromal TILs and TILs that migrate to the stroma adjacent to the invasive tumor front are
considered to be peripheral TILs (14, 15). Stromal TILs have been associated with improved
overall survival (OS), increased metastasis-free survival, reduced risk of relapse and reduced
distance recurrence in TNBC (16). Furthermore, a high level of stromal TILs has been associated
with improved pathological complete response (pCR) following neoadjuvant chemotherapy
(NAC), validating TILs as a predictive biomarker in TNBC (15-17). In a non-NAC setting,
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peripheral TILs have been associated with longer OS and disease-free survival (DFS) among
TNBC patients in multivariate analyses (14). Paradoxically, the presence of TILs has been
associated with more aggressive clinico-pathological tumor characteristics in BC such as high
grade, high stage, high Ki-67, lymph node metastasis, a triple negative breast tumor phenotype,
and young age at diagnosis (17-23). Thus, we were interested in evaluating if there was a disparity
in the presence of TILs between AAs and EAs and if TILs can function as a risk-prognostic
biomarker among TNBC patients of African ancestry. We compared the presence of stromal and
peripheral TILs between AA and EA TNBC patients, in a non-NAC setting, observed at Emory
University Hospital (EUH) in Atlanta, GA and assessed the predictive and prognostic value of
TILs among these patient populations.
6.3

Results

6.3.1 Clinico-pathological characteristics among racially-distinct TNBC patients
We compared clinico-pathological characteristics between AA (N=87) and EA (N=34)
TNBC patients observed at EUH (Table 1). We observed a significant difference in nuclear grade
(p=0.04) between AA and EA TNBC patients, with 94.3% of AA and 82.4% of EA patients
classified as grade 3. A significant difference was observed in mitotic index (p=0.0001) between
the races wherein which 78.2% of AAs exhibited a score of 3 compared to 38.2% of EAs. We also
observed significantly higher Nottingham grade in AA compared to EA TNBC patients (p=0.008),
in which 85.1% of AAs were diagnosed at grade 3 compared to 58.8% of EAs. These findings
corroborate previous studies reporting higher grade and mitotic index among AA compared to EA
TNBCs. We also compared BC biomarker expression between AA and EA TNBC patients (Table
2). We observed significant differences in retinoic acid receptor-α (RARα) (p=0.02) and β-catenin
(p=0.01) between the racial groups in which 50.6% of AAs and 67.7% of EAs were positive for
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RARα expression and 80.5% of AAs and 50% of EAs were positive for β-catenin expression.
Elevated levels of RARα have been associated with more ER-positive compared to ER-negative
BCs (32). β-catenin has been shown to be required for tumorigenesis of TNBC cells through
promoting migration, stemness, anchorage-independent growth, and chemosensitivity (33). Like
TILs, β-catenin has been shown to be more upregulated in TNBCs compared to non-TNBCs and
both nuclear and cytoplasmic β-catenin expression levels were recently found to positively
correlate with stromal lymphocytic infiltration in BC, suggesting that Wnt/β-catenin signaling may
be playing a critical role in BC anti-tumoral immunity (23). Thus, differential expression of these
markers observed between AA and EA TNBCs may be playing a role in the disparity in clinical
outcomes between the racial groups.
6.3.2 AAs harbor more TILs than EAs among early-stage TNBC patients
We analyzed differences in the presence of stromal and peripheral TILs between AA
(N=87) and EA (N=34) TNBC patients (Figure 1). We discovered a trend of higher levels of
stromal TILs in AAs compared to EAs among all TNBC patients (p=0.06) and significantly higher
among non-adjuvant chemotherapy treated AA compared to EA patients (p=0.01) (Fig 1A).
Interestingly, among early-stage (I-II) (N=103) TNBC patients, AAs (N=71) harbored
significantly more stromal TILs than EAs (N=32) (p=0.02) however, not among late-stage (IIIIIIC) (N=18) TNBC patients (p=0.62) (Fig 1B,C). Among non-adjuvant chemotherapy treated
early-stage TNBC patients, stromal TILs were also higher in AAs compared to EAs (p=0.01) (Fig
1B). Among radiation and non-radiation treated early-stage TNBC patients, we observed a trend
of high levels of stromal TILs in AAs than EAs (p=0.07) (Fig1B). We did not observe significant
differences in peripheral TILs between the races (data not shown).
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6.3.3 TILs are associated with more aggressive disease features among early-stage AA
TNBC patients
We examined associations between stromal TILs (Table 3) and peripheral TILs (Table 4)
with demographic variables and clinico-pathological parameters among racially-distinct earlystage TNBC patients to elucidate the prognostic role of TILs among these patient populations.
Among treated and non-treated early-stage AA and EA patients, stromal and peripheral positively
correlated with aggressive clinico-pathological features such as higher tubule formation, nuclear
grade, mitotic index, Ki-67 and Nottingham grade (p<0.05). However, among early-stage AA
patients, stromal and peripheral TILs negatively correlated with age at diagnosis (ρ=-0.25; p=0.03
and ρ=-0.30; p=0.01, respectively) and among early-stage EA patients, high levels of stromal TILs
were associated with increased lymph node positivity (ρ=0.43; p=0.02) and greater total lymph
node involvement (ρ=0.45; p=0.01).
To glean additional insight into the role of TILs in TNBC, we examined if TILs are
associated with biomarkers routinely assessed among BC patients in the clinic. Correlations of
stromal and peripheral TILs with breast clinico-pathological biomarker expression among raciallydistinct TNBC patients can be found in Tables 5 and 6, respectively. Among early-stage AA
patients, stromal TILs negatively correlated with AR expression (ρ=-0.25; p=0.04) and positively
correlated with PD-1 (ρ=0.56; p<0.0001) and BAP1 (ρ=0.3; p=0.02). However, among early-stage
EA TNBC patients, stromal TILs positively correlated with BAP1 (ρ=0.44; p=0.03), PD-1
(ρ=0.43; p=0.02), nuclear HSET (ρ=0.50; p=0.02), and EGFR (ρ=0.58; p=0.004) expression.
Similar associations were also observed with peripheral TILs except among adjuvant
chemotherapy treated early-stage AA patients, peripheral TILs negatively correlated with protein
regulator of cytokinesis 1 (PRC1) expression (ρ=-0.28; p=0.05) and among non-radiation treated
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early-stage AA patients, peripheral TILs positively correlated with human epidermal growth factor
receptor 4 (HER4) expression (ρ=0.43; p=0.02).
6.3.4 High TIL levels predict better survival among early-stage AA TNBC patients
We next investigated if the presence of TILs is associated with better or worse survival
among all and racially-distinct TNBC patients. TILs were stratified into high and low subgroups
and Kaplan-Meier analyses were performed to determine the impact of TILs on 10-year OS
(Figure 2). We also assessed unadjusted and adjusted associations of peripheral TILs (Table 7)
with 10-year OS using Cox proportional hazard regression models. Stromal TILs were unable to
significantly predict OS (data not shown). However, we discovered that high peripheral TIL levels
predicted better 10-year OS among all patients as well as among radiation treated patients after
adjusting for age, Nottingham grade, and stage (p=0.019; hazard ratio (HR): 0.344; 95% CI:0.1410.838 and p=0.043; HR:0.284; 95% CI:0.084-0.963, respectively). Among all AA patients, high
peripheral TIL levels also predicted significantly longer 10-year OS in Kaplan-Meier analysis
(p=0.007) (Fig 2A) and after controlling for age, Nottingham grade, and stage (p=0.003;
HR:0.229; 95% CI:0.084-0.622). High peripheral TIL levels also predicted longer 10-year OS
among adjuvant chemotherapy (p=0.015; HR:0.230; 95% CI:0.070-0.755) and radiation (p=0.014;
HR:0.167; 95% CI:0.040-0.697) treated AA patients irrespective of age, Nottingham grade, and
stage and in Kaplan-Meier analyses (p<0.05) (Fig 2B,C). Among early-stage AA patients, high
peripheral TIL levels predicted better 10-year OS after adjusting for age, Nottingham, and stage
(p=0.045; HR:0.273; 95% CI:0.077-0.969) and in Kaplan-Meier analyses (p=0.05) (Fig 2D).
Furthermore, high peripheral TIL levels predicted better 10-year OS among non-adjuvant
chemotherapy treated early-stage AA patients in multivariate (p=0.041; HR:0.031; 95% CI:0.0010.865) and Kaplan-Meier analyses (p=0.006) (Fig 2E). High peripheral TIL levels also predicted
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better 10-year OS among non-radiation treated early-stage AA patients in Kaplan-Meier analyses
(p=0.04) (Fig 2F). Peripheral TILs were unable to significantly predict OS among EA TNBC
patients (data not shown).
We also performed Kaplan-Meier analyses and computed Cox proportional hazard
regression models to determine the impact of stromal and peripheral TIL levels on DFS over a 5and 10-year period among TNBC patients. High stromal (Table 8) and peripheral (Table 9) TIL
levels were able to predict significantly better 10-year DFS among radiated-treated AA patients in
multivariate analyses (p=0.015; HR:0.230; 95% CI:0.070-0.755 and p=0.029; HR:0.31; 95%
CI:0.11-0.89, respectively). High peripheral TIL levels were able to predict better 10-year DFS
among all AA patients in multivariate analyses (p=0.035; HR:0.36; 95% CI:0.14-0.93) (Table 13).
Among early-stage AA patients, high peripheral TIL levels were able to predict better 10-year
DFS (p=0.027; HR:0.30; 95% CI:0.10-0.87) as well as among radiation-treated early-stage AA
patients (p=0.022; HR:0.259; 95% CI:0.08-0.823) (Table 13). Our Kaplan-Meier analyses reveal
that high peripheral TIL levels were able to predict significantly better 5-year DFS among
radiation-treated early-stage AA patients (p=0.047) (Figure 3). Peripheral TILs were unable to
significantly predict DFS among EA TNBC patients (data not shown).
6.3.5 Distinctions in TIL subsets between AA and EA TNBC patients
TILs represent a heterogeneous population of immune cells harboring pro-tumorigenic and
anti-tumorigenic properties. To glean deeper insight into distinctions in the types of infiltrating
immune cells present in the tumor microenvironment among racially-distinct triple negative breast
tumors, we utilized the CYBERSORT tool and LM22 to estimate the relative proportions of 22
immune cell phenotypes among gene expression profiles from AA (N=41) and EA (N=87) TNBC
patient tissue specimens in TCGA dataset and analyzed for significant differences between the
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races (Figure 4). Interestingly, we observed AAs harbored a significantly higher proportion of T
regulatory cells (Tregs) (p=0.046) and lower proportion of M2 macrophages (p=0.04) than EAs
among TNBCs (Fig 4A). We also observed that AAs harbored a weakly significantly lower
proportion of naïve B cells (p=0.08) and weakly significantly higher proportion of memory B cells
(p=0.09) than EAs among TNBC samples (Fig 4B).
6.3.6 Differentially expressed immune-related genes, pathways and gene ontologies between
AA and EA TNBC patients
We also investigated differential expression of immune-related genes, pathways, and gene
ontologies between AA compared to EA TNBC patients isolated from TCGA breast dataset.
Utilizing the DESeq2 software tool, we analyzed differences in expression of 15,942 genes
between AA (N=41) and EA (N=87) TNBC patients in TCGA breast dataset. We observed that
resistin (RETN), triggering receptor expressed on myeloid cells like 4 (TREML4), C-C motif
chemokine ligand 3 like 1 (CCL3L1), and leukocyte associated immunoglobulin like receptor 2
(LAIR2) immune-related genes were significantly more upregulated among AA compared to EA
TNBC patients (p<0.00001) (Figure 5). Log2 fold changes can be found in Table 10. RETN and
TREM-4 genes were expressed with a log2 fold change of almost 2 times higher among AA
compared to EA TNBCs. We also utilized the GAGE and Pathview packages to analyze
differences in biological pathways or experimentally-derived differential expression sets and gene
ontologies, respectively between AA and EA TNBCs in TCGA breast dataset. We observed
significantly more upregulation of the proinflammatory expression sets, intestinal immune
network for IgA production (p=0.006) and hematopoietic cell lineage (p=0.028), in AA compared
to EA TNBC patients (Table 11). We also discovered significantly more upregulation of the
proinflammatory gene ontologies hematopoietic or lymphoid organ development, hemopoiesis,
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leukocyte differentiation, immune effector process, lymphocyte differentiation, and immune
system development among AA compared to EA TNBC patients (p<0.001) (Table 12). Significant
downregulation of immune-related genes and processes were not observed among AA compared
to EA TNBCs (data not shown).
6.4

Discussion
TNBC remains a formidable challenge for clinicians worldwide, underscoring the urgent

need for more promising pharmacologically-targetable and/or risk-predictive biomarkers. AA
women are even more at a disadvantage as they exhibit notably higher TNBC incidence and
mortality rates than women of other ethnicities. The advent of cancer immunology and studies
investigating the role of the tumor microenvironment in tumor progression has birthed an array of
alternative and promising immunological targets that may enhance clinical risk-prognostication
and serve as viable therapeutic options for TNBC patients.
Our group discovered that stromal TILs were significantly higher in AAs compared to EAs
among early-stage but not among late-stage TNBC patients suggesting racial disparities in TILs
exist in the early-stages of the disease and a greater presence of TILs may be associated with
African ancestry. This finding is consistent with previous studies reporting that TILs are associated
with more aggressive breast tumor phenotypes such as TNBC status, advanced grade and stage,
lymph node metastasis, and younger age at diagnosis, which are features typically associated with
BC patients of African descent. Among early-stage AA TNBC patients, stromal and peripheral
TILs were associated with younger age at diagnosis and aggressive tumor characteristics such as
high nuclear grade, mitotic index, tubule formation, and Nottingham grade, which may rationalize
younger age at diagnosis and a more aggressive disease course among AA compared to EA TNBC
patients. Ma et. al reported that CD8+ T cells strongly correlated with stromal TIL in BC

119

suggesting that CD8+ T cells, in particular, may be more prevalent among AA compared to EA
TNBCs, although further investigation is needed (23).
Interestingly, we discovered that stromal and peripheral TILs were associated with lack of
AR expression among early-stage AA TNBC patients suggesting that the increased presence of
TILs may be associated with their higher prevalence of quadruple negative breast cancer (QNBC)
among AA compared to EA TNBC patients (11). Stromal and peripheral TILs also positively
correlated with PD-1 among early-stage AA TNBC patients. A high TIL count has been predictive
of a positive response to anti-PD-1 or anti-PD-L1 antibodies (16). Hence, anti-PD-1/PD-L1
therapy may be beneficial for AA TNBC patients with high TIL counts and TILs may serve as a
strong predictive biomarker for immune checkpoint therapy response for AA patients. Stromal and
peripheral TILs also positively correlated with BAP1 among early-stage AA and EA TNBC
patients suggesting a link between an anti-tumor inflammatory/immune response and DNA
damage. Thus, TILs may also serve as a predictive biomarker for response to platinum-based
agents such as cisplatin and carboplatin. Among early-stage AA TNBC patients, high peripheral
TIL levels predicted longer 10-year OS in Kaplan-Meier analyses and after controlling for age,
Nottingham grade, and stage suggesting that a high peripheral TIL count may be predictive of a
better prognosis. We also observed that high peripheral TIL levels predicted longer 10-year OS
among adjuvant chemotherapy- and radiation- treated AA TNBC patients and longer 5-year DFS
among radiation-treated early-stage AA patients, suggesting peripheral TILs may be able to predict
response to treatment in AA patients. Thus, the administration of adoptive cell therapy using TILs
to TNBC patients of African ancestry harboring low levels of lymphocytic infiltration may be
beneficial in improving their survival rates. A combination of TIL immunotherapy and PD-1/PDL1 checkpoint blockade therapy may elicit a more robust response.
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Our in silico analyses revealed a trend of lower proportions of naïve B cells and higher
proportions of memory B cells in AA compared to EA TNBCs corroborating our in vivo findings
of increased lymphocytic infiltration among AA TNBC patients. Furthermore, we observed
significantly lower proportions of M2 macrophages in AA compared to EA TNBCs, although
previous studies have reported higher counts of tumor-associated macrophages of a M2 phenotype
in AA compared to EA breast tumors (34-36). M2 macrophages are immunosuppressive and
implicated in interfering with the anti-tumoral immune response thus, our finding further suggest
increased anti-tumor immune activity in AA compared to EA TNBCs (37). However, interestingly
we observed a significantly greater proportion of Tregs among AA compared to EA TNBCs
suggesting increased immunosuppressive activity among TNBC patients of African ancestry. Ma
and colleagues recently showed that FOXP3+ Tregs strongly correlated with stromal TILs, and
particularly CD8+ T cells, in BC suggesting that our observation of increased lymphocytic
infiltration among AA compared to EA triple negative breast tumors may be associated with their
higher levels of Tregs observed in our study (23). Perhaps a greater presence of suppressive T cells
could be counteracting a greater presence of antitumoral TILs, still subjecting AAs to a worse
clinical prognosis. Further investigation is warranted to determine how differences in the
composition of the tumor immune microenvironments among racially-distinct TNBCs could be
underlying the disparate clinical outcomes observed among AA patients.
Further in silico analyses by our group revealed that the proinflammatory genes, RETN,
TREM-4, CCL3L1, and LAIR2, were significantly more upregulated in AA compared to EA
TNBCs. RETN and TREM-4 genes were expressed almost 2 folds higher among AA compared to
EA TNBCs. Stewart and colleagues also reported that RETN was expressed 2.25 folds higher in
AA compared to EA BC patients in TCGA dataset (38). Martin et. al observed C-X-C motif
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chemokine 10 and 11 being expressed 5.96 and 1.96 folds higher, respectively in AA compared to
EA BC patients (34). We also observed more upregulation of proinflammatory KEGG pathways
among AAs compared to EAs such as the intestinal immune network for IgA production and
hematopoietic cell lineage as well as key proinflammatory gene ontologies such as lymphoid organ
development, leukocyte and lymphocyte differentiation, hemopoiesis, and immune effector
process.
Our study is the first to uncover a previously unrecognized disparity in an important member
of the tumor immune microenvironment, TILs, between racially distinct TNBC patients and
encourages further investigation of racial disparities in TILs among these patient populations. Our
work provides valuable risk-prognostic information of TILs to better guide clinicians in the
optimization of treatment paths for early-stage AA TNBC patients. These findings support the
need for increased evaluation of TILs in the clinic for early-stage AA TNBC patients and suggest
immunotherapy could be exploited as an effective therapeutic strategy for TNBC patients of
African ancestry with low lymphocytic infiltration. However, robust validation of our findings in
additional non-NAC and NAC treated patient cohorts as well as more characterization of immune
cell subsets among racially-distinct triple negative breast tumors will be critical to achieving these
aims.
6.5

Methods

6.5.1 Study Cohort
We analyzed a cohort of 121 TNBC patients treated at EUH in Atlanta, GA from 2002
(initial day of diagnosis) to 2016 (last day of contact). The percentage of stromal and peripheral
TILs was assessed in hematoxylin- and eosin- stained patient specimens as described by
Krishnamurti and colleagues (14). Stromal TILs were evaluated according to the International
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TILs working group 2014 in which the percentage of stromal tissues occupied by infiltrating
lymphocytes and plasma cells were estimated (24). Intratumoral lymphocytes, or lymphocytes in
direct contact with tumor cells, were excluded from the evaluation as no patients in this study
underwent NAC. Peripheral TILs were also evaluated as the percentage of stromal lymphocytes
occupying the entire circumference of the invasive tumor front with a width of roughly one dozen
tumor cells (14). The percentage of stromal and peripheral TILs were estimated in intervals
including <5%, 5-10%, 11-50% and >50%. Patient demographic characteristics, clinicopathological variables, and BC biomarker status were recorded for each patient. Demographic
characteristics include self-reported race and age at the time of diagnosis. This article referred to
the 7th edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer
Control (UICC) TNM Classification and Stage groupings for BC (25). Expression of all BC
biomarkers investigated in this study was determined through immunohistochemical (IHC)
staining and scored as Hscore (percentage x intensity), Nper (nuclear percentage) and Nhscore
(nuclear percentage x intensity). Negativity was determined as <1% expression and positivity was
determined as ≥1% expression for all biomarkers. Information on patient treatment was recorded
including adjuvant chemotherapy and radiation therapy.
6.5.2 Follow Up
Initial diagnosis and follow-up of patients occurred between 2002 and 2016. Initial dates
of diagnoses, treatment start and completion dates, and last dates of contact were recorded for each
patient. Survival status (alive/dead) was also recorded for each patient in addition to survival time.
The date of last follow-up for the last patient seen is March 3, 2016.
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6.5.3 Infiltrating Immune Cell Composition and Differential Gene Expression
Determination
We queried The Cancer Genome Atlas (TCGA) breast dataset from the TCGA portal in
Oncomine for all TNBC patients (26, 27). Publically-available ER/PR/HER2 IHC data was used
to determine TNBC status. We utilized the Cell type Identification By Estimating Relative Subsets
of known RNA Transcripts (CIBERSORT) tool, which is a deconvolution algorithm that uses a
set of reference gene expression values, to resolve intratumoral immune cell composition in gene
expression data from tumor samples of mixed cell types (28). The Leukocyte gene signature matrix
(LM22), which is comprised of 547 genes that resolves 22 human hematopoietic cell phenotypes
[seven T cell types, naïve and memory B cells, plasma cells, natural killer (NK) cells, and myeloid
subsets] in tumor samples, was used to identify proportions of each immune cell type in TNBC
patients based on their gene expression profiles in the TCGA dataset (28). To avoid false positives,
gene expression data was processed using 1000 permutations. As the input data was normalized,
the quantile normalization option was disabled. According to the available race data, we selected
128 AA and EA samples out of 145 TNBC samples. We performed differential gene expression
analysis between the ethnic groups using the DESeq2 software tool (29). Differentially expressed
genes with a p value of <0.05 and log2fold change of above +1 and below -1 were selected in this
study. Differential expression analyses of Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways and gene ontologies between the ethnic groups were predicted by GAGE and Pathview
packages, respectively (30, 31). Heat maps were generated to depict the relative proportion of
select immune cells and differentially expressed genes among each patient group of interest.
6.5.4 Statistical Analysis
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs).
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Chi-square tests were performed to analyze differences in demographic characteristics, breast
clinico-pathological variables and biomarker expression, as well as treatment information between
AA and EA TNBC patients. SAS 9.4 program was used to generate test statistics and 2-tailed
univariate p-values were reported. Wilcoxon rank-sum tests were performed to determine
differences in the means of stromal and peripheral TILs between AA and EA patient populations.
Pearson correlation coefficients (ρ) were computed to determine associations between stromal and
peripheral TILs with demographic and breast clinico-pathological variables and biomarker
expression among AA and EA TNBC patients. Spearman’s rank correlation coefficients (ρ) were
computed for categorical covariates. Unadjusted and adjusted multivariate Cox proportional
hazard regression models were computed to assess the impact of TILs on 10-year OS and DFS
before and after controlling for age, Nottingham grade, and stage. The Kaplan-Meier analysis was
conducted using SAS 9.4 program to estimate survival function for AA and EA TNBC patients
over a 5- or 10- year period based on high and low TIL levels. A log-rank test was used to stratify
stromal and peripheral TILs into high (³10) and low (<10) groups to evaluate associations of a
high and low presence of TILs with better or worse survival among racially-distinct TNBC
patients. Wilcoxon rank-sum tests were performed to determine significant differences in the
proportions of immune cell fractions between AA and EA TNBCs after generating CYBERSORT
outputs. P-value cut-offs were not used. The Wald test was used to test for significance among
differentially expressed genes between the racial groups using the DESeq2 software tool.
6.6

Tables and Figures
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Table 6.1 Clinico-pathological characteristics of AA and EA TNBC patients observed at EUH
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Table 6.1 Clinico-pathological characteristics of AA and EA TNBC patients observed at EUH
AA (n=87)
Clinical characteristic

EA (n=34)

n

%

n

%

p value

Age
20-40

6

6.9

3

8.82

41-60

53

60.92

16

47.06

61-80

28

32.18

15

44.12

1

N/A

N/A

N/A

N/A

2

5

5.75

6

17.65

3

82

94.25

28

82.35

0.39

Nuclear grade
0.04

Tubule formation
1

1

1.15

1

2.94

2

11

12.64

6

17.65

3

75

86.21

27

79.41

0.59

Mitotic Index
1

8

9.2

10

29.41

2

11

12.64

11

32.35

3

68

78.16

13

38.24

0.0001

Nottingham grade
1

1

1.15

1

2.94

2

12

13.79

13

38.24

3

74

85.06

20

58.82

0.008

Stage
I

28

32.18

18

52.94

II

43

49.43

14

41.18

III

13

14.94

2

5.88

IIIC

3

3.45

0

0

Negative

61

70.11

27

79.41

Positive

26

29.89

7

20.59

0.12

Nodal status
0.68

Total lymph node involvement
0

3

3.45

1

2.94

3-Jan

26

29.88

10

29.41

9-Apr

27

31.05

14

41.17

>=10

31

35.62

9

26.48
35.29

0.1

Ki-67 (%)
0-20

21

24.14

12

21-40

10

11.49

1

2.94

41-60

7

8.05

7

20.59

61-80

15

17.24

3

8.82

81-100

34

39.08

11

32.36

0.54

TNM Staging
T
T0

N/A

N/A

TX

N/A

N/A

Tis

N/A

T1

34

39.08

22

64.71

T2

45

51.72

11

32.35

T3

5

5.75

0

0

T4

3

3.45

1

2.94
76.47

0.06

N/A

N
N0

58

66.67

26

NX

3

3.45

1

2.94

N1

14

16.09

5

14.71

N2

9

10.34

2

5.88

N3

3

3.45

0

0

0.56

M
M0

N/A

MX

87

M1

N/A

N/A
100

34

100

N/A

N/A

Adjuvant Chemotherapy
Yes

63

72.41

25

73.53

No

8

9.2

3

8.82

Missing/Unknown

16

18.39

6

17.65

Yes

46

52.87

24

70.59

No

26

29.89

9

26.47

Missing/Unknown

15

17.24

1

2.94

0.94

Radiation therapy
0.37

Abbreviations: AA, African American; EA, European American; T, tumor size; N, lymph node metastasis; M, distant metastasis;
*P value s were calculated using the chi-square test.
Significant p values in table are in bold font.
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Table 6.2 Breast cancer biomarker expression among AA and EA TNBC patients observed at
EUHTable 6.2 Breast cancer biomarker expression among AA and EA TNBC patients observed at EH
AA (n=87)
Biomarkers

EA (n=34)

n

%

n

%

Negative

61

70.11

22

64.71

Positive

16

18.39

5

14.71

Missing/Unknown

10

11.5

7

20.58

p value

AR (Nper)
0.52

HSET (Nhscore)
Negative

N/A

Positive

64

73.56

N/A
24

70.59

Missing/Unknown

23

26.44

10

29.41

N/A

FOXM1 (Nper)
Negative

1

1.15

2

5.88

Positive

65

74.71

23

67.65

Missing/Unknown

21

24.14

9

26.47

Negative

36

41.38

15

44.12

Positive

26

29.89

10

29.41

Missing/Unknown

25

28.73

9

26.47

Negative

27

31.03

6

17.65

Positive

44

50.57

23

67.65

Missing/Unknown

16

18.4

5

14.7

Negative

37

42.53

15

44.12

Positive

40

45.98

11

32.35

Missing/Unknown

10

11.49

8

23.53

0.7

PRC1 (Nper)
0.57

RARα (Nper)
0.02

Aurora A (Nhscore)
0.34

Survivin (Nper)
Negative

3

3.45

1

2.94

Positive

70

80.46

23

67.65

Missing/Unknown

14

16.09

10

29.41

0.76

BAP1 (Nper)
Negative

6

6.9

5

14.71

Positive

67

77.01

20

58.82

Missing/Unknown

14

16.09

9

26.47

0.27

β-catenin (Hscore)
Negative

7

8.05

5

14.71

Positive

70

80.46

17

50

Missing/Unknown

10

11.49

12

35.29

Negative

17

19.54

6

17.65

Positive

70

80.46

28

82.35

Negative

26

29.89

8

23.53

Positive

43

49.43

17

50

Missing/Unknown

18

20.68

9

26.47

Negative

36

41.38

11

32.35

Positive

33

37.93

13

38.24

Missing/Unknown

18

20.69

10

29.41

Negative

37

42.53

12

35.29

Positive

39

44.83

15

44.12

Missing/Unknown

11

12.64

7

20.59

0.01

PD1 (Hscore)
0.21

EGFR (Hscore)
0.22

HER3 (Hscore)
0.59

HER4 (Hscore)
0.45

Abbreviations; AA, African-American; EA, European-American; AR, Androgen Receptor; FOXM1, Forkhead box 1 protein; PRC1, protein regulator of
cytokinesis 1; RARα, Retinoic acid receptor α; BAP1, BRCA1 associated protein 1, PD1, Programmed cell death protein 1; EGFR, epidermal growth
factor receptor; HER3, human epidermal growth factor receptor 3; HER4, human epidermal growth factor receptor 4; Hscore (percentage x intensity),
Nper (nuclear percentage), and Nhscore (nuclear percentage x intensity); N/A, non-applicable.*P value s were calculated using the chi-square test.
Significant p values in table are in bold font.
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Table 6.3 Correlation of stromal TILs with demographic and clinico-pathological variables
among early-stage racially-distinct TNBC patients
Table 6.3 Correlation of stromal TILs with demographic and clinico-pathological variables among early-stage racially-distinct TNBC patients
Clinico-pathological variables
Age a

LN_pos a

LN_tota

Tumor size (cm)a

Tubule formationb

Nuclear grade b

Mitotic index b

ρ

-0.25

0.11

0.08

-0.07

0.28

0.2

0.18

0.3

p value

0.03

0.37

0.49

0.57

0.02

0.1

0.14

0.01

Patients
Early-stage AA
Early-stage AA Chemo
Early-stage AA Non-Chemo
Early-stage AA Rad
Early-stage AA Non-Rad
Early-stage EA
Early-stage EA Chemo
Early-stage EA Non-Chemo
Early-stage EA Rad
Early-stage EA Non-Rad
a
b

Nott. grade b

ρ

-0.26

0.11

0.09

-0.09

0.27

0.2

0.16

0.3

p value

0.04

0.37

0.5

0.49

0.03

0.11

0.2

0.01

ρ

-0.31

0.08

-0.12

0.28

0.55

0.34

0.51

0.54

p value

0.18

0.73

0.62

0.22

0.01

0.13

0.02

0.01

ρ

-0.24

0.04

0.04

-0.03

0.37

0.17

0.17

0.34

p value

0.1

0.77

0.81

0.83

0.01

0.27

0.26

0.02

ρ

-0.23

0.28

0.2

-0.19

0.34

0.33

0.31

0.39

p value

0.28

0.18

0.34

0.39

0.03

0.04

0.06

0.02

ρ

-0.3

0.43

0.45

0.01

0.06

0.27

0.42

0.42

p value

0.09

0.02

0.01

0.95

0.75

0.14

0.02

0.02

ρ

-0.3

0.42

0.43

-0.05

0.16

0.28

0.34

0.37

p value

0.12

0.02

0.02

0.78

0.41

0.15

0.07

0.05

ρ

0.56

.

0.05

0.72

-0.64

0.19

0.55

0.37

p value

0.11

.

0.9

0.03

0.06

0.63

0.12

0.32

ρ

-0.37

0.4

0.45

0.08

-0.04

0.15

0.36

0.43

p value

0.08

0.06

0.03

0.71

0.86

0.49

0.09

0.04

ρ

-0.12

.

0.23

-0.04

0.24

0.62

0.5

0.41

p value

0.73

.

0.52

0.91

0.51

0.05

0.14

0.23

Pearson correlation test (ρ)

Spearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node; Pos, positive; Tot, total; Nott, Nottingham. Missing values are attributed to an insufficient number of
patients to analyze.
Significant p values in table are in bold font.
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Table 6.4 Correlation of peripheral TILs with demographic and clinico-pathological variables
among early-stage racially-distinct TNBC patients
Table 6.4 Correlation of peripheral TILs with demographic and clinico-pathological variables among early-stage racially-distinct TNBC patients
Clinico-pathological variables
Patients
Early-stage AA
Early-stage AA Chemo
Early-stage AA Non-Chemo
Early-stage AA Radiation
Early-stage AA Non-Rad
Early-stage EA
Early-stage EA Chemo
Early-stage EA Non-Chemo
Early-stage EA Rad
Early-stage EA Non-Rad
a

Age a

Nuclear grade b

Mitotic index b

Nott. grade b

Ki67%a

ρ

-0.3

0.12

0.2

0.26

0.03

p value

0.01

0.31

0.1

0.03

0.83

ρ

-0.28

0.13

0.18

0.27

0.04

p value

0.03

0.3

0.14

0.03

0.74

ρ

-0.51

0.34

0.48

0.51

0.1

p value

0.02

0.13

0.03

0.02

0.68
0.15

ρ

-0.25

0.04

0.16

0.27

p value

0.09

0.78

0.27

0.06

0.33

ρ

-0.44

0.37

0.36

0.44

-0.12

p value

0.01

0.02

0.02

0.01

0.46

ρ

-0.32

0.4

0.48

0.53

0.35

p value

0.07

0.02

0.01

<0.01

0.05

ρ

-0.34

0.5

0.42

0.52

0.33

p value

0.07

0.01

0.02

<0.01

0.08

ρ

-0.27

0.18

0.64

0.46

0.56

p value

0.49

0.63

0.06

0.21

0.12

ρ

-0.44

0.24

0.41

0.47

0.34

p value

0.04

0.27

0.05

0.02

0.11

ρ

-0.13

0.74

0.6

0.65

0.4

p value

0.73

0.01

0.07

0.04

0.26

Pearson correlation test (ρ)

b

Spearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; Nott, Nottingham.
Significant p values in table are in bold font.

130

Table 6.5 Correlations of stromal TILs with clinico-pathological biomarkers among earlystage racially-distinct TNBC patients
Table 6.5 Correlation of stromal TILs with clinico-pathological biomarkers among early-stage racially-distinct TNBC patients
Clinico-pathological biomarkers
Patients
Early-stage AA
Early-stage AA Chemo
Early-stage AA Non-Chemo
Early-stage AA Rad
Early-stage AA Non-Rad
Early-stage EA
Early-stage EA Chemo
Early-stage EA Non-Chemo
Early-stage EA Rad
Early-stage EA Non-Rad

AR

HSET

EGFR

BAP1

ρ

-0.255

-0.023

0.049

0.296

PD-1
0.56

p value

0.044

0.87

0.715

0.022

<.0001

ρ

-0.258

-0.018

0.055

0.284

0.589

p value

0.053

0.902

0.704

0.038

<.0001

ρ

-0.35

0.023

0.023

0.376

0.445

p value

0.131

0.931

0.929

0.113

0.043

ρ

-0.191

0.036

-0.007

0.35

0.705

p value

0.32

0.865

0.973

0.068

<.0001

ρ

-0.235

0.084

0.018

0.314

0.672

p value

0.134

0.623

0.917

0.048

<.0001

ρ

-0.223

0.495

0.576

0.445

0.427

p value

0.284

0.019

0.004

0.03

0.015

ρ

-0.164

0.473

0.575

0.394

0.412

p value

0.454

0.03

0.005

0.07

0.026

ρ

-0.818

0.749

-0.669

0.34

0.305

p value

0.09

0.145

0.217

0.455

0.425

ρ

-0.219

0.634

0.695

0.551

0.512

p value

0.399

0.006

0.002

0.018

0.013

ρ

-0.106

-0.318

0.123

0.479

0.67

p value

0.802

0.602

0.817

0.337

0.048

Abbreviations: ρ, pearson correlation coefficient; Chemo, adjuvant chemotherapy; Rad, radiation.
Significant p values in table are in bold font.
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Table 6.6 Correlation of peripheral TILs with clinico-pathological biomarkers among raciallydistinct TNBC patients.
Table 6.6 Correlation of peripheral TILs with clinico-pathological biomarkers among racially-distinct TNBC patients
Clinico-pathological biomarkers
Patients
Early-stage AA
Early-stage AA Chemo
Early-stage AA Non-Chemo
Early-stage AA Rad
Early-stage AA Non-Rad
Early-stage EA
Early-stage EA Chemo
Early-stage EA Non-Chemo
Early-stage EA Rad
Early-stage EA Non-Rad

AR

HSET

PRC1

BAP1

PD-1

HER4

ρ

-0.241

-0.063

-0.268

0.262

0.323

0.065

p value

0.057

0.656

0.05

0.044

0.006

0.617

ρ

-0.263

-0.051

-0.284

0.271

0.35

0.057

p value

0.048

0.732

0.051

0.047

0.004

0.673

ρ

-0.364

0.058

-0.016

0.368

0.212

0.064

p value

0.115

0.825

0.947

0.121

0.355

0.8

ρ

-0.273

0.104

-0.26

0.264

0.432

-0.067

p value

0.08

0.54

0.12

0.1

0.002

0.671

ρ

-0.263

-0.215

-0.286

0.324

0.125

0.427

p value

0.133

0.271

0.133

0.071

0.454

0.015

ρ

-0.295

0.572

-0.005

0.431

0.317

-0.133

p value

0.153

0.005

0.983

0.036

0.077

0.517

ρ

-0.216

0.549

0.003

0.361

0.307

-0.179

p value

0.323

0.01

0.989

0.099

0.105

0.403

ρ

-0.645

0.64

-0.368

0.548

0.668

-0.02

p value

0.24

0.245

0.542

0.203

0.049

0.97

ρ

-0.287

0.646

0.009

0.463

0.293

-0.063

p value

0.264

0.005

0.971

0.053

0.174

0.805

ρ

-0.326

0.444

.

0.373

0.339

-0.292

p value

0.431

0.454

.

0.41

0.337

0.482

Abbreviations: ρ, pearson correlation coefficient; Chemo, adjuvant chemotherapy; Rad, radiation. Missing values are attributed to an
insufficient number of patients to analyze.
Significant p values in table are in bold font.
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Table 6.7 Prediction
peripheral
TILsTILs
onon10-year
OSamong
among
racially-distinct
TNBC patients.
Table 6.7. of
Prediction
of peripheral
10-year OS
racially-distinct
TNBC patients.
All patients

p-value; HR (95% CI)

p-value; HR (95% CI)

Unadjusted model

Adjusted model

Early and late stage
Overall

0.1159; 0.518 (0.228, 1.176)

0.0189; 0.344 (0.141, 0.838)

Chemotherapy

0.2790; 0.598 (0.236, 1.517)

0.0879; 0.403 (0.142, 1.144)

Non-Chemotherapy

0.2097; 0.422 (0.110, 1.624)

0.2426; 0.368 (0.069, 1.968)

Radiation

0.1277; 0.428 (0.144, 1.275)

0.0434; 0.284 (0.084, 0.963)

Non-Radiation

0.1761; 0.463 (0.152, 1.412)

0.1682; 0.380 (0.096, 1.505)

Overall

0.3981; 0.633 (0.219, 1.828)

0.2861; 0.545 (0.179, 1.662)

Chemotherapy

0.8389; 0.880 (0.258, 3.009)

0.9041; 0.923 (0.249, 3.415)

Non-Chemotherapy

0.1023; 0.234 (0.041, 1.336)

0.0887; 0.200 (0.031, 1.276)

Radiation

0.4018; 0.504 (0.102, 2.499)

0.3716; 0.464 (0.086, 2.498)

Non-Radiation

0.1227; 0.367 (0.103, 1.310)

0.1574; 0.371 (0.094, 1.467)

p-value; HR (95% CI)

p-value; HR (95% CI)

Unadjusted model

Adjusted model

Early-stage

AA
Early and late stage
Overall

0.0106; 0.303 (0.121, 0.757)

0.0026; 0.229 (0.084, 0.622)

Chemotherapy

0.0387; 0.326 (0.113, 0.994)

0.0154; 0.230 (0.070, 0.755)

Non-Chemotherapy

0.0449; 0.218 (0.049, 0.966)

0.0818; 0.147 (0.017, 1.274)

Radiation

0.0228; 0.239 ( 0.070, 0.819)

0.0141; 0.167 (0.040, 0.697)

Non-Radiation

0.0965; 0.358 (0.107, 1.202)

0.1399; 0.301 (0.061, 1.483)

Early-stage
Overall

0.0653; 0.326 (0.099, 1.074)

0.0445; 0.273 (0.077, 0.969)

Chemotherapy

0.2313; 0.428 (0.107, 1.716)

0.265; 0.429 (0.097, 1.900)

Non-Chemotherapy

0.0249; 0.075 (0.008, 0.721)

0.0408; 0.031 (0.001, 0.865)

Radiation

0.1344; 0.255 (0.042, 1.527)

0.1159; 0.208 (0.029, 1.473)

Non-Radiation

0.0524; 0.235 (0.054, 1.015)

0.1199; 0.283 (0.058, 1.389)

Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model adjusted for age, Nottingham grade, and stage.
Peripheral TILs were treated as a categorical variable.
Significant p values in table are in bold font.
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Table 6.8 Prediction of stromal TILs on 10-year DFS among racially-distinct TNBC patients.

Table 6.8 Prediction of stromal TILs on 10-year DFS among racially-distinct TNBC
patients.
All patients
p-value; HR (95% CI)
p-value; HR (95% CI)
Unadjusted model
Adjusted model
Early and late stage
Overall
0.399; 0.58 ( 0.17, 2.02)
0.079; 0.31 ( 0.08, 1.14)
Chemotherapy
0.253; 0.42 ( 0.09, 1.86)
0.093; 0.27 ( 0.05, 1.24)
Non-Chemotherapy
0.637; 1.78 ( 0.16, 19.6)
0.575; 0.40 ( 0.01, 9.62)
Radiation
0.189; 0.36 ( 0.08, 1.63)
0.047; 0.21 ( 0.04, 0.98)
Non-Radiation
0.566; 2.01 ( 0.18, 22.2)
0.748; 0.59 ( 0.02, 13.9)
Early-stage
0.0607; 0.139 (0.018,
Overall
0.155; 0.22 ( 0.03, 1.75)
1.093)
Chemotherapy
0.175; 0.24 ( 0.03, 1.88)
0.098; 0.17 ( 0.02, 1.38)
Non-Chemotherapy
0.997; 0.00 ( - )
0.998; 0.00 ( - )
0.0546; 0.131 (0.016,
Radiation
0.126; 0.20 ( 0.02, 1.56)
1.041)
Non-Radiation
0.997; 0.00 ( - )
0.997; 0.00 ( - )
AA
Early and late stage
Overall
Chemotherapy
Non-Chemotherapy
Radiation
Non-Radiation

p-value; HR (95% CI)

p-value; HR (95% CI)

Unadjusted model

Adjusted model

0.522; 0.65 ( 0.18, 2.36)
0.3610; 0.493 (0.108,
2.250)
0.5600; 2.281 (0.142,
36.51)
0.298; 0.44 ( 0.09, 2.05)
0.733; 1.51 ( 0.13, 16.7)

0.154; 0.38 ( 0.10, 1.42)
0.1968; 0.363 (0.078,
1.692)
1.000; 0.02 ( - )
0.123; 0.29 ( 0.06, 1.39)
0.669; 0.51 ( 0.02, 11.0)

Early-stage
Overall
Chemotherapy
Non-Chemotherapy
Radiation
Non-Radiation

0.1779; 0.243 (0.031,
1.902)
0.215; 0.27 ( 0.03, 2.14)
0.997; 0.00 ( - )
0.152; 0.21 ( 0.02, 1.75)
0.997; 0.00 ( - )

0.097; 0.17 ( 0.02, 1.37)
0.175; 0.23 ( 0.02, 1.90)
1.000; 0.11 (- )
0.113; 0.18 ( 0.02, 1.49)
0.997; 0.00 ( - )

Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model
adjusted for age, Nottingham grade, and stage. Overall TILs were treated as a
categorical variable. (-), indicates that 95% CIs were unable to be generated.
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Table 6.9 Prediction of peripheral TILs on 10-year DFS among racially-distinct TNBC
patients.
Table 6.9. Prediction of peripheral TILs on 10-year DFS among racially-distinct TNBC patients.
All patients

p-value; HR (95% CI)

p-value; HR (95% CI)

Unadjusted model

Adjusted model

Early and late stage
Overall

0.330; 0.63 ( 0.24, 1.59)

0.035; 0.36 ( 0.14, 0.93)

Chemotherapy

0.484; 0.69 ( 0.24, 1.94)

0.164; 0.47 ( 0.17, 1.35)

Non-Chemotherapy

0.342; 0.31 ( 0.02, 3.45)

0.997; 0.00 ( - )

Radiation

0.341; 0.61 ( 0.22, 1.68)

0.029; 0.31 ( 0.11, 0.89)

Non-Radiation

0.949; 0.92 ( 0.08, 10.1)

0.334; 0.25 ( 0.01, 4.17)

Overall

0.184; 0.49 ( 0.17, 1.40)

0.027; 0.30 ( 0.10, 0.87)

Chemotherapy

0.393; 0.60 ( 0.19, 1.91)

0.195; 0.46 ( 0.14, 1.48)

0.997; 0.00 ( - )

0.998; 0.00 ( - )

0.2176; 0.490 (0.158, 1.523)

0.0219; 0.259 (0.082, 0.823)

0.615; 0.49 ( 0.03, 7.85)

0.3801; 0.281 (0.016, 4.793)

p-value; HR (95% CI)

p-value; HR (95% CI)

Unadjusted model

Adjusted model

Early-stage

Non-Chemotherapy
Radiation
Non-Radiation
AA
Early and late stage
Overall

0.308; 0.57 ( 0.20, 1.66)

0.111; 0.42 ( 0.14, 1.22)

Chemotherapy

0.343; 0.57 ( 0.18, 1.80)

0.302; 0.54 ( 0.17, 1.72)

Non-Chemotherapy

0.607; 0.48 ( 0.03, 7.72)

1.000; 0.00 ( - )

Radiation

0.245; 0.49 ( 0.15, 1.62)

0.135; 0.39 ( 0.11, 1.34)

Non-Radiation

0.936; 0.90 ( 0.08, 9.99)

0.386; 0.29 ( 0.01, 4.74)

Overall

0.195; 0.45 ( 0.13, 1.49)

0.120; 0.38 ( 0.11, 1.28)

0.2856; 0.501 (0.141, 1.781)

0.4096; 0.584 (0.162, 2.099)

0.998; 0.00 ( - )

1.000; 0.00 ( - )

Radiation

0.102; 0.33 ( 0.08, 1.24)

0.1144; 0.292 (0.063, 1.346)

Non-Radiation

0.613; 0.48 ( 0.03, 7.82)

0.427; 0.32 ( 0.01, 5.30)

Early-stage
Chemotherapy
Non-Chemotherapy

Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional hazard model adjusted for age,
Nottingham grade, and stage. Overall TILs were treated as a categorical variable. (-), indicates that 95%
CIs were unable to be generated.
Significant p values and corresponding HR and confidence intervals in table are in bold font.

136

Table 6.10 Immune-related genes upregulated in AA compared to EA TNBC patients in
TCGA
dataset.
Table
6.10. Immune-related
genes upregulated in AA compared to EA TNBC patients in TCGA dataset.
Gene

Gene name

log2FoldChange

p value

RETN

resistin

1.890840792

4.97E-10

TREML4

triggering receptor expressed on myeloid cells like 4

1.677117556

2.34E-09

CCL3L1

C-C motif chemokine ligand 3 like 1

1.356316644

1.50E-06

LAIR2

leukocyte associated immunoglobulin like receptor 2

1.238761571

4.96E-06

Table 6.11 Immune-related pathways upregulated in AA compared to EA TNBC patients in
TCGA
dataset. pathways upregulated in AA compared to EA TNBC patients in TCGA dataset.
Table 6.11
Immune-related
Pathway

p-value

hsa04672 Intestinal immune network for IgA production

0.006

hsa04640 Hematopoietic cell lineage

0.028
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Figure 6.1 Comparison of stromal TILs among racially-distinct TNBC patients.
Comparison of stromal TILs among AA and EA TNBC patients (39), among early-stage AA and
EA TNBC patients, (39) and late-stage AA and EA TNBC patients overall and with or without
adjuvant chemotherapy (chemo) or radiation (rad) treatment. No record of not having received
treatment for late-stage patients. *p<0.05.
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Figure 6.2 Peripheral TILs predict OS among early-stage AA TNBC patients.
Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test.
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on
survival over a 10-year period among AA TNBC patients. Prediction of high and low peripherals
TILs on 10-year OS among (39) all AA patients, (39) adjuvant chemotherapy-treated AA patients,
(39) radiation-treated AA patients, (39) early-stage AA patients, (39) non-adjuvant chemotherapy
treated early-stage AA patients and (F) non-radiation treated early-stage AA patients.
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Figure 6.3 Peripheral TILs predict DFS among early-stage AA TNBC patients.
Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test.
Kaplan-Meier curve was generated to estimate impact of high and low peripheral TIL levels on
DFS over a 5-year period among early-stage AA TNBC patients treated with radiation.
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Figure 6.4 Comparison of intratumoral immune cell fractions between AA and EA TNBC
samples.
CIBERSORT tool was used to determine the proportions of distinct infiltrating immune cells
among AA and EA TNBCs isolated from the TCGA breast dataset. No cut-offs for p-values were
used. The color gradient from green to red represents the increasing fractions of intratumoral
immune cells. (39) Immune cell fractions that showed statistically significant differences between
the races with a greater proportion of Tregs and smaller proportion of M2 macrophages among
AAs compared to EAs. (39) Immune cell fractions that showed weakly statistically significant
differences (0.05>p<0.1) between the races with a smaller proportion of naïve B cells and greater
proportion of memory B cells among AAs compared to EAs.
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Figure 6.5 Differentially expressed immune-related genes among AA and EA TNBC samples.
The DESeq2 tool was used to determine differences in the expression of immune-related genes
between AA and EA TNBC patients isolated from the TCGA breast dataset. Genes that were
significantly differentially expressed between the racially-distinct TNBC patients (p<0.05) and a
log2fold change of above +1 were included in the heat map to depict the relative expression levels
of each gene. The color gradient from red to green represents increasing expression of each gene.
RETN (resistin), LAIR2 (leukocyte associated immunoglobulin like receptor 2), TREML4
(triggering receptor expressed on myeloid cells like 4), and CCL3L1 (C-C motif chemokine ligand
3 like 1) genes were found to be significantly more upregulated in AA compared to EA samples
(p<0.00001).
6.7
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7

TUMOR-INFILTRATING LYMPHOCYTES AS RISK-PROGNOSTIC

BIOMARKER AMONG EARLY-STAGE QUADRUPLE NEGATIVE BREAST
CANCER PATIENTS
7.1

Abstract
Quadruple negative breast cancer (QNBC) is defined by a lack of estrogen and

progesterone receptors, human epidermal growth factor receptor 2, and androgen receptor (AR).
Some studies suggest the absence of AR expression in triple negative breast cancer (TNBC)
confers a more aggressive disease course. We compared stromal and peripheral TILs between
early-stage AR-negative and AR-positive TNBC patients at Emory Hospital in Atlanta, GA and
analyzed a publically-available gene expression dataset for distinctions in infiltrating immune cell
phenotypes between AR- low and high expressing TNBC patents. Among early-stage TNBC
patients (N=94), we observed more stromal (p=0.002) and peripheral (p=0.018) TILs in ARnegatives (N=76) compared to AR-positives (N=18). Our in silico results suggest increased antitumoral immune activity among AR-low compared to AR-high expressing TNBCs. Among earlystage AR-negative patients, stromal and peripheral TILs correlated negatively with younger age at
diagnosis (p<0.01). High peripheral TILs count was associated with longer 10-year disease-free
survival among AR-negative patients in multivariate analyses (p=0.026; HR: 0.062). Our findings
uncover previously unrecognized distinctions in the tumor immune microenvironment between
AR-negative and AR-positive triple negative breast tumors and suggest that TILs may be a
promising, alternative risk-prognostic biomarker that could be exploited therapeutically for earlystage QNBC patients.
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7.2

Introduction
Triple negative breast cancer (TNBC) is an aggressive form of breast cancer defined by the

absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor
2 (HER2/neu) expression. Thus, TNBC patients do not benefit from conventional endocrine
therapy and HER2-targeted systemic treatments as therapeutic options

1,2

. Furthermore,

anthracycline-taxane based chemotherapy is unable to completely eliminate most triple negative
breast tumors. Quadruple negative breast cancers (QNBCs) represent a subgroup of TNBCs that
lack androgen receptor expression. Approximately 45-88% of TNBCs lack nuclear AR expression
3,4

. Thus, unlike AR-positive TNBCs, QNBC patients are excluded from receiving AR-targeted

therapy as an alternative treatment option. Although the prognostic role of AR in TNBC remains
controversial, a lack of AR expression has been associated with poor differentiation, high clinical
stage, high Ki-67, high mitotic index, increased lymphovascular invasion, increased risk of
recurrence and distant metastasis, and worse 5-year disease-free survival (DFS) and overall
survival

5-9

. Thus, novel, alternative risk-prognostic biomarkers and therapeutic targets are

urgently needed to abrogate an aggressive disease course and avert a poor prognosis among this
patient population.
Upon neoplastic transformation, tumor-infiltrating lymphocytes migrate to the tumor site
to prevent tumor progression 10,11. Stromal TILs reside in the stromal compartment of the tumor,
while peripheral TILs occupy the invasive tumor front 12,13. Stromal TILs have been reported to
be more prognostic in TNBC than peripheral TILs as stromal TILs have been associated with
longer OS, increased metastasis-free survival and reduced distance recurrence as well as
improved pathological complete response (pCR) following neoadjuvant chemotherapy in TNBC
12,14,15

. In fact, for every 10% increase in stromal TILs, a 15% reduction in relapse risk and 17%
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reduction in death risk has been reported. However, recently among TNBC patients not treated
with neoadjuvant chemotherapy, peripheral TILs were similarly associated with longer OS and
DFS 13. Paradoxically, an increased presence of stromal TILs have been associated with more
aggressive breast tumor features such as high grade, high stage, high Ki-67, lymph node
metastasis, a triple negative breast tumor phenotype and younger age at diagnosis 15-20. Thus, we
were interested in evaluating if there are differences in the presence of stromal and peripheral
TILs between AR-negative and AR-positive TNBCs and investigating if stromal and peripheral
TILs can function as a risk-predictive and prognostic biomarker for early-stage QNBC patients.
We compared TIL counts between AR-negative and AR-positive TNBC patients observed at
Emory University Hospital (EH) in Atlanta, GA in a non-neoadjuvant chemotherapy setting and
assessed the predictive and prognostic role of TILs among QNBC patients.
7.3

Results

7.3.1 Clinico-pathological characteristics and biomarker expression among AR-negative and
AR-positive TNBC patients
We analyzed differences in associations with demographic and clinico-pathological
characteristics as well as treatment status between AR-negative (N=89) and AR-positive (N=21)
TNBC patients observed at EH (Table 1). We observed a significant difference in associations
with nuclear grade between the groups. Among AR-negative patients, 96% presented as grade 3
as opposed to 81% among AR-positive patients (p=0.02). We also observed modest differences in
associations with Nottingham grade and radiation therapy administration based on AR status.
Among AR-negative patients, 85% presented with a Nottingham grade of 3 while only 71% of
AR-positive patients presented with a grade of 3 (p=0.06). Among AR-negative patients, 62%
were reported to have received radiation therapy while only 38% of AR-positive patients
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underwent the treatment (p=0.05). We also compared differences in associations with breast cancer
biomarker expression between AR-negative and AR-positive TNBC patients (2). We observed
differences in associations with HSET expression between the patient groups. Among AR-positive
patients, 76% were positive for HSET expression as opposed to 82% of AR-negative patients
(p=0.01). Similarly, modest differences in HER3 expression emerged, where 46% of AR-positive
patients were positive for the marker as opposed to 43% of AR-negative patients (p=0.07).
7.3.2 Early-stage AR-negative harbor more TILs than early-stage AR-positive TNBC
patients
We investigated differences in the presence of stromal and peripheral TILs between ARnegative (N=89) and AR-positive (N=21) TNBC patients (Figure 1). We observed that stromal
TIL levels were higher in AR-negative compared to AR-positive TNBC patients (p=0.001) as well
as among non-adjuvant chemotherapy-treated (p=0.012) and radiation-treated (p=0.011) TNBC
patients (Fig 1A). Stromal TILs were also higher in AR-negative (N=76) compared to AR-positive
(N=18) early-stage (I-II) (N=94) TNBC patients (p=0.002) as well as among non-adjuvant
chemotherapy-treated (p=0.040) and radiation-treated (p=0.049) early-stage TNBC patients
(p=0.01) (Fig 1B). We also observed significant differences in peripheral TIL count between ARnegative and positive TNBC patients. Peripheral TIL levels were higher in AR-negative compared
to AR-positive TNBC patients (p=0.017) as well as among non-adjuvant chemotherapy-treated
(p=0.012) and radiation-treated (p=0.025) TNBC patients (Fig 1C). Peripheral TILs were also
higher in AR-negative compared to AR-positive early-stage TNBC patients (p=0.018) as well as
among non-adjuvant chemotherapy-treated (p=0.039) and radiation-treated (p=0.031) early-stage
TNBC patients (Fig 1D). We observed no differences in stromal or peripheral TIL count among
late-stage (III-IIIC) patients.
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7.3.3 TILs are associated with more aggressive disease among AR-negative TNBC patients
We examined correlations between stromal (Table 3A) and peripheral (Table 3B) TILs
with demographic and clinico-pathological variables among AR-negative and AR-positive TNBC
patients. Regarding demographic variables, stromal TILs negatively correlated with age at
diagnosis among all (ρ=-0.325; p=0.002) and early-stage (ρ=-0.320; p=0.005) AR-negative
patients. Stromal TILs positively correlated with tubule formation (ρ=0.221; p=0.038) among ARnegative patients and positively correlated with nuclear grade among early-stage AR-positive
patients (ρ=0.499; p=0.035). Peripheral TILs also negatively correlated with age at diagnosis
among all (ρ=-0.307; p=0.003) and early-stage (ρ=-0.318; p=0.005) AR-negative patients as well
as among early-stage AR-positive patients (ρ=-0.495; p=0.037). Among AR-positive patients,
peripheral TILs were associated with high nuclear (ρ=0.603; p=0.008) and Nottingham (ρ=0.589;
p=0.010) grades.
To further explore the prognostic role of TILs in QNBC, we analyzed associations of
stromal (Table 4A) and peripheral (Table 4B) TILs with expression of common breast cancer
biomarkers among AR-negative and AR-positive TNBC patients. Interestingly, stromal TILs
positively correlated with BRCA1-associated protein 1 (BAP1) and programmed death cell protein
1 (PD1) expression among all (ρ=0.292; p=0.011, ρ=0.469; p<0.0001, respectively) and earlystage (ρ=0.282; p=0.024, ρ=0.480; p<0.0001, respectively) AR-negative patients. Among ARpositive patients, stromal TILs positively correlated with BAP1 expression (ρ=0.531; p=0.034).
Peripheral TILs positively correlated with PD1 among all (ρ=0.401; p<0.0001) and early-stage
(ρ=0.392; p<0.001) AR-negative patients as well. However, peripheral TILs positively correlated
with forkhead box protein 1 (FOXM1) expression among all AR-negative patients (ρ=0.253;
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p=0.028). Peripheral TILs also positively correlated with BAP1 expression (ρ=0.60; p=0.02)
among all (ρ=0.652; p=0.006) and early-stage (ρ=0.603; p=0.017) AR-positive patients.
7.3.4 High TIL levels were associated with better survival among early-stage AR-negative
TNBC patients
We investigated the prognostic power of TILs among AR-negative TNBC patients in both
Kaplan-Meier analyses and Cox proportional hazard regression models. We examined associations
of stromal and peripheral TILs with DFS among AR-negative patients in Kaplan-Meier analyses
(Figure 2). High peripheral TIL levels were associated with significantly longer 10-year DFS
among all (p=0.037) (Fig 2A) and moderately longer 10-year DFS among early-stage AR-negative
patients (p=0.053) (Fig 2B). High peripheral TIL count was also associated with longer 10-year
DFS among all non-adjuvant chemotherapy-treated (p=0.001) (Fig 2C) and early-stage nonadjuvant chemotherapy treated (p<0.0001) AR-negative patients (Fig 2D). Furthermore, high
peripheral TIL levels were associated with better 10-year DFS among radiation-treated early-stage
AR-negative patients (p=0.044) (Fig 2E). We did not observe associations of stromal TILs with
DFS among AR-negative patients. We also observed associations with peripheral TILs and DFS
in univariate and multivariate Cox proportional hazard regression models among AR-negative
TNBC patients (Table 5). High peripheral TIL levels were associated with longer 10-year DFS
before (p=0.013; HR: 0.055 95% CI: 0.005-0.542) and after (p=0.026; HR: 0.062 95% CI: 0.0050.721) adjusting for age at diagnosis and Nottingham grade among non-adjuvant chemotherapytreated AR-negative TNBC patients.
Peripheral TILs were also associated with OS among AR-negative TNBC patients in
Kaplan Meier analysis (Figure 3) and in Cox proportional hazard regression models (Table 6).
High peripheral TIL count was associated with longer 10-year OS among all (p=0.001) (Fig 3A)
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and early-stage (p<0.0001) (Fig 3B) non-adjuvant chemotherapy-treated AR-negative patients.
We observed similar results in univariate and multivariate analyses in which high peripheral TIL
levels were associated with longer 10-year OS among non-adjuvant chemotherapy-treated ARnegative patients before (p=0.013; HR: 0.055 95% CI: 0.005-0.542) and after (p=0.026; HR: 0.158
95% CI: 0.027-0.930) adjusting for age at diagnosis and Nottingham grade.
7.3.5 Distinctions in TIL subsets between aggressive and less aggressive TNBCs
TILs are comprised of a heterogeneous population of immune cell phenotypes harboring
pro-tumorigenic and anti-tumorigenic characteristics. To discern distinctions in the types of
infiltrating immune cells present in the tumor microenvironment between AR-negative and ARpositive TNBCs, we used the CYBERSORT tool and LM22 to estimate the relative proportions of
22 immune cell phenotypes among gene expression profiles from AR-low and AR-high expressing
TNBC patient tissue specimens in the TCGA dataset and analyzed for significant differences
(Figure 4). We observed significantly lower proportions of naïve B cells (p=0.04) and resting mast
cells (p=0.048) among AR-low (N=16) compared to AR-high (N=41) TNBCs using a p-value cutoff of p<0.01 (Fig 4A). Furthermore, we observed weakly significantly lower proportions of
resting natural killer (NK) cells (p=0.05) and weakly significantly higher proportions of activated
NK cells (p=0.097) among AR-low (N=37) compared to AR-high (N=106) TNBCs without using
a p-value cut-off (Fig 4B).
7.4

Discussion
TNBC patients have the least amount of targeted treatment options compared to other

breast cancer patients. A subgroup of TNBCs that lack expression of AR are even more at a
disadvantage as they are often exempt from receiving AR-targeted therapy as opposed to ARexpressing TNBCs. Hence, there is an urgent need for alternative pharmacologically-targetable
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and/or risk-predictive biomarkers for this unique group of TNBC patients. However, studies
uncovering novel therapeutic targets or biomarkers for QNBC patients remain scarce. Cancer
immunotherapy or exploiting intrinsic mechanisms of the tumor-host immune system is rapidly
gaining momentum as a promising alternative strategy in eradicating tumors 21. The immune-rich
TNBC landscape has identified TNBC patients as strong candidates for novel immunotherapeutic
intervention

21

. However, the role of the tumor immune microenvironment in QNBC remains

elusive. Xiu and colleagues recently revealed that PD-L1 is overexpressed in QNBC compared to
TNBC tumors (unpublished data) and PD-L1 is associated with a high level of TILs 22. Hence, we
investigated differences in TIL levels between QNBC and TNBC patients in a non-neoadjuvant
chemotherapy setting and investigated the role of TILs as a potential, novel risk-prognostic
biomarker and therapeutic target for QNBC patients.
We examined differences in associations with demographic, clinico-pathological variables,
treatment, and biomarker expression between AR-negative and AR-positive TNBCs. We observed
that high nuclear and Nottingham grades (grade 3) was more associated with AR-negative
compared to AR-positive status among TNBC patients. This finding corroborates previous studies
revealing a lack of AR expression is associated with high-grade tumors. AR-negative status was
also modestly more associated with receipt of radiotherapy compared to AR-positive status.
Furthermore, positive HSET and HER3 expression was more associated with AR-positivity
compared to AR-negativity among TNBC patients. A previous study reported HER4 mRNA
expression levels were higher in AR-positive compared to AR-negative TNBCs suggesting
expression of EGFR family members may be associated with AR status 23.
We observed a significantly higher presence of stromal and peripheral TILs in ARnegatives compared to AR-positives among all and early-stage TNBC patients. This finding is
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consistent with a recent study by Davis and colleagues reporting expression of CD4 and CD8 T
cell markers as well as expression of key immune checkpoint inhibitors, PD-1, PD-L1, and CTLA4, were significantly more upregulated among AR-negative compared to AR-positive TNBC
patients in TCGA dataset24. Thus, within the highly immunogenic TNBC landscape, the QNBC
subgroup may exhibit increased immune signaling activity compared to AR-expressing TNBCs
suggesting QNBCs to be even more of an ideal candidate for immunotherapeutic intervention.
Furthermore, this finding corroborates previous reports of increased lymphocytic infiltration
among more aggressive breast tumor phenotypes and parallels literature reports of TILs being
more prevalent among TNBCs compared to non-TNBCs.
We also examined associations of TILs with demographic and clinico-pathological
characteristics among AR-negative and AR-positive TNBCs. Stromal and peripheral TILs were
associated with younger age at diagnosis and aggressive clinico-pathological characteristics such
as higher tubule formation, nuclear grade, and Nottingham grade among all and early-stage ARnegative and AR-positive patients, which is consistent with previous studies, cited earlier,
reporting that TILs are associated with younger age at diagnosis and more aggressive disease.
We also analyzed associations of TILs with breast clinico-pathological biomarkers among
AR-negative and AR-positive TNBC patients to glean additional insight into the prognostic and
mechanistic role of TILs among these patient populations. Both stromal and peripheral TILs were
associated with increased PD-1 among QNBC patients. PD-1 is frequently expressed on cytotoxic
CD8+ T cells and thus, is associated with high levels of TILs, which is consistent with our findings
12

. Hence, TILs may serve as a predictive biomarker for response to immune checkpoint therapy

for QNBC patients. Stromal TILs were also linked to high BAP1 expression among early-stage
AR-negative patients suggesting increased lymphocytic infiltration may be associated with
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increased DNA damage response in QNBC patients. BAP1 is a nuclear-localized, ubiquitin
carboxy-terminal hydrolase, that binds to the RING finger domain of BRCA1 to facilitate BRCA1mediated DNA damage response and arrest of breast cancer cell proliferation25. Thus, high TIL
levels may also predict positive response to platinum-based agents such as cisplatin and
carboplatin among QNBC patients. Peripheral but not stromal TILs were associated with high
FOXM1 expression among AR-negative patients. FOXM1 is a transcription factor that regulates
cell cycle progression, specifically mitotic division, chromosome segregation and genomic
stability26,27. It has been found to be overexpressed in approximately 85% of TNBCs and its
upregulation has been suggested to play a critical role in carcinogenesis through stimulating cell
proliferation and tumor metastasis28. Thus, the increased presence of stromal TILs among ARnegative patients may reflect increased aberrant cell division and chromosome segregation errors
and may predict a positive response to FOXM1 inhibitors. Among AR-positive patients, high
peripheral TIL levels were also linked to increased BAP1 expression or DNA damage suggesting
an increased anti-tumor inflammatory response may be associated with genomic instability among
TNBC patients irrespective of AR status.
To further explore the role of TILs as a potential prognostic biomarker for QNBC patients,
we investigated associations of TIL levels with clinical outcomes among AR-negative patients.
We discovered that high peripheral TIL levels were associated with longer DFS and OS among
early-stage QNBC patients in Kaplan-Meier and all QNBC patients multivariate analyses, which
corroborate previous studies showing that a greater presence of TILs is associated with a better
prognosis in TNBC. High peripheral TIL levels were also linked to longer DFS among radiationtreated early-stage AR-negative patients suggesting that TILs may be able to predict response to
radiotherapy in QNBC patients.
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Our in silico analyses discerning distinctions in the proportions of infiltrating immune cell
subsets between AR-high and AR-low expressing TNBCs supports our findings of increased antitumor immune activity among QNBC patients. We observed significantly lower proportions of
naïve B cells and resting mast cells as well as a trend of less resting NK cells and more activated
NK cells in AR-low compared to AR-high TNBCs, suggesting increased anti-tumor immune
activity in QNBCs compared to TNBCs. These findings corroborate our in vivo findings of
increased lymphocytic infiltration among AR-negative TNBC patients and support previous
reports of a greater presence of immune cell infiltration associated with more aggressive breast
cancer. However, further investigation is necessary to unravel the composition of the tumor
immune microenvironment of AR-negative TNBC tumors for precise immunotherapeutic
intervention.
Our work suggest a novel, alternative risk-predictive and prognostic biomarker for
QNBC patients who are insusceptible to AR-targeted treatment as opposed to AR-positive
TNBCs. TILs are currently being tested in clinical trials as a therapeutic strategy for TNBC
patients29. Adoptive T cell therapy has already shown promising results in clinical trials for
melanoma patients as an approximate 50% reduction in tumor size was observed among half of
the patients 30. Thus, the administration of TIL immunotherapy to QNBC patients harboring low
levels of TILs may be beneficial for this patient population and serves as a potential, alternative
therapeutic option for this challenging disease. The addition of PD-1/PD-L1 checkpoint
blockade therapy to TIL immunotherapy may elicit a more robust response among this patient
population. Our study may also encourage the development of novel immunotherapeutic
strategies designed to counteract mechanisms that restrict tumor lymphocytic infiltration, which
may be advantageous for early-stage QNBC patients. Our work encourages further investigation
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of tumor-host immune interactions among AR-negative TNBCs to uncover more novel
immunotherapeutic targets. Conveniently, groups such as the International TILs Working Group
in 2014 and the International Immuno-Oncology Biomarker Working Group on Breast Cancer
have developed standardized methodologies for evaluating stromal TILs in hematoxylin and
eosin (H&E) stained tumor tissue sections as standard routine histopathological practice 31,32.
These methodologies encourage the implementation of TILs in the clinic as a standard clinicopathological parameter for prediction of patient prognosis. Our study suggests evaluation of TILs
should be done routinely in the clinic for AR-negative TNBC patients, who lack other prognostic
markers and treatment options. However, our findings were uncovered in a non-neoadjuvant
chemotherapy setting which represents a limitation to our study. Validation of our findings in
additional non-neoadjuvant chemotherapy and neoadjuvant chemotherapy treated patient cohorts
as well as more characterization of immune cell subsets among AR-enriched and non-enriched
triple negative breast tumors will be critical, however, to establishing TILs as a robust prognostic
biomarker and therapeutic strategy for QNBC patients.
7.5

Methods

7.5.1 Study Cohort
We analyzed a cohort of 121 TNBC patients observed at EH in Atlanta, GA from 2002
(initial day of diagnosis) to 2016 (last day of contact). We obtained approval and informed consent
from the Emory University Institutional Review Board to gain access to patient information and
samples used in this study and to perform the experiments conducted in this article. We have a
human subjects assurance on file. The study was conducted in accordance with relevant
guidelines/regulations. The percentage of stromal and peripheral TILs was assessed in
hematoxylin- and eosin- stained patient specimens as described by Krishnamurti and colleagues
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. Stromal TILs were evaluated according to the International TILs working group 2014 in which

the percentage of stromal tissues occupied by infiltrating lymphocytes and plasma cells were
estimated

32

. Intratumoral lymphocytes, or lymphocytes in direct contact with tumor cells, were

excluded from the evaluation as no patients in this study underwent neoadjuvant chemotherapy.
Peripheral TILs were also evaluated as the percentage of stromal lymphocytes occupying the entire
circumference of the invasive tumor front with a width of roughly one dozen tumor cells. The
percentage of stromal and peripheral TILs were estimated in intervals including <5%, 5-10%, 1150% and >50%. Patient demographic characteristics, clinico-pathological variables, and breast
cancer biomarker status were recorded for each patient. This article referred to the 7th edition of
the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC)
TNM Classification and Stage groupings for breast cancer 33. Demographic characteristics include
self-reported race and age at the time of diagnosis. Patient treatment was recorded including
adjuvant chemotherapy and radiation therapy.
7.5.2 Immunohistochemistry and scoring
Biomarker expression was evaluated through standard immunohistochemical (IHC)
staining and scored as Hscore (percentage x intensity), Nper (nuclear percentage) and Nhscore
(nuclear percentage x intensity). Intensity of staining were scored as 0=none, 1=low,
2=moderate, and 3=high. No patients in this study underwent neoadjuvant chemotherapy.
Negativity was determined as <1% expression and positivity was determined as ≥1% expression
for all biomarkers. Antibody details and concentrations can be found in Supplementary Table
S3. The maximum score for any given H-score is 300. Patient samples were stained, scored, and
reviewed at EH. Scoring was performed by two independent pathologists blinded to clinical
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annotation and individual scores were averaged. TNBC patients negative or positive for AR
(Nper) were classified as AR-negative and AR-positive TNBC patients, respectively.
7.5.3 Follow Up
Initial diagnosis of patients occurred between 2002 and 2016. Median duration of followup for EH was approximately 6 years. Initial dates of diagnoses, treatment start and completion
dates, and last dates of contact were recorded for each patient. Survival status (alive/dead) was
also recorded for available patients in addition to survival time. The date of last follow-up for the
last patient seen is March 3, 2016.
7.5.4 Gene Expression Dataset and Infiltrating Immune Cell Composition Determination
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset from
the TCGA portal for all TNBC patients

34

. Publically available ER/PR/HER2/AR

Immunohistochemical data was used to determine TNBC/QNBC status and a log-rank test was
performed to stratify TNBC patients into AR-low and AR-high expressing subgroups. We utilized
the Cell type Identification By Estimating Relative Subsets of known RNA Transcripts
(CYBERSORT) tool, which is a deconvolution algorithm that uses a set of reference gene
expression values, to resolve intratumoral immune cell composition in gene expression data in
tumor samples of mixed cell types

35

. The Leukocyte gene signature matrix (LM22), which is

comprised of 547 genes that resolves 22 human hematopoietic cell phenotypes [seven T cell types,
naïve and memory B cells, plasma cells, natural killer cells, and myeloid subsets] in tumor samples,
was used to identify proportions of each immune cell type in TNBC patients based on their gene
expression profiles in the TCGA dataset

35

. To avoid false positives, gene expression data was

processed using 1000 permutations. As the input data was normalized, the quantile normalization
option was disabled.
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7.5.5 Statistical Analysis
The significance level for all analyses was p<0.05 and 95% confidence intervals estimated.
SAS 9.4 program was used to generate test statistics and 2-tailed univariate p-values were reported.
Chi-square tests were performed to analyze differences in associations with demographic
characteristics, breast clinico-pathological variables and biomarkers, as well as treatment
information between AR-negative and AR-positive TNBC patients. Wilcoxon rank-sum tests were
performed to determine differences in the means of stromal and peripheral TILs between ARnegative and AR-positive TNBC patients. Pearson correlation coefficients (ρ) were computed to
determine correlations between stromal and peripheral TILs with demographic and clinicopathological variables as well as biomarker expression among AR-negative and AR-positive
TNBC patients. Spearman’s rank correlation coefficients (ρ) were generated for categorical
variables. Unadjusted and adjusted multivariate Cox proportional hazard models were computed
to assess the impact of TILs on 10-year OS and disease-free survival (DFS) before and after
controlling for age and Nottingham grade. The Kaplan-Meier analysis was conducted using SAS
9.4 program to estimate survival function for AR-negative TNBC patients over a 10- year period
based on high and low TIL levels. A log-rank test was used to stratify stromal and peripheral TILs
into high (³10) and low (<10) groups to evaluate associations of a high and low presence of TILs
with better or worse survival for Kaplan-Meier analyses. Wilcoxon rank-sum tests were performed
to determine significant differences in the proportions of immune cell fractions between AR-low
and AR-high expressing TNBCs after generating CIBERSORT outputs. A p-value cutoff of <0.01
was used. A log-rank test was also performed to identify the appropriate cut-off for low and high
expression of AR among TNBC patients in the TCGA dataset.
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7.6

Tables and Figures

Table 7.1 Clinico-pathological characteristics of AR-negative and AR-positive TNBC patients
observed at EH.

160

Table 7.2 Breast cancer biomarker expression among AR-positive and AR-negative TNBC
patients observed at EH.
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Table 7.3 Antibodies and dilutions used for immunohistochemical biomarker staining at EH.
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Table 7.4 Correlation of stromal TILs with demographic and clinico-pathological variables
among AR-negative and AR-positive TNBC patients.
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Table 7.5 Correlation of stromal TILs with clinico-pathological biomarkers among ARnegative and AR-positive TNBC patients.
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Table 7.6 Prediction of peripheral TILs for 10-year DFS among AR-negative TNBC patients.
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Figure 7.1 Comparison of stromal and peripheral TILs between AR- negative and AR-positive
TNBC patients.
Comparison of stromal TILs between all AR- negative and AR-positive TNBC patients (A) and
early-stage AR-negative and AR-positive TNBC patients (B) overall and with or without adjuvant
chemotherapy (chemo) or radiation (rad) treatment. Comparison of peripheral TILs between all
AR- negative and AR-positive TNBC patients (C) and early-stage AR-negative and AR-positive
TNBC patients (D) overall and with or without adjuvant chemotherapy (chemo) or radiation (rad)
treatment. *p<0.05, **p<0.01.
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Figure 7.2 Peripheral TILs are associated with disease-free survival among early-stage ARnegative TNBC patients.
Peripheral TILs were stratified into high (≥30) and low (<30) subgroups using a log-rank test.
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on
disease-free survival (DFS) over a 10-year period among AR-negative TNBC patients. Prediction
of high and low peripherals TILs on 10-year DFS among all AR-negative patients (A), early-stage
AR-negative patients (B), non-adjuvant chemotherapy-treated AR-negative patients (C), nonadjuvant chemotherapy-treated early-stage AR-negative patients (D), and radiation-treated earlystage AR-negative patients (E).
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Figure 7.3 Peripheral TILs are associated with overall survival among early-stage ARnegative TNBC patients.
Peripheral TILs were stratified into high (≥15) and low (<15) subgroups using a log-rank test.
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on
overall survival over a 10-year period among AR-negative TNBC patients. Prediction of high and
low peripherals TILs on 10-year OS among all and early-stage non-adjuvant chemotherapytreated AR-negative patients.
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Figure 7.4 Comparison of intratumoral immune cell fractions between AR- low and high
TNBC samples.
CIBERSORT tool was used to determine the proportions of distinct infiltrating immune cells
among AR- low and high TNBCs isolated from the TCGA breast dataset. The color gradient from
green to red represents the increasing fractions of intratumoral immune cells. Immune cell
fractions that showed statistically significant differences between AR- low and high TNBCs with
lower proportions of naïve B cells and resting mast cells among AR-low compared to AR-high
TNBCs with a p-value cut-off of <0.01. Immune cell fractions that showed weakly statistically
significant differences (0.05>p<0.1) between the races with a smaller proportion of resting NK
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cells and greater proportion of activated NK cells among AR-low compared to AR-high TNBCs
with no p-value cut-off.
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8

RACIAL DISPARITIES IN LYMPHOCYTIC INFILTRATION AMONG EARLYSTAGE AFRICAN-AMERICAN AND EUROPEAN-AMERICAN QUADRUPLE
NEGATIVE BREAST TUMORS

8.1

Abstract

The role of androgen receptor (AR) in TNBC remains controversial, however, some studies
report that lack of AR expression in TNBC or quadruple negative breast cancer (QNBC) confers
a more aggressive disease course. Emerging evidence suggests that QNBC is more prevalent
among women of African descent. Tumor infiltrating lymphocytes (TILs) are inflammatory
mediators have been associated with favorable clinical outcomes and response to neoadjuvant
and adjuvant chemotherapy but more aggressive disease characteristics in TNBC. We compared
stromal and peripheral TILs between AA (N=55) and EA (N=20) QNBC patients treated at
Emory University Hospital in Atlanta, GA. We also performed differential gene expression
analysis between AA and EA QNBC patients in a publicly available gene expression dataset.
Among early-stage (I-II) QNBC patients (N=63), we observed more stromal TILs in AA TNBCs
(N=44) compared with EA TNBCs (N=19) (p=0.047). Stromal TILs negatively correlated with
age at diagnosis among all (ρ=-0.272; p=0.044) and positively correlated with programmed cell
death protein 1 (PD1) expression among early-stage (ρ=0.460; p=0.001) AA QNBC patients .
High peripheral TIL levels predicted longer 10-year OS among early-stage AA QNBC patients
in multivariate analyses (p=0.015; HR:0.155). Our gene expression analyses revealed significant
upregulation of biological pathways, gene ontologies, and genes reflecting increased proinflammatory activity in AA compared with EA AR-low expressing TNBCs. Our findings
indicate a previously unrecognized racial disparity in the tumor immune microenvironment

173

among early-stage QNBCs. Furthermore, peripheral TIL levels may be able to serve as a riskprognostic biomarker for early-stage AA QNBC patients.
8.2

Introduction
Triple negative breast cancer (TNBC) is the most difficult form of breast cancer to treat

owing to its lack of the pharmacologically targetable biomarkers of proliferation, estrogen
receptor, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu)
(1) [1]. The disease disproportionately afflicts younger women as well as women of African
descent(2-4). TNBC patients of African ancestry also exhibit more unfavorable clinicopathological characteristics and acquire more aggressive TNBC subtypes such as basal-like and
androgen receptor-negative TNBC or quadruple negative breast cancer (QNBC) compared with
TNBC patients of European descent (3, 5-10). Furthermore, our group recently reported that AAs
experience poorer survival than EAs among QNBC patients (unpublished data). Owing to
variability in AR staining cut-offs, roughly 45-88% of TNBCs have been reported to lack AR
nuclear expression(11). AR-targeted therapies have emerged as a promising alternative therapeutic
strategy for AR-expressing TNBCs(12, 13). However, most AR-negative TNBCs are less
susceptible to AR-targeted therapy. Furthermore, the prognostic role of AR in TNBC remains
controversial, however, a lack of AR expression has been associated with poor differentiation, high
clinical stage, high Ki-67, high mitotic index, increased lymphovascular invasion, increased risk
of recurrence and distant metastasis, and worse 5-year disease-free survival and overall survival
(OS) (14-19). Hence, an increased prevalence of AR-negative TNBC among AA women may be
contributing to the racial disparate burden in TNBC. Thus, novel alternative biomarkers and
therapies targeting AA QNBC are urgently needed to help alleviate this burden.
Tumor infiltrating lymphocytes (TILs) have emerged as key mediators of the anti-tumoral
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inflammatory response. Upon neoplastic transformation, TILs migrate to the tumor site to prevent
progression (20, 21). TILs that migrate to the tumor stroma are considered stromal TILs and
stromal TILs that occupy the invasive tumor front or periphery of the tumor are considered
peripheral TILs(22, 23). Accumulating evidence suggests that stromal TILs have a strong
prognostic role in TNBC. Stromal TILs have been associated with improved overall survival (14),
increased metastasis-free survival, reduced risk of relapse and reduced distance recurrence in
TNBC (24). For every 10% increase in stromal TILs, a 15% reduction in relapse risk and 17%
reduction in death risk has been reported(24). Furthermore, a high level of stromal TILs has been
associated with improved pathological complete response following neoadjuvant chemotherapy
(NAC), validating TILs as a predictive biomarker in TNBC (23-25). Recently in a non-NAC
setting, peripheral TILs were associated with high Nottingham grade as well as longer OS and
disease-free survival among TNBC patients in univariate and multivariate analyses(22).
Paradoxically, the presence of stromal TILs has been associated with more aggressive clinicopathological tumor characteristics in BC such as high grade, high stage, high Ki-67, lymph node
metastasis, a TNBC phenotype, and young age at diagnosis (25-31). Furthermore, Davis et al.
recently reported that T cell immune response and checkpoint markers were significantly more
upregulated among QNBC compared to TNBC patients in the TCGA dataset and AA QNBCs were
more enriched in immune gene signatures compared to EA QNBCs(32). Thus, we were interested
in evaluating if there was a disparity in the presence of TILs among AA and EA QNBC tumors
and if TILs could function as a risk-prognostic biomarker in QNBC patients of African descent.
8.3

Results

8.3.1 Clinico-pathological characteristics among racially-distinct QNBC patients
We compared clinico-pathological variables and treatment information between AA
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(n=55) and EA (n=20) QNBC patients observed at EH (Table 2). We observed a significant
difference in associations with mitotic index between AA and EA QNBC patients (p=0.012). We
observed a significantly greater proportion of AA patients with a high mitotic score compared with
EA patients, wherein 61.33% of AAs and 13.3% of EAs exhibited a mitotic count of 3. We also
discovered a significant difference in associations with Nottingham grade and race. A significantly
greater percentage of AA patients exhibited a high Nottingham grade compared with EA patients
in which, 66.7% of AAs and 17.3% of EAs exhibited a score of 3. We also examined differences
in associations with expression of established clinical biomarkers in BC between AA and EA
QNBC patients to gain more insight into differences in disease pathology between these patient
populations (Table 3). We only observed a significant difference in associations with β-catenin
expression between the racially-distinct QNBC patients (p=0.049), with 62.7% of AA QNBCs
positive for β-catenin compared with only 16% of EA QNBCs.
8.3.2 AAs harbor more TILs than EAs among early-stage QNBC patients
We investigated differences in the presence of stromal and peripheral TILs between AA
(N=55) and EA (N=20) QNBC patients (Figure 1). We observed that stromal TILs were weakly
higher in AAs compared with EAs among all QNBC patients (p=0.1) (Fig 1A). We also examined
disparities in stromal and peripheral lymphocytic infiltration among racially-distinct early-stage
QNBC patients to consider if distinctions in TIL count in early-stage disease could be influencing
differences in prognosis between patients of African and European descent. Among early-stage (III) (N=63) QNBC patients, AAs (N=44) harbored significantly more stromal TILs than EAs
(N=19) (p=0.047). We also investigated if racial differences persisted based on type of treatment
received among early-stage patients to evaluate if treatment could be impacting racial disparities
in tumor lymphocytic infiltration. Among early-stage QNBC patients treated with radiation, AAs
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(N=24) exhibited a higher presence of stromal TILs than EAs (N=14) (p=0.05) but not among
chemotherapy-treated patients. We did not observe significant differences in peripheral TILs
between the racial groups among all QNBC patients and among the subset of early-stage QNBC
patients regardless of radiation treatment (Fig 1B).

8.3.3 TILs are associated with more aggressive disease features among early-stage AA
QNBC patients
We examined correlations of stromal (Table 4) and peripheral TILs (Table 5) with
demographic and clinico-pathological variables among all and early-stage racially-distinct QNBC
patients. Correlation coefficients of stromal and peripheral TILs with demographic and clinicopathological characteristics among QNBC patients can be found in Tables 6 and 7, respectively.
Among AA patients, stromal TILs negatively correlated with age at diagnosis (ρ=-0.272; p=0.044).
Stromal TILs also negatively correlated with age at diagnosis among early-stage EA patients (ρ=0.844; p=0.004). Moreover, stromal TILs positively correlated with lymph node involvement
among all EA patients (ρ=0.461; p=0.041). Regarding clinical biomarkers, stromal TILs positively
correlated with programmed cell death protein 1 (PD1) expression among early-stage AA patients
(ρ=0.460; p=0.001) as well as chemotherapy- and radiation- treated early-stage (ρ=0.662;
p<0.0001, ρ=0.725; p<0.0001, respectively) AA patients. Furthermore, stromal TILs positively
correlated with expression of the ligand for PD1, programmed cell death ligand 1 (PD-L1), among
chemotherapy- and radiation- treated early-stage (ρ=0.513; p=0.004, ρ=0.545; p=0.006,
respectively) AA patients. Stromal TILs also significantly correlated with PD1 and PD-L1
expression among early-stage chemotherapy- and radiation- treated early-stage EA patients.
However, stromal TILs also positively correlated with epidermal growth factor receptor (EGFR)
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expression among early-stage EA patients (ρ=0.867; p=0.012) as well as with BRCA1-associated
protein 1 (BAP1) among radiation-treated early-stage EA patients (ρ=0.661; p=0.038).
We observed similar associations with peripheral TILs among racially-distinct QNBC
patients. Peripheral TILs also negatively correlated with age at diagnosis among all AA patients
(ρ=-0.289; p=0.032) and among early-stage EA patients (ρ=-0.784; p=0.012). Furthermore,
peripheral TILs positively correlated with lymph node involvement and among early-stage
(ρ=0.440; p=0.015) and chemotherapy-treated early-stage (ρ=0.381; p=0.038) AA patients.
Peripheral TILs also positively correlated with lymph node involvement (ρ=0.481; p=0.032) and
lymphovascular invasion (ρ=0.457; p=0.043) among EA patients and these associations persisted
among chemotherapy- and radiation treated early-stage EA patients. Peripheral TILs also
positively correlated with PD1 among early-stage AA (ρ=0.289; p=0.034) and chemotherapy- and
radiation treated (ρ=0.390; p=0.033, ρ=0.476; p=0.019, respectively) early stage AA patients.
However, peripheral TILs positively correlated with EGFR expression among early-stage
(ρ=0.867; p=0.012) and radiation-treated early-stage (ρ=0.717; p=0.020) EA patients.
8.3.4 High TIL levels associated with better survival among early-stage AA QNBC patients
We investigated the prognostic value of stromal and peripheral TILs among raciallydistinct QNBC patients to elucidate the role of TIL count in the racially disparate burden in QNBC
disease. We analyzed the impact of TILs on survival in early-stage disease and examined the
influence of treatment on TILs and prognosis to gain more insight into the prognostic role of
lymphocytic infiltration. Stromal and peripheral TILs were stratified into high and low subgroups
using a log-rank test and Kaplan-Meier analyses were performed to determine the impact of TILs
on survival over a 10-year period (Figure 2). We observed that peripheral TILs were associated
with significantly with longer 10-year overall survival (14) among all AA QNBC patients
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(p=0.013) (Fig 2A). Furthermore, peripheral TILs were associated with significantly better 10year OS among radiation treated (p=0.032) but not chemotherapy treated (p=0.095) AA patients
(Fig 2A-C). High peripheral TIL levels were also associated with significantly longer OS among
early-stage AA QNBC patients (p=0.011) (Fig 2D). Moreover, high peripheral TILs levels were
associated with significantly better 10-year OS among radiation treated early-stage (p=0.031) but
not among chemotherapy-treated early-stage (p=0.074) AA patients (Fig 2E-F). Associations of
peripheral TILs with OS among EA QNBC patients were not observed (data not shown).
Associations of stromal TILs with OS were also not observed among both AA and EA patients.
We also assessed unadjusted and adjusted associations of stromal and peripheral TILs with
10-year OS among AA and EA QNBC patients by computing univariate and multivariate Cox
proportional hazard regression models adjusted for age, grade, and stage (Table 8). Similarly, in
Kaplan-Meier analyses, high peripheral TIL levels predicted longer 10-year OS among AA QNBC
patients in unadjusted (p=0.020; HR:0.290) and in multivariate Cox proportional hazard regression
model (p=0.027; HR:0.272). Among radiation-treated AA QNBC patients, high peripheral TIL
levels also predicted significantly longer 10-year OS in adjusted analyses (p=0.042; HR:0.025).
Furthermore, among early-stage AA QNBC patients, high peripheral TILs predicted significantly
better 10-year OS before (p=0.020; HR:0.290) and after adjusting for potential confounding factors
(p=0.015; HR:0.15). Peripheral TILs were unable to predict survival among EA QNBC patients.
Stromal TIL were unable to predict survival among both AA and EA QNBC patients.
8.3.5 Increased upregulation of immune response-related genes, pathways and gene
ontologies among AA compared with EA AR-low expressing TNBC patients
We investigated differential expression of immune response-related genes, pathways, and
gene ontologies between AA compared with EA AR-low expressing TNBC patients isolated from
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TCGA breast dataset. We utilized the GAGE and Pathview packages to analyze differences in
biological pathways or experimentally-derived differential expression sets and gene ontologies,
respectively between AA and EA AR-low expressing TNBCs in TCGA breast dataset. We
observed significantly more upregulation of the leukocyte transendothelial migration expression
set among AA compared with EA AR-low expressing TNBC samples (p=0.049) (Table 9). We
also observed significantly more upregulation of gene ontologies reflecting a pro-inflammatory
immune response such as innate immune response, interferon-gamma-mediated signaling
pathway, type I interferon-mediated signaling pathway, interleukin-1 secretion, vasodilation, and
natural killer cell differentiation and activation (p<0.05) among AA compared with EA AR-low
expressing TNBC patients (Table 10). We also observed significantly more upregulation of proinflammatory genes among AA compared to EA QNBC patients (p<0.05) (Table 11).
8.4

Discussion
Recent evidence suggest that women of African ancestry are also disproportionately

afflicted by QNBC, indicating that AA patients are less susceptible to AR-targeted therapy than
EA patients. The role of the tumor immune microenvironment in the racial disparate burden in
QNBC remains elusive. Hence, we investigated the prognostic and predictive role of TIL among
racially-distinct QNBC patients to determine their potential as a promising risk-prognostic
biomarker and/or therapeutic target among QNBC patients of African descent.
We observed a significantly greater proportion of AA patients with a high mitotic score
and Nottingham grade than EA patients suggesting QNBC patients of African descent exhibit more
aggressive disease features than QNBC patients of European descent. These findings also
corroborate Bhattarai et al.’s findings suggesting a poorer prognosis among AA compared with
EA QNBC patients (unpublished data). We also discovered a significantly greater proportion of
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AAs positive for β-catenin compared with EAs among QNBC patients. Wnt/β-catenin signaling is
highly upregulated in TNBC and associated with increased risk for metastasis(39). β-catenin has
been found to positively correlate with stromal lymphocytic infiltration in BC, suggesting that
Wnt/β-catenin signaling may be playing a critical role in BC anti-tumoral immunity(31).
Furthermore, β-catenin overexpression was recently reported to underlie an aggressive disease
course among AA QNBC patients. Thus, differential expression of this marker between AA and
EA QNBCs may be playing a role in the racial disparate burden in QNBC.
We discovered that the percentage of stromal TILs were significantly higher among AA
compared with EA among early-stage QNBC patients as well as among early-stage QNBC patients
treated with radiotherapy. Thus, a higher TIL count may be reflective of increased antitumoral
immune response among AAs compared with EAs in early-stage QNBC disease. We speculate
that increased inflammatory activity among AA tumors, despite their poorer clinical outcomes
compared to EAs, might be reflective of an enhanced immune response as a result of their more
aggressive disease. Among AA QNBC patients, both stromal and peripheral TILs were associated
with younger age at diagnosis, which corroborates previous reports of increased tumor
lymphocytic infiltration among TNBC patients diagnosed at a younger age. Furthermore,
peripheral TILs were associated with increased lymph node involvement among early-stage AA
QNBC patients as well as chemotherapy-treated early-stage AA QNBC patents, which is also
similar to previous reports of increased tumor lymphocytic infiltration associated with greater
lymph node involvement in TNBC. In regards to clinical biomarkers, both stromal and peripheral
TILs were associated with increased PD1 expression among early-stage AA QNBC patients as
well as among chemotherapy- and radiation- treated early-stage AA QNBC patients suggesting
elevated levels of PD1-expressing TILs and immunosuppression among this patient population in

181

early-stage disease irrespective of treatment. Stromal TILs were also associated with increased
PD-L1 expression among chemotherapy- and radiation- treated early-stage AA QNBC patients,
further indicating increased TIL immunosuppression among AA QNBC patients in the early stages
of their disease. Among EA QNBC patients, high stromal and peripheral TIL levels were also
associated with younger age at diagnosis as well as increased lymph node involvement and
lymphovascular invasion. Stromal TILs positively correlated with BAP1 among radiation-treated
early-stage EA patients suggesting TILs may be associated with increased DNA damage response
among these patients.
We observed that high peripheral TIL levels predicted significantly better 10-year OS
among all and early-stage AA QNBC patients in both Kaplan-Meier and multivariate analyses.
Furthermore, high peripheral TIL levels predicted significantly better 10-year OS among all and
early-stage radiation treated AA QNBC patients in Kaplan-Meier analyses and among all radiation
treated AA QNBC patients in multivariate analyses. Thus, these findings indicate that peripheral
TIL levels may be able to risk-stratify early-stage QNBC patients of African descent for better or
worse survival and that peripheral TILs may be able to predict response to radiotherapy among
AA QNBC patients. Furthermore, our results suggest therapies that induce antitumoral immunity
such as adoptive T cell therapy may be selectively beneficial for QNBC patients of African
descent.
Our gene expression analyses revealed significantly more upregulation of proinflammatory genes, biological pathways, and gene ontologies among AA compared with EA ARlow expressing TNBC patients in the TCGA breast dataset. Particularly, we observed significantly
more enrichment of the leukocyte transendothelial migration biological pathway among AA
compared with EA AR-low expressing TNBCs suggesting AA QNBC patients may exhibit more
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recruitment of pro-inflammatory mediators. Furthermore, gene ontologies reflecting increased T
cell and NK cell antitumoral immunity were significantly more upregulated among AA compared
with EA AR-low expressing TNBCs. Moreover, genes encoding chemokines and cytokines as well
as other key mediators in the T- and NK- cell-mediated antitumoral immune response were
significantly more upregulated in AA compared with EA among AR-low expressing TNBC
samples. In addition, the innate immune response gene ontology was significantly more
upregulated among AA compared with EA AR-low expressing TNBC samples suggesting
increased innate immunity among QNBC patients of African compared with European descent.
Our study uncovers previously unrecognized racial differences in the tumor immune
microenvironment among QNBCs, reveals a novel, alternative risk-prognostic biomarker and
suggests early-stage AA QNBC patients harboring lower levels of TILs may be ideal candidates
for TIL immunotherapy, particularly among those undergoing radiotherapy. However, robust
validation of our results in additional non-NAC and NAC patient cohorts as well as
characterization of TIL immune subsets in early-stage QNBC patients of African ancestry will be
critical to successfully achieving this aim.
8.5

Methods

8.5.1 Study Cohort
We analyzed a cohort of 75 TNBC patients negative for AR expression (AR Nh-score)
among 121 TNBC patients treated at Emory University Hospital (EH) in Atlanta, GA from 2002
(initial day of diagnosis) to 2016 (last day of contact). We obtained approval and permission from
the institutional review board at EH to gain access to patient information and samples used in this
study. The percentage of stromal and peripheral TILs was assessed in hematoxylin- and eosinstained patient specimens as described by Krishnamurti and colleagues (22). TILs were evaluated
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according to the International TILs working group 2014 in which the percentage of stromal tissues
occupied by infiltrating lymphocytes and plasma cells were estimated(33). Intratumoral
lymphocytes, or lymphocytes in direct contact with tumor cells, were excluded from the evaluation
and only stromal lymphocytes were counted. Peripheral TILs were evaluated as the percentage of
stromal lymphocytes occupying the entire circumference of the invasive tumor front with a width
of roughly one dozen tumor cells(22). The percentage of stromal and peripheral TILs were
estimated in intervals including <5%, 5-10%, 11-50% and >50%. Patient demographic
characteristics, clinico-pathological variables, and breast cancer (BC) biomarker status were
evaluated and recorded for each patient. Demographic characteristics include self-reported race
and age at the time of diagnosis. This article referred to the 7th edition of the American Joint
Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM Classification
and Stage groupings for BC (34). Information on patient treatment was also recorded including
adjuvant chemotherapy and radiation therapy. No patients in this study underwent NAC.
8.5.2 Immunohistochemistry and scoring
Expression of all BC biomarkers investigated in this study was determined through
immunohistochemical (IHC) staining and scored as H-score (percentage x intensity), Nper
(nuclear percentage) and Nh-score (nuclear percentage x intensity). Intensity of staining were
scored as 0=none, 1=low, 2=moderate, and 3=high. Negativity was determined as <1% expression
and positivity was determined as ≥1% expression for all biomarkers. Antibody details and
concentrations can be found in Table 1. The maximum score for any given H-score is 300.
Negativity was determined as <1% expression and positivity was determined as ≥1% expression
for all biomarkers. Patient samples were stained, scored, and reviewed at EH. Scoring was
performed by two independent pathologists blinded to clinical annotation and individual scores
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were averaged.
8.5.3 Follow Up
Initial diagnosis of patients occurred between 2002 and 2016. Median duration of followup for EH was approximately 6 years. Initial dates of diagnoses, treatment start and completion
dates, and last dates of contact were recorded for each patient. Survival status (alive/dead) was
also recorded for each patient in addition to survival time. The date of last follow-up for the last
patient seen is March 3, 2016.
8.5.4 Differential Gene Expression Determination
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset from
the TCGA portal for all TNBC patients(35). Publically-available ER/PR/HER2/AR IHC data was
used to determine TNBC and QNBC status. We performed a log-rank test to identify the optimal
cut-off to stratify the TNBC patients into high- (³160.43) and low- (<160.43) AR expressing
patients. According to the race data, we selected AA and EA samples out of the AR-low expressing
TNBC samples. We performed differential gene expression analysis for 15,942 genes between the
ethnic groups using the DESeq2 software tool(36). Differential expression analyses of Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontologies between the ethnic
groups were predicted by GAGE and Pathview packages, respectively(37, 38).
8.5.5 Statistical Analysis
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs).
Chi-square tests were performed to analyze differences in demographic characteristics, breast
clinico-pathological variables and biomarkers, and treatment information between AA and EA
QNBC patients. SAS 9.4 program was used to generate test statistics and 2-tailed univariate pvalues were reported. Wilcoxon rank-sum tests were performed to determine differences in the
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means of stromal and peripheral TILs between AA and EA patient populations. Pearson correlation
coefficients (ρ) were computed to determine associations between stromal and peripheral TILs
with demographic and breast clinico-pathological variables and biomarkers among AA and EA
QNBC patients. Spearman’s rank correlation coefficients (ρ) were computed for categorical
covariates. Unadjusted and adjusted multivariate Cox proportional hazard regression models were
computed to assess the impact of TILs on 10-year OS before and after controlling for age,
Nottingham grade, and stage. The Kaplan-Meier analysis was conducted using SAS 9.4 program
to estimate survival function for AA and EA QNBC patients over a 5- or 10- year period based on
high and low TIL levels. A log-rank test was used to stratify stromal and peripheral TILs into high
and low groups to evaluate associations of a high and low presence of TILs with better or worse
survival among racially-distinct QNBC patients. The Wald test was used to test for significance
among differentially expressed genes between the racial-distinct patient populations using the
DESeq2 software tool.
8.6

Tables and Figures

Table 8.1 Antibodies and dilutions used for immunohistochemical biomarker staining at EH.
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Table 8.1 Antibodies and dilutions used for immunohistochemical biomarker staining at EH.
Subcellular
Biomarker
location
Clone
Source
Species
Dilution
FOXM1
monoclonal
Nuclear
(NPER)
G-5
Santa Cruz
mouse
1:200
monoclonal
AR (NPER)
Nuclear
AR441
ThermoFisher
mouse
1:200
PRC1
Nuclear
(NPER)
H-70
Santa Cruz
polyclonal rabbit
1:100
AURORA A
(NHNuclear
SCORE)
AB1287
Abcam
polyclonal Rabbit
1:20
SURVIVIN
Nuclear
(NPER)
71G4b7
Cell Signaling polyclonal Rabbit
1:400
BAP1
monoclonal
Nuclear
(NPER)
BAP1(c-4)
Santa Cruz
mouse
1:40
b-CATENIN
monoclonal
Nuclear
(H-SCORE)
E-5
Santa Cruz
mouse
1:160
PD1 (Hmonoclonal
Membrane
SCORE)
NAT105
Abcam
mouse
1:100
PD-L1 (HMembrane
SCORE)
E1L3N
Cell Signaling
polyclonal rabbit
1:200
RARa (HNuclear
SCORE)
C-20
Santa Cruz
polyclonal rabbit
1:20
EGFR (HLife
monoclonal
Membrane
SCORE)
C31G7
technologies
mouse
1:25
HER3 (Hmonoclonal
Membrane
SCORE)
DAK-H3-IC
Dako
mouse
1:25
HER4 (Hmonoclonal
Cytoplasmic
SCORE)
HFR-1
Abcam
mouse
3:1

Abbreviations; FOXM1, Forkhead box 1 protein; AR, androgen receptor; PRC1, protein
regulator of cytokinesis 1; RARα, Retinoic acid receptor α; BAP1, BRCA1 associated protein
1; PD1, Programmed cell death protein 1; PD-L1, Programmed cell death ligand 1, H-score,
percentage x intensity; Nper, nuclear percentage; Nh-score, nuclear percentage x intensity;
N/A, not applicable.

Table 8.2 Clinico-pathological and treatment characteristics of AA and EA QNBC patients
observed at EH.
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Table 8.2. Clinico-pathological and treatment characteristics of AA and EA QNBC
patients observed at EH
AA (n=55)
EA (n=20)
Clinical
characteristic
Age

n

%

n

%

20-40

5

6.67

2

2.67

41-60

34

45.33

10

13.33

61-80

16

21.33

8

10.67

1

0

0

0

0

2

2

2.67

2

2.67

3

53

70.67

18

24

1

0

0

0

0

2

6

8

4

5.33

3

49

65.33

16

21.33

1

4

5.33

4

5.33

2

5

6.67

6

8

3

46

61.33

10

13.33

1

0

0

0

0

2

5

6.67

7

9.33

3

50

66.67

13

17.33

I

15

20

10

13.33

II

29

38.67

9

12

III

9

12

1

1.33

IIIC

2

2.67

0

0

Negative

38

50.67

16

21.33

Positive
Total lymph
node
involvement
0

17

22.67

4

5.33

2

2.67

0

0

5-Jan

24

32

9

12

10-Jun

11

14.67

7

9.33

p value

0.635

Nuclear grade
0.278

Tubule
formation
0.306

Mitotic Index
0.012

Nottingham
grade
0.007

Stage
0.204

Nodal status
0.352

0.191

Table 8.3 Breast cancer biomarker expression among AA and EA QNBC patients observed at
EH.
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Table 8.3 Breast cancer biomarker expression among AA and EA QNBC patients observed
at EH
AA (n=87)
EA (n=34)
Biomarker

n

%

N

%

p value

Negative

1

1.33

2

2.67

0.279

Positive

45

60

15

20

Missing/Unknown

9

12

3

4

Negative

23

30.67

12

16

Positive

19

25.33

6

8

Missing/Unknown

13

17.33

2

2.67

Negative

20

26.67

5

6.67

Positive

30

66.67

15

33.33

Missing/Unknown
Aurora A (Nhscore)

5

6.67

0

0

Negative

27

36

11

14.67

Positive

26

34.67

7

9.33

Missing/Unknown

2

2.67

2

2.67

Negative

2

2.67

1

1.33

Positive

48

64

15

20

Missing/Unknown

5

6.67

4

5.33

Negative

1

1.33

0

0

Positive

46

61.33

15

20

Missing/Unknown

8

10.67

5

6.67

Negative

6

8

5

6.67

Positive

47

62.67

12

16

Missing/Unknown

2

2.67

3

4

FOXM1 (Nper)

PRC1 (Nper)
0.278

RARα (Nper)
0.182

0.424

Survivin (Nhscore)
0.410

BAP1 (Nper)
0.491

β-catenin (Hscore)

PD-1 (H-score)

0.049

0.858
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Table
8.4 Correlation
of stromal
TILs
with
clinico-pathological
Table
8.4. Correlation
of stromal
TILs
with
clinico-pathologicalvariables
variables and
and biomarkers
biomarkers
among early-stageamong
AA and
EA QNBC
early-stage
AApatients.
and EA QNBC patients
Patients
Overall
AA

ρ
p
value
n

Clinico-pathological variables and biomarkers
PD1 (HPD-L1 (HEGFR (HAgea
LN totalb
score)a
score)a
score)a
-0.272
0.112
0.595
0.250
0.070

BAP1a

0.044

0.414

<.0001

0.066

0.648

0.167

55

55

55

55

45

47

0.164

0.460

0.239

0.129

0.186

0.235

0.001

0.081

0.389

0.226

0.205

Earlystage
AA

ρ
p
value
n

-0.216

54

54

54

54

47

44

Earlystage
AA
Chemo

ρ
p
value
n

-0.248

0.238

0.662

0.513

-0.037

0.185

0.186

0.205

<.0001

0.004

0.862

0.375

30

30

30

30

25

25

Earlystage
AA Rad

ρ
p
value
n

-0.158

0.213

0.725

0.545

0.027

0.252

0.462

0.318

<.0001

0.006

0.907

0.283

24

24

24

24

21

20

-0.174

0.461

0.749

0.365

0.749

0.433

Overall
EA

ρ
p
value
n

0.477

0.041

<.001

0.113

<.001

0.107

19

20

18

20

18

15

ρ
p
value

-0.844

0.547

0.520

0.330

0.867

0.463

0.004

0.128

0.152

0.386

0.012

0.248

n

9

9

9

9

7

8

ρ

0.369

0.452

0.586

0.586

0.836

0.478

0.215

0.079

0.017

0.017

<.001

0.116

13

16

16

16

14

12

0.153

0.526

0.658

0.351

0.840

0.661

0.403

0.053

0.011

0.219

<.001

0.038

Earlystage
EA
Earlystage
EA
Chemo
Earlystage
EA Rad

p
value
n
ρ
p
value

0.117

n
32
14
14
14
13
Pearson correlation test (ρ)
b
Spearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node.
a

10
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Table 8.5
Correlation
of peripheral
TILs
variables
Table
8.5. Correlation
of peripheral
TILswith
with clinico-pathological
clinico-pathological variables
and and biomarkers
biomarkers
among
early-stage
AA
and
EA
QNBC
patients
among early-stage AA and EA QNBC patients.

Patients
ρ
Overall
AA

Earlystage
AA
Earlystage
AA
Chemo

Earlystage
AA Rad

p
value

0.032

0.307

0.426

n

55

55

55

ρ

-0.247

0.066

p
value

0.072

n
ρ
p
value
n
ρ
p
value
n
ρ
Overall
EA

Earlystage
EA
Earlystage
EA
Chemo
Earlystage
EA Rad

Clinico-pathological variables and biomarkers
PD-1
EGFR
Nottingham
LN
(Ha
a
Age
LVI
(Hb
b
score
total
a
score
score)
)a
-0.289
0.140
0.109
0.033
0.047
0.157

p
value
n

0.251

0.044

0.831

0.734

0.771

45

55

47

0.440

55
0.098

0.007

0.289

0.105

0.633

0.015

0.480

0.961

0.034

0.496

54

54

30

47

54

44

-0.231

-0.071

0.381

54
0.153

-0.054

0.390

0.036

0.219

0.711

0.038

0.421

0.797

0.033

0.865

30

30

30

30

25

30

25

-0.141

-0.022

0.285

0.303

-0.156

0.476

0.088

0.510

0.918

0.178

0.150

0.500

0.019

0.712

2

24

24

24

21

24

20

-0.213

0.383

0.481

0.457

0.173

0.311

0.401

0.367

0.096

0.032

0.043

0.493

0.182

0.138

20

20

20

20

18

20

15

ρ
p
value
n

-0.784

0.646

0.629

0.475

0.867

0.540

0.428

0.012

0.060

0.070

0.196

0.012

0.134

0.291

9

9

9

9

7

9

8

ρ
p
value

-0.454

0.435

0.582

0.570

0.607

0.321

0.442

0.077

0.092

0.018

0.021

0.021

0.226

0.150

n

16

16

16

16

14

16

12

ρ
p
value

0.135

0.534

0.584

0.611

0.592

0.439

0.717

0.463

0.049

0.028

0.020

0.033

0.116

0.020

n
32
14
14
14
13
14
Pearson correlation test (ρ)
b
Spearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node; LVI,
lymphovascular invasion.
a

BAP1
a
(Nper)

10
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Table
Correlation
stromalTILs
TILs with
with clinico-pathological
clinico-pathological variables
Table
8.68.6.
Correlation
ofofstromal
variablesand
and biomarkers
biomarkers
among
early-stage
QNBC
patients
among early-stage QNBC patients.
Clinico-pathological variables and biomarkers
Age

Nottingham
scoreb

LN
totalb

PD-1 (Hscore)a

PD-L1 (Hscore)a

-0.289

0.256

0.196

0.455

0.270

0.012

0.026

0.092

<.0001

0.019

75.000

75

75

75

75

ρ
p
value

-0.274

0.230

0.228

0.452

0.246

0.030

0.069

0.072

<0.001

0.052

n

63.000

63

63

63

63

ρ

-0.264

0.215

0.260

0.468

0.448

0.077

0.151

0.081

0.001

0.002

46.000

46

46.000

46

46

ρ
p
value

-0.229

0.321

0.235

0.574

0.510

0.167

0.050

0.156

<0.001

0.001

n

38.000

38

38

38

38

a

Patients
ρ
Overall

Early

Chemo

Rad

a

p
value
n

p
value
n

Pearson correlation test (ρ)
Spearman’s rank correlation test (ρ)
Abbreviations: Chemo, adjuvant chemotherapy; Rad, radiation; LN, lymph node.
b
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TableTable
8.7 Correlation
of peripheral
TILs
with
clinico-pathological
8.7. Correlation
of peripheral
TILs
with
clinico-pathologicalvariables and biomarkers
among
early-stage
QNBCamong
patients.
variables
and biomarkers
early-stage QNBC patients
Clinico-pathological variables and biomarkers
Agea

LN totalb

PD-1 (Hscore)a

PD-L1 (Hscore)a

-0.276

0.200

0.322

0.213

0.016

0.085

0.005

0.067

75

75

75

75

ρ
p
value

-0.289

0.338

0.301

0.199

0.021

0.007

0.017

0.118

n

63

63

63

63

ρ
p
value
n

-0.275

0.392

0.265

0.365

0.064

0.007

0.076

0.013

46

46

46

46

ρ

-0.225

0.310

0.370

0.423

p
value

0.175

0.058

0.022

0.008

Patients
ρ
Overall

Early

Chemo

Rad

p
value
n

n
38
38
38
38
Pearson correlation test (ρ)
b
Spearman’s rank correlation test (ρ)
Abbreviations: Early, early-stage (I-II); Chemo, adjuvant chemotherapy; Rad,
radiation; LN, lymph node.
a
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Table
8.8
Prediction
for 10-year
10-yearOS
OSamong
amongAA
AA
QNBC patients.
Table
8.8.
Predictionofofperipheral
peripheralTILs
TILs for
QNBC
patients.

AR-Negative
patients

p value; HR (95% CI)

p value; HR (95% CI)

Unadjusted model

Adjusted model

Early and late
stage
Overall

0.020; 0.290 (0.102, 0.290)

0.027; 0.272 (0.086,0.864)

Chemotherapy

0.153; 0.377 (0.099,1.438)

0.162; 0.338 (0.074,1.547)

Radiation

0.074; 0.231 (0.046, 1.155)

0.042; 0.025 (0.001,0.879)

0.023; 0.208 (0.054, 0.804)

0.015; 0.155 (0.034, 0.694)

0.761 ;0.71 (0.078, 6.455)

0.0617; 0.548 (0.052,5.815)

Early-stage
Overall
Chemotherapy

Radiation 0.079; 0.081 (0.005,1.339)
0.997; 0.000 (0,000,0.000)
Abbreviations: HR, hazard ratio; CI, confidence interval; Cox proportional
hazard model adjusted for age, Nottingham grade, and stage. Peripheral TILs
were treated as a categorical variable.
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Table 8.9
Immune
responseresponse
related-pathways
significantly upregulated in AAs compared to
Table
8.9. Immune
related-pathways
EAs
among
AR-low
TNBC
patients
in
TCGA
significantly more upregulated in AAs compareddataset.
to EAs
among AR-low TNBC patients in TCGA dataset.
Statistical
p
Pathway
q value
mean
value
hsa04512 ECM2.554
0.006
0.933
receptor interaction
hsa04510 Focal
2.078
0.019
0.933
adhesion
hsa04962
Vasopressin1.97
0.027
0.933
regulated water
reabsorption
hsa04720 Long-term
1.711
0.045
0.933
potentiation
hsa04670
Leukocyte
1.661
0.049
0.933
transendothelial
migration
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Table 8.10. Immune response-related gene ontologies more

upregulated
among
AA compared gene
to EAontologies
AR-low samples
in TCGA among AA compared
Table
8.10 Immune
response-related
more upregulated
database.
to EA AR-low samples in
TCGA database.
Gene ontology
GO:0045087 innate immune response
GO:0071347 cellular response to
interleukin-1
GO:0034341 response to interferongamma
GO:0060333 interferon-gammamediated signaling pathway
GO:0071346 cellular response to
interferon-gamma
GO:0034340 response to type I
interferon
GO:0070555 response to interleukin-1
GO:0060337 type I interferon-mediated
signaling pathway
GO:0071357 cellular response to type I
interferon
GO:0050701 interleukin-1 secretion
GO:0050704 regulation of interleukin-1
secretion
GO:0042311 vasodilation
GO:0032088 negative regulation of NFkappaB transcription factor activity
GO:0001779 natural killer cell
differentiation
GO:0002526 acute inflammatory
response
GO:0042089 cytokine biosynthetic
process
GO:0032732 positive regulation of
interleukin-1 production
GO:0050716 positive regulation of
interleukin-1 secretion
GO:0031331 positive regulation of
cellular catabolic process
GO:0032649 regulation of interferongamma production
GO:0030101 natural killer cell activation
GO:0042035 regulation of cytokine
biosynthetic process

p-value
0.004
0.010
0.010
0.013
0.014
0.019
0.020
0.021
0.021
0.023
0.028
0.030
0.033
0.035
0.036
0.038
0.041
0.041
0.042
0.044
0.046
0.049
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Table 8.11 Immune-related genes significantly upregulated in AAs compared to EAs among
Table 8.11. Immune-related genes significantly more upregulated in AAs compared to
AR-lowEAs
TNBC
patients
inTNBC
the TCGA
database.
among
AR-low
patients
in the TCGA database.
Gene

Symbol

ENSG00000203710

CR1

ENSG00000152672

CLEC4F

ENSG00000121966

CXCR4

ENSG00000189377

CXCL17

ENSG00000276409

CCL14

ENSG00000150630

VEGFC

ENSG00000185201

IFITM2

ENSG00000081985

IL12RB2

ENSG00000164330

EBF1

ENSG00000112936

C7

ENSG00000066056

TIE1

ENSG00000176435

CLEC14
A

ENSG00000138795

LEF1

ENSG00000186047

DLEU7

ENSG00000006016

CRLF1

ENSG00000173757

STAT5B

ENSG00000072736

NFATC3

ENSG00000188211

NCR3L
G1

Name
complement
C3b/C4b receptor 1
(Knops blood group)
C-type lectin domain
family 4 member F
C-X-C motif
chemokine receptor
4
C-X-C motif
chemokine ligand 17
C-C motif
chemokine ligand 14
vascular endothelial
growth factor C
interferon induced
transmembrane
protein 2
interleukin 12
receptor subunit
beta 2
early B-cell factor 1
complement C7
tyrosine kinase with
immunoglobulin like
and EGF like
domains 1
C-type lectin domain
family 14 member A
lymphoid enhancer
binding factor 1
deleted in
lymphocytic
leukemia, 7
cytokine receptor
like factor 1
signal transducer
and activator of
transcription 5B
nuclear factor of
activated T-cells 3
natural killer cell
cytotoxicity receptor
3 ligand 1

Base
mean

log2Fold

32.382

1.529

<0.001

37.483

1.762

<0.001

2758.089

1.322

<0.001

260.445

1.649

0.001

86.378

1.51

0.002

109.034

0.921

0.002

2450.015

1.232

0.002

435.675

1.317

0.003

94.082

1.063

0.003

42.535

1.424

0.004

312.695

0.958

0.005

240.377

0.904

0.006

285.862

0.955

0.008

5.205

1.004

0.012

346.321

1.192

0.012

1414.081

0.553

0.012

728.145

0.49

0.013

22.919

0.966

0.021

Change

p value
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Figure 8.1 Comparison of stromal and peripheral TILs among racially-distinct QNBC
patients.
Comparison of stromal and peripheral TILs between all (overall), early-stage (I-II) (early), earlystage chemotherapy- and radiation- treated AA and EA QNBC patients. Abbreviations: Chemo
refers to chemotherapy and Rad refers to radiation treatment. *p<0.05
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Figure 8.2 Peripheral TILs associated with overall survival among early-stage AA QNBC
patients.
Peripheral TILs were stratified into high (≥10) and low (<10) subgroups using a log-rank test.
Kaplan-Meier curves were generated to estimate impact of high and low peripheral TIL levels on
overall survival over a 10-year period among AA QNBC patients. Prediction of high and low
peripherals TILs on 10-year OS among all (A), chemotherapy-treated (B), radiation-treated (C),
early-stage (I-II) (D), chemotherapy treated early-stage (E) and radiation treated early-stage (F)
AA QNBC patients

8.7
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9

LACK OF HER4 SIGNALING PREDICTS POOR PROGNOSIS AMONG

BIOGEOGRAPHICALLY-DISTINCT TRIPLE NEGATIVE BREAST CANCER
PATIENTS: A MULTI-INSTITUTIONAL STUDY
9.1

Abstract
Triple negative breast cancer (TNBC) disproportionately afflicts African-American (AA)

women compared to European-American (EA) women. West African (WA) women exhibit
higher TNBC incidence and mortality rates than AA women. Identification of biomarkers
underlying this global burden are urgently needed. We analyzed differences in expression of
breast cancer (BC)-related immunohistochemical biomarkers between self-reported European,
EA, AA, and WA TNBC patients treated at Nottingham University in Nottingham, UK, Emory
University in Atlanta, GA, and Olabisi Onabanjo University Teaching Hospital in Sagamu,
Nigeria, respectively. We discovered differences in expression of the human epidermal growth
factor receptor (HER) family; HER1/EGFR, HER3 and HER4 between the racial groups
(p<0.0001). HER4 cytoplasmic H-score and a summation of EGFR membrane and HER4
cytoplasmic H-scores (EGFR-HER4) decreased with increasing self-reported African ancestry.
Differential gene expression analysis revealed that EGFR (ERBB1) and HER4 (ERBB4) genes
were expressed lower among AA compared to EA TNBC samples (p<0.05). A lack of HER4
expression was associated with higher Nottingham grade (p=0.03) and mitotic index (p=0.03)
among AA patients and higher Ki67 (p=0.04) among early-stage AA patients. In multivariate
models, low EGFR-HER4 score predicted shorter 10-year overall (p=0.03; HR: 33.33) and
disease-free (p=0.04; HR: 33.33) survival among non-chemotherapy treated AA patients.
Furthermore, peroxisome proliferator-activated receptor (PPAR) signaling was downregulated
more among TNBC patients with low compared to high EGFR-HER4 scores (p=0.04). These
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results suggest that HER4 signaling differs among biogeographically-distinct TNBC patients and
that lack of HER4 and EGFR-HER4 expression may predict more aggressive disease among AA
and indigenous African TNBC patient populations. Our findings also suggest that the PPAR
signaling pathway has potential therapeutic implications among patients with low HER4 and
EGFR-HER4 scores.
9.2

Introduction
Triple negative breast cancer (TNBC) comprises a fifth of breast cancer (BC) cases

worldwide but remains the most fatal subgroup of BC owing to its more aggressive clinical
disease course. TNBC is defined by a lack of estrogen receptor (ER) and progesterone receptor
(PR) expression, and human epidermal growth factor receptor 2 (HER2) amplification
underscoring the urgent need for identification of treatment targets for this patient populatiGon.
Studies suggest that biogeographic ancestry may be a critical driver of aggressive TNBC.
African-American (AA) women are disproportionately afflicted with TNBC 1, tend to be
diagnosed at a younger age and show more aggressive clinicopathological features at
presentation than European-American TNBC patients. Furthermore, West African (WA) women
experience significantly higher TNBC incidence and mortality rates than AA women2-7. WAs
also present with TNBC at a younger age and with higher grade compared to AAs among TNBC
patients. Moreover, TNBC is more prevalent among WA women compared to women residing in
Europe and other parts of the world.
The human epidermal growth factor receptor (EGFR) family consists of four tyrosine
kinase receptors (EGFR/HER1, HER2, HER3, and HER4) that stimulate growth signaling
pathways involved in cell proliferation, growth, survival, and differentiation. EGFR is
overexpressed in at least 50% of TNBCs, which is notably higher than in other BC subtypes8.
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High EGFR copy number, immunoreactivity and membrane expression have been shown to be
independent prognostic indicators of poorer overall survival (OS) and disease-free survival
(DFS) in TNBC, suggesting EGFR to be a potentially targetable and risk-predictive biomarker in
TNBC9-12. HER3 is the only receptor in the family that is catalytically inactive and requires
dimerization with other members in order to be actived13. HER3 overexpression has been
reported in approximately 20-30% of invasive breast carcinomas14. Reports on the prognostic
role of HER3 in BC remain conflicted however, it has been associated with poorer overall
survival (OS) and DFS in TNBC13,15.
HER4 is reported to be downregulated in 18-75% of BCs and upregulated in 7-29% of
cases16. In comparison to non-TNBCs, its expression has been reported to be significantly lower
among TNBCs17. It can exist in four isoforms due to alternative mRNA splicing and one of these
isoforms can be cleaved and released into the cytoplasm as a soluble HER4 intracellular domain
(4ICD) that can translocate to the nucleus18-20. 4ICD displays a diverse range of roles including
modulating cell proliferation and pro-apoptotic pathways21,22. 4ICD has been reported to impede
breast tumor progression by activating genes that promote cellular differentiation and inhibit
proliferation23. Thus, 4ICD is often associated with a favorable prognosis such as longer DFS in
BC and TNBCs13,24-26. 4ICD has also been associated with luminal and well-differentiated
histology, ER and PR positivity, low histological grade, and low Ki6727. However, reports on the
prognostic value of HER4 in TNBC remain conflicted 17,28.
We conducted a multi-institutional study in which we screened European, US (EA and
AA), and Nigerian for differences in immunohistochemical (IHC) expression of BC-related
biomarkers. Interestingly, we only observed significant differences in EGFR, HER3, and HER4
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expression between all four ethnic groups. We also investigated the prognostic role of these
markers among these ethnically-distinct patient populations.
9.3

Results

9.3.1 Distinctions in clinico-pathological characteristics and survival among
biogeographically-distinct TNBC patient populations
We assessed differences in associations with demographic characteristics, clinicopathological variables and treatment information between UK, EA, AA and Nigerian TNBC
patients (Table 1). The Nigerian cohort had the highest percentage of patients diagnosed with
TNBC before 40 and the lowest percentage of postmenopausal patients. The Nigerian cohort had
the largest percentage of patients with tubule formation score of 3 and the AA cohort had the
highest percentage of patients with a mitotic score of 3, nuclear grade of 3, clinical stage of 3,
and highest Ki-67 scores. Stage information was unavailable for the Nigerian cohort. We also
compared associations with IHC expression of 11 BC-related markers between all four cohorts
(Table 2).
We compared OS in Kaplan-Meier analyses between all four cohorts (Figure 1). We
observed significant differences in OS between all 4 cohorts (p<0.0001). Nigerian patients
exhibited shorter 5-year OS than UK patients and AA patients exhibited shorter 5-year OS than
EA patients (Fig 1A). Nigerian patients also exhibited shorter 10-year OS than UK patients and
AA patients exhibited shorter 10-year OS than EA patients (Fig 1B).
9.3.2 TNBC patients of African descent show low HER4 expression
We screened all four ethnic groups for differences in expression of 11 common BCrelated IHC biomarkers in Table S2 (data not shown). We discovered significant differences in
only the EGFR family (EGFR, HER3 and HER4) between all four patient populations suggesting
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a role for this family in driving distinct tumor biology among the biogeographically-distinct
cohorts (p<0.0001) (Figure 2). Interestingly, HER4 expression directly decreased with
increasing presumed African ancestry as expression was highest among European and EA
patients but lowest among Nigerian and AA patients (p<0.0001) (Fig 2C). Since, the receptors
often heterodimerize to initiative signaling activity, we assessed differences in the combined
scores of EGFR and HER3 (Fig 2D), EGFR and HER4 (Fig 2E) and HER3 and HER4 (Fig 2F)
between the study cohorts. Interestingly, we also observed that EGFR-HER4 score was highest
among European and EA patients but lowest among Nigerian and AA patients (p<0.0001) (Fig
2D-E). Mean values of EGFR family expression levels among each racial group can be found in
Table 3. Owing to a different HER4 antibody used among the Nigerian cohort, we excluded
Nigerian patients from our comparison analyses involving HER4 and EGFR-HER4 scores and
yielded similar results (Figure 3). Representative images of membrane EGFR and cytoplasmic
HER4 staining can be found in Fig 3Ai and ii, respectively. HER4 (Fig 3B) and EGFR-HER4
(Fig 3C) scores directly decreased with increasing presumed African ancestry (p<0.0001).
9.3.3 Low EGFR-HER4 expression is associated with more aggressive disease features
among patients of African descent
Since HER4 and EGFR-HER4 scores decreased with increasing presumed African
ancestry, we determined associations of HER4 and EGFR-HER4 scores with clinicopathological
parameters among all (Table 4) and early-stage (I-II) (Table 5) TNBC patients for each ethnic
group. HER4 expression negatively correlated with Ki67 percentage among EA patients
(p=0.04). Furthermore, EGFR-HER4 negatively correlated with pT of TNM staging (p=0.04)
among the UK cohort. Among early-stage UK patients, EGFR-HER4 negatively correlated with
tubule formation (p=0.03). Among AA patients, HER4 negatively correlated with Nottingham
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grade (p=0.03) and mitotic index (p=0.03). Furthermore, among early-stage AA patients, HER4
expression negatively correlated with Ki67 percentage (p=0.04).
We also analyzed correlations of HER4 and EGFR-HER4 scores with IHC biomarkers
associated with BC tumorigenesis/progression among all (Table 6) and early-stage (Table 7)
TNBC patients from the UK and US (AA and EA) cohorts. The biomarkers mentioned in this
section were not assessed among Nigerian patients. We observed that cytoplasmic HER4
expression correlated positively with nuclear AR (p=0.02) and RARα (p=0.02) expression
among European patients. Furthermore, EGFR-HER4 correlated positively with stromal tumor
infiltrating lymphocytes (TILs) among EA patients (p=0.04). We observed similar results among
early-stage European and EA patients. Among AA patients, EGFR-HER4 also correlated
positively with nuclear AR expression (p=0.03). However, in contrast to European patients,
HER4 correlated negatively with nuclear RARα (p=0.03) expression among AA TNBC.
Furthermore, HER4 expression correlated negatively with PD1 expression among AA patients
(p=0.03). We also observed similar results among early-stage AA patents with the exception of
PD1.
9.3.4 Low HER4 and EGFR-HER4 expression predict worse prognosis among TNBC
patients of African ancestry
We also assessed the prognostic role of cytoplasmic HER4 and EGFR-HER4 among
ethnically-distinct TNBC patients by investigating the impact of their expression on survival.
The IHC expression of cytoplasmic HER4 and EGFR-HER4 was stratified into high and low
subgroups among each ethnic cohort and the impact of high and low expression of HER4 and
EGFR-HER4 scores on 5- and 10- year survival was estimated through Kaplan-Meier analysis
(Figure 4). Low HER4 and EGFR-HER4 predicted worse survival among patients of both
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African and European descent. Low EGFR-HER4 predicted significantly shorter 10-year OS
among non-chemotherapy-treated AA patients (p=0.040) (Fig 4A). Low HER4 (Fig 4B) and
EGFR-HER4 (Fig 4C) predicted significantly shorter 5-year OS among UK patients (p=0.008
and p=0.023, respectively). Furthermore, among early-stage UK patients, low HER4 (Fig 4D)
and EGFR-HER4 (Fig 4E) predicted significantly shorter 5-year OS (p=0.001 and p=0.006,
respectively). Moreover, among chemotherapy-treated early-stage UK patients, low HER4 was
associated with significantly poorer survival (p=0.007) (Fig 4F). We also investigated the impact
of HER4 and EGFR-HER4 on DFS among ethnically-distinct TNBC patients using KaplanMeier analyses and yielded similar results (Figure 5).
We also investigated the prognostic role of HER4 and EGFR-HER4 among the
ethnically-distinct TNBC patient populations by computing Cox proportional hazard regression
models adjusted for age, grade, and stage. Similar to Kaplan-Meier analyses, low HER4 and
EGFR-HER4 predicted poorer survival among patients of European and African descent. Low
HER4 expression predicted significantly shorter 5-year OS among all (p=0.04; HR: 1.59) and
early-stage (p=0.004; HR: 2.00) UK patients (Table 8). Low EGFR-HER4 also predicted shorter
5-year OS among early-stage (p=0.011; HR: 2.08) and early-stage radiation treated UK patients
(p=0.006; HR: 2.78) in adjusted models (Table 9). Furthermore, we observed that low HER4
(Table 10) and EGFR-HER4 (Table 11) predicted shorter 5-year DFS among all radiation
treated and early-stage radiation treated UK patients. Low EGFR-HER4 predicted significantly
shorter 5-year OS in adjusted model among non-radiation treated AA patients (p=0.036; HR: 20)
(Table 4). Low EGFR-HER4 also predicted shorter 10-year OS in multivariate analyses among
non-chemotherapy and non-radiation treated AA patients as well as among early-stage nonradiation treated AA patients (Table 12). Similar to OS results, low EGFR-HER4 was associated
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with shorter 5-year (Table 4) and 10-year DFS among non-radiation treated AA patients as well
as shorter 10-year DFS among non-chemotherapy treated AA patients (Table 13).
9.3.5 EGFR and EGFR signaling-related genes are underexpressed among AA TNBC
patients compared to EA TNBC patients
We also investigated differential expression of EGFR and EGFR signaling-related genes
between AA (n=41) and EA (n=87) TNBC patients in the TCGA RNA sequenced dataset to
confirm our protein expression results. Utilizing the DESeq2 software tool, we analyzed
differences in expression of 15,942 genes between AA and EA TNBC patients in TCGA breast
dataset. Log2fold changes can be found in Table 14. In line with our protein expression findings,
the genes encoding EGFR (ERBB1) and HER4 (ERBB4) were significantly more downregulated
in AA compared to EA samples (p<0.05). We also observed significant underexpression of the
EGFR pathway receptor substrate 8 (EPS8) and 15 (EPS15) genes in AA compared to EA
patients (p<0.05). Furthermore, we observed significant underexpression of genes encoding the
ligands for EGFR and HER4 such as neuregulin 3 (NRG3), neuregulin 4 (NRG4), and heparin
binding EGF like growth factor (HBEGF) (p<0.05) in AA compared to EA patients. Moreover,
we also discovered underexpression of genes encoding key molecules in downstream pathways
of EGFR and HER4 in AA compared to EA samples (p<0.05).
9.3.6 Peroxisome proliferator-activated receptor signaling more upregulated among high
compared to low EGFR-HER4 gene-expressing TNBC patients
We also identified differentially-expressed biological pathways (Table 15) and gene
ontologies (Table 16) between high (n=85) and low (n=58) EGFR-HER4 gene-expressing
subgroups among TNBC patients in TCGA dataset. Interestingly, we discovered significant
upregulation of the peroxisome proliferator-activated receptor (PPAR) signaling pathway among
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high compared to low EGFR-HER4 expressing patients (p=0.036). We also observed significant
upregulation of pathways regulated by PPAR signaling among high compared to low EGFR-HER4
(p<0.05). We also discovered significant upregulation of gene ontologies reflecting metabolic and
catabolic processes regulated by PPAR signaling (p<0.05) as well as other gene ontologies
indicative PPAR signaling (p<0.05). Furthermore, we found significant upregulation of gene
ontologies reflecting inflammatory activity, which is modulated by PPAR signaling (p<0.05).

9.4

Discussion
The absence of conventional BC markers, ER, PR, and HER2, in triple negative breast

tumors has prompted the investigation into alternative actionable targets. We screened all four
ethnic groups (Europeans, EAs, AAs, and West Africans) for differences in expression levels of
11 common BC biomarkers. TNBC patients in the UK cohort are comprised of predominantly
Europeans who harbor low levels of African ancestry. EAs have been reported to harbor
anywhere between 1-2% African ancestry depending on the region of the US they reside32. AAs
represent a highly admixed population with a reported average of 24% of European ancestry,
which also varies according to the region of the US they reside32. AAs harbor a reported average
of 73.2% of African ancestry, most of which can be traced back to western Africa according to
genetic studies. Genetic ancestry typing was not performed in our study.
Interestingly, the EGFR family members were the only biomarkers that exhibited
significant differences in expression levels between all four biogeographically-distinct patient
populations. Furthermore, expression of HER4 and EGFR-HER4 showed lowest expression in
Nigerian patients and highest expression in UK patients. Our gene expression analyses
corroborated our protein expression findings as we observed significant downregulation of
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ERBB1 and ERBB4 among AA compared to EA TNBC samples. As consistent with the
literature mentioned earlier, cytoplasmic HER4 and EGFR-HER4 was associated with more
favorable disease features among TNBC patients of both European and African descent. Our
findings of low HER4 expression and EGFR-HER4 score among AA and Nigerian patients
compared to their European counterparts may rationalize their increased presentation of poor
prognostic disease features among TNBC patients of African compared to European descent. We
discovered cytoplasmic HER4 and EGFR-HER4 expression was prognostic among
biogeographically-distinct patients in both Kaplan-Meier and multivariate analyses as high
expression of these markers predicted better survival.
PPAR signaling was the key pathway that was discovered to be significantly upregulated
among high compared to low EGFR-HER4 score patients. PPAR signaling has been reported to
regulate glucose homeostasis, steroid hormone biosynthesis, lipid metabolism, hydrogen
peroxide metabolism, insulin signaling, inflammation, and cell cycle regulation33-37. The role of
PPAR signaling in cancer remains controversial, however the pathway has been reported to
exhibit an antitumor effect in BC by reducing cell growth and proliferation and inducing
differentiation and apoptosis. Hence, a lack of EGFR-HER4 signaling may be associated with a
poorer prognosis among TNBC patients of African descent owing to a deficiency in PPAR
signaling. PPAR agonists may be promising therapeutic strategies for TNBC patients of African
descent lacking EGFR-HER4 signaling.
Our study further corroborates previous findings revealing that patients of African
ancestry tend to lack expression of common BC targets such as ER, PR, HER2, AR and now
HER4 expression. Our findings present additional biomarkers that can risk-stratify patients of
African descent during the early stages of the disease to improve their clinical management.
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9.5

Methods

9.5.1 Patient Cohorts
We procured TNBC patient datasets from 3 different institutions: (1) Nottingham
University Hospital (NH) in Nottingham, UK, (2) Emory University Hospital (EH) in Atlanta,
GA, and (3) Olabisi Onabanjo University Teaching Hospital (OOTH) in Sagamu, Nigeria. NH,
EH and OOTH cohorts were comprised of 322, 121 and 307 TNBC patients, respectively. NH
patients were diagnosed between 2007-2013, EH patients were diagnosed between 2002-2016
and the OOTH patients were diagnosed between 2011-2016. We obtained consent and
permission from the institutional review boards at each institution to obtain access to deidentified
patient information used in this study. None of the patients treated at EH received neoadjuvant
chemotherapy.
9.5.2 Immunohistochemistry and scoring
Biomarker expression was determined through standard IHC staining and scored as Hscore (percentage x intensity), Nper (nuclear percentage) and NH-score (nuclear percentage x
intensity). Intensity of staining were scored as 0=none, 1=low, 2=moderate, and 3=high.
Negativity was determined as <1% expression and positivity was determined as ≥1% expression
for all biomarkers. Antibody details and concentrations can be found in Table 17. The maximum
score for any given H-score is 300 and for combined (summed) H-scores is 600. Combined
biomarker scores were determined by summing the scores for each biomarker to yield a single
score. NH and OOTH patient samples were centrally stained, scored, and reviewed at NH. EH
patient samples were stained, scored, and reviewed at EH. Scoring was performed by two
independent pathologists blinded to clinical annotation and individual scores were averaged.

213

9.5.3 Follow-Up
Median duration of follow-up for each cohort was approximately 6 years for EH, 5 years
for NH, and 1 year for OOTH patients. Survival status (alive/dead) was recorded for each patient
at last follow-up in addition to survival time.
9.5.4 Statistical Analyses
The significance level for all analyses was set to p<0.05 with 95% confidence intervals
(CIs). Chi-square tests were performed to analyze differences in frequency of demographic
characteristics, breast clinicopathological variables and biomarkers, as well as treatment
information between UK, AA, EA, and Nigerian TNBC patients. SAS 9.4 program was used to
generate test statistics and 2-tailed univariate p-values were reported. One-way ANOVA tests were
performed to determine differences in mean expression of BC biomarkers between all four patient
groups. Associations between HER4 H-score and combined EGFR and HER4 H-scores (EGFRHER4) with demographic and breast clinico-pathological variables and biomarkers among each
ethnic group were determined by computing Spearman’s rank correlation coefficients (ρ) for
categorical covariates and Pearson correlation coefficients for continuous covariates. Unadjusted
and adjusted multivariate Cox proportional hazard regression models were computed to assess the
impact of HER4 and EGFR-HER4 scores on 5- and 10-year OS and disease-free survival (DFS)
before and after controlling for age, Nottingham grade and stage. The Kaplan-Meier analysis was
conducted using SAS 9.4 program to estimate survival function for each patient group based on
high and low expression levels of HER4 and EGFR-HER4 score. A log-rank test was used to
stratify HER4 and EGFR-HER4 scores into high and low subgroups.
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9.5.5 Differential Gene Expression Analysis
We queried The Cancer Genome Atlas (TCGA) breast dataset for TNBC patients.
Publically-available ER/PR/HER2 IHC data was used to determine TNBC status. We performed
differential gene expression analysis between high and low EGFR-HER4 gene-expressing
subgroups using the DESeq2 software tool29. EGFR-HER4 scores were determined by summing
the normalized gene expression values for each biomarker. Differential expression analyses of
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontologies between
high and low EGFR-HER4-expressing TNBC patients were predicted by GAGE and Pathview
packages, respectively30,31. High and low EGFR-HER4-expressing TNBC patients were stratified
according to the median.
9.6

Tables and Figures

Table 9.1 Clinico-pathological characteristics and treatment information of
biogeographically-distinct TNBC patient populations.
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Table 9.2 Breast cancer biomarker expression among biogeographically-distinct TNBC patient
populations.
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Table 9.3 Differences in HER family member expression between ethnically-distinct TNBC
patient populations.
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Table 9.4 Correlation of HER4 and EGFR-HER4 scores with clinicopathological variables
among biogeographically-distinct TNBC patients.

Table 9.5 Correlation of HER4 and EGFR-HER4 scores with clinicopathological variables
among biogeographically-distinct early-stage TNBC patients.
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Table 9.6 Correlation of HER4 and EGFR-HER4 scores with clinical BC biomarkers among
biogeographically-distinct TNBC patients.

Table 9.7 Correlation of HER4 and EGFR-HER4 scores with clinical BC biomarkers among
biogeographically-distinct early-stage TNBC patients.
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Table 9.8 Impact of cytoplasmic HER4 on 5-year survival among biogeographically-distinct
TNBC patients.
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Table 9.9 Prediction of EGFR-HER4 scores on 5-year overall survival among
biogeographically-distinct TNBC patients.
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Table 9.10 Prediction of HER4 with 5-year disease-free survival among biogeographicallydistinct TNBC patients.
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Table 9.11 Prediction of EGFR-HER4 score on 5-year disease-free survival among
biogeographically-distinct TNBC patients.
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Table 9.12 Prediction of EGFR-HER4 score on 10-year overall survival among raciallydistinct TNBC patients.
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Table 9.13 Prediction of EGFR-HER4 score on 10-year disease-free survival among raciallydistinct TNBC patients.
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Table 9.14 Genes significantly upregulated among AA compared to EA TNBC patients in
TCGA dataset.
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Table 9.15 Biological pathways upregulated or downregulated among high compared to low
EGFR-HER4 expressing TNBC patients in TCGA dataset.
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Table 9.16 Gene ontologies upregulated or downregulated among high compared to low
EGFR-HER4 expressing TNBC patients in TCGA dataset.
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GO:0006067 ethanol metabolic process

0.035

GO:0002702 positive regulation of production of molecular mediator of immune response

0.035

GO:0002443 leukocyte mediated immunity

0.036

GO:0002700 regulation of production of molecular mediator of immune response

0.038

GO:0002065 columnar/cuboidal epithelial cell differentiation

0.038

GO:0002697 regulation of immune effector process

0.038

GO:0009404 toxin metabolic process

0.038

GO:0010565 regulation of cellular ketone metabolic process

0.039

GO:0006979 response to oxidative stress

0.04

GO:0009636 response to toxin

0.04

GO:0010560 positive regulation of glycoprotein biosynthetic process

0.041

GO:0019400 alditol metabolic process

0.042

GO:0006694 steroid biosynthetic process

0.043

GO:0097237 cellular response to toxin

0.044

GO:0002377 immunoglobulin production

0.044

GO:0035725 sodium ion transmembrane transport

0.045

GO:0006921 cellular component disassembly involved in execution phase of apoptosis

0.046

GO:0042102 positive regulation of T cell proliferation

0.046

GO:0002021 response to dietary excess

0.046

GO:0010884 positive regulation of lipid storage

0.046

GO:0032615 interleukin-12 production

0.047

GO:0032655 regulation of interleukin-12 production

0.047

GO:0002250 adaptive immune response

0.048

GO:0032609 interferon-gamma production

0.049

GO:0060081 membrane hyperpolarization

0.049

Downregulated gene ontologies
GO:0045664 regulation of neuron differentiation

<0.001

GO:0010975 regulation of neuron projection development

<0.001

GO:0051960 regulation of nervous system development

<0.001

GO:0050767 regulation of neurogenesis

<0.001

GO:0007409 axonogenesis

<0.001

GO:0048812 neuron projection morphogenesis

<0.001

GO:0045047 protein targeting to ER

<0.001

GO:0072599 establishment of protein localization to endoplasmic reticulum

<0.001

GO:0019080 viral genome expression

0.001

GO:0019083 viral transcription

0.001

GO:0006613 cotranslational protein targeting to membrane

0.001

GO:0006614 SRP-dependent cotranslational protein targeting to membrane

0.001

GO:0006414 translational elongation

0.001

GO:0006415 translational termination

0.001

GO:0048667 cell morphogenesis involved in neuron differentiation

0.001

GO:0019058 viral infectious cycle

0.001

GO:0050770 regulation of axonogenesis

0.001

GO:0070972 protein localization to endoplasmic reticulum

0.001

GO:0031344 regulation of cell projection organization

0.001

GO:0060284 regulation of cell development

0.002

GO:0022604 regulation of cell morphogenesis

0.002

GO:0006612 protein targeting to membrane

0.002

GO:0010769 regulation of cell morphogenesis involved in differentiation

0.002
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Table 9.17 Antibodies and dilutions used for immunohistochemical biomarker staining.
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Figure 9.1 Overall survival among ethnically-distinct TNBC patients.
Comparison of 5-year (A) and 10-year (B) overall survival between UK, EA, AA and Nigerian
TNBC patient cohorts treated at NH, EH and OOTH respectively, using Kaplan-Meier survival
analyses. A log-rank test was used to determine statistical differences in survival between the
patient groups. p<0.05 was set as the level of significance.
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Figure 9.2 Comparison of EGFR family members between ethnically-distinct TNBC patients.
Box and whisker plots comparing IHC expression of EGFR (p<0.0001) (A), HER3 (p<0.0001)
(B), HER4 (p<0.0001) (C), combined EGFR-HER3 (p<0.0001) (D), combined EGFR-HER4
(p<0.0001) (E) and combined HER3-HER4 (p<0.0001) (F) scores between European (UK), EA,
AA, and Nigerian TNBC patients. One-way ANOVA test was performed to determine
significant differences between the racial groups. p<0.05 was considered significant.
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Figure 9.3 Comparison of HER4 and combined EGFR-HER4 scores between
biogeographically-distinct TNBC patients.
Representative microscopic images of membrane EGFR (Ai) and cytoplasmic HER4 (Aii) IHC
staining. Box and whisker plots comparing IHC expression of cytoplasmic HER4 (B) and
combined EGFR-HER4 (C) scores between European (UK), EA, and AA TNBC patients. Oneway ANOVA test was performed to determine significant differences in expression of the
markers between the biogeographically-distinct patient populations. Images acquired at 200x
magnification. p<0.05 was considered significant.
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Figure 9.4 HER4 and combined EGFR-HER4 score predict overall survival among
biogeographically-distinct TNBC patients.
HER4 and combined EGFR-HER4 scores were stratified into high (≥4 for HER4; ≥5 for EGFRHER4) and low (<4 for HER4; <5 for EGFR-HER4) subgroups using a log-rank test. The impact
of high and low expression of HER4 and combined EGFR-HER4 score on 5- and 10-year
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survival among treated TNBC patients of African and European descent was estimated through
Kaplan-Meier analyses. Survival curves (10-year OS) of non-chemotherapy-treated AA patients
stratified based on high vs. low expression of EGFR-HER4 (A), survival curves (5-year OS) of
UK TNBC patients stratified based on high vs. low HER4 score (B), survival curves (5-year OS)
of UK TNBC patients stratified based on high vs. low EGFR-HER4 score (C), survival curves
(5-year OS) of early-stage UK TNBC patients stratified based on high vs. low HER4 expression
(D), survival curves (5-year OS) of early-stage UK TNBC patients stratified based on high vs.
low EGFR-HER4 expression (E), and survival curves (5-year OS) of chemotherapy-treated
early-stage UK TNBC patients stratified based on high vs. low HER4 expression (F). p<0.05
was considered significant.
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Figure 9.5 HER4 and combined EGFR-HER4 score predict disease-free survival among
biogeographically-distinct TNBC patients.
HER4 and combined EGFR-HER4 scores were stratified into high (≥4 for HER4 and ≥5 for
EGFR-HER4) and low (<4 for HER4 and <5 for EGFR-HER4) subgroups using a log-rank test.
The impact of high and low expression of HER4 and combined EGFR-HER4 score on 5- and 10-
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year disease-free survival (DFS) among treated TNBC patients of African and European descent
estimated through Kaplan-Meier analyses. Survival curves (10-year DFS) of non-chemotherapytreated AA patients stratified based on high vs. low expression of EGFR-HER4 (A), survival
curves (5-year DFS) of radiation-treated UK patients stratified based on high vs. low expression
of HER4 (B) and EGFR-HER4 (C), survival curves (5-year DFS) of radiation-treated early-stage
UK patients stratified based on high vs. low expression HER4 (D) and combined EGFR-HER4
scores (E), and survival curves (5-year DFS) of chemotherapy-treated early-stage UK patients
stratified based on high vs. low expression of HER4 (F). p<0.05 was considered significant.
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10 LACK OF COMBINED IMMUNOHISTOCHEMICAL HER3-HER4 SCORE
PREDICTS POOR PROGNOSIS AMONG EARLY-STAGE AFRICAN-AMERICAN
QUADRUPLE NEGATIVE BREAST CANCER PATIENTS
10.1 Abstract
Quadruple negative breast cancer (QNBC) has recently emerged as a subgroup of triple
negative breast cancer (TNBC) and is defined by the absence of androgen receptor (AR), which
differentiates them from TNBC. Although controversial, a lack of AR expression in TNBC has
been reported to confer an aggressive disease course. Recent evidence suggest that QNBC
disproportionately affects women of African descent. The role of the other three members of the
epidermal growth factor receptor (EGFR) family (EGFR/HER1, HER3, HER4) in AA QNBC
remains underexplored. We compared individual and combined immunohistochemical (IHC)
expression scores of these EGFR family members between formalin-fixed, paraffin-embedded
resection AR-negative and AR-positive AA TNBC patient samples from Emory Hospital in
Atlanta, GA. We performed differential gene expression analyses to determine differences in
mRNA expression of the EGFR family members and downstream signaling between AR-low
and AR-high expressing AA TNBC patients in a publically-available dataset. Combined IHC
HER3 and HER4 expression (HER3-HER4 score) was significantly lower among QNBC (n=48)
compared to TNBC (n=14) early-stage (I-II) AA patients (p=0.04). Gene expression analyses
revealed lower HER4 expression and downstream signaling among AR-low compared to ARhigh expressing AA TNBC patients. Lack of HER3-HER4 score was associated with high Ki-67
percentage (p=0.03) and Nottingham score (p=0.04) among early-stage AA QNBC patients.
Moreover, low HER3-HER4 score predicted shorter 10-year overall survival among early-stage
AA QNBC patients in Kaplan-Meier analysis (p=0.047). In silico analyses revealed more
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downregulation of pro-apoptotic genes as well as gene ontologies reflecting cell death, loss of
cell-cell contact, and pro-inflammatory pathways among AR-low compared to AR-high AA
TNBC samples (p<0.05). However, we observed more upregulation of biological pathways and
gene ontologies reflecting cell cycle progression, cell proliferation, and DNA damage repair
response among AR-low compared to AR-high AA TNBC patients (p<0.05). Our findings
suggest that a low HER3-HER4 score may be associated with early-stage QNBC disease among
AAs and may serve as a valuable risk-prognostic biomarker for this patient population. Our
results also indicate that early-stage AA QNBC patients lacking HER3-HER4 expression may
exhibit sensitivity to therapies targeting cell cycle progression and DNA damage response.
10.2 Introduction
Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer that
continues to confound researchers and clinicians today. TNBC is characterized by a lack of
expression of the pharmacologically-targetable biomarkers, estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) expression rendering
this subgroup of breast cancer patients refractory to traditional endocrine and HER2-targeted
systemic therapies (1). Anthracycline- and taxane- based chemotherapy remain the cornerstone
of TNBC treatment however, about 30-40% of TNBC patients achieve pCR and experience
improved disease-free survival (DFS)(2, 3). The disease is further typified by more aggressive
tumor characteristics such as higher grade, clinical stage, and proliferation, a more aggressive
clinical course characterized by increased lymph node, cerebral, and visceral metastasis, and a
poorer prognosis defined by higher mortality rates compared to non-TNBCs(4-9). Furthermore,
TNBC disproportionately afflicts younger and African-American (AA) women(10). Moreover,
within the inherently aggressive subtype, AAs exhibit more aggressive disease features, acquire
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more aggressive TNBC subtypes, and suffer poorer clinical outcomes compared to EuropeanAmericans (EAs) patients (11-17). Androgen receptor (AR) has recently emerged as a promising
therapeutic target for TNBC patients, however AAs have been reported to lack expression of AR
or harbor quadruple negative breast cancer (QNBC) disease significantly more than EAs among
TNBC patients rendering them more refractory to AR-targeted therapies(17). Furthermore,
although the prognostic role of AR in TNBC remains controversial, a lack of AR expression has
been reported to be associated with poor differentiation, high clinical stage, high Ki-67, high
mitotic index, increased lymphovascular invasion, increased risk of recurrence and distant
metastasis, and worse 5-year disease-free survival (DFS) and overall survival (OS) suggesting
the high absence of AR expression among AAs may be contributing to the racial disparate
burden in TNBC (18-22). Furthermore, our group recently reported that AA’s exhibit poorer
survival than EAs among QNBC patients. Thus, novel alternative risk-prognostic biomarkers and
therapeutic strategies are urgently needed to target QNBC disease in AA women.
The human epidermal growth factor receptor (EGFR) family plays a critical role in cell
proliferation, growth, survival, and differentiation through stimulating key growth signaling
pathways such as PI3 kinase, Ras-Raf-MAPK, JNK, and PLCg(23-25). The family is comprised
of four structurally related tyrosine kinase receptors ((EGFR/HER1, HER2, HER3, and HER4)
that are activated upon ligand binding, hetero- or homo- dimerization of these receptors, and
subsequent phosphorylation of tyrosine residues on the intracellular tyrosine kinase domain(26).
Aberrant expression of these receptors can stimulate carcinogenesis by promoting loss of cell
adhesion, polarity, and initiating invasion and angiogenesis(27, 28). EGFR is overexpressed in
approximately 50% of TNBCs, which is significantly higher compared to other BC subtypes(17,
24). High EGFR copy number, immunoreactivity, and expression have been reported to
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independently predict poorer overall survival (OS) and disease-free survival (DFS) in TNBC
providing evidence for EGFR as a potentially targetable and risk-predictive biomarker in
TNBC(29-32). HER3 is the only receptor in the family that is catalytically inactive and can only
be activated if it dimerizes with other members in the family(33). The receptor has been reported
to be overexpressed in roughly 20-30% of invasive breast carcinomas. Evidence on the
prognostic role of HER3 in breast cancer are conflicted however, the receptor has been linked to
poorer OS and DFS in TNBC. HER4 is the only family member to exist in four isoforms as a
result of alternative mRNA splicing(34). One of these isoforms can be cleaved as a soluble
HER4 intracellular (4ICD) in the cytoplasm and translocate to the nucleus(35-37). HER4 has
been consistently reported to modulate cell proliferation and pro-apoptotic pathways and thus has
been linked to a favorable prognosis in BC and specifically among TNBCs33, (33, 38-41).
Furthermore, elevated HER4 gene expression levels during chemotherapy has been shown to
predict response to neoadjuvant chemotherapy in breast cancer(42).
It may be worthy to investigate the role of the other three EGFR family members as
alternative risk-predictive and/or therapeutic targets in QNBC owing to its inherent lack of ER,
PR, HER2, and AR expression. The role of the EGFR growth factor receptor family in QNBC
and in the racial disparate burden remains elusive, however recent evidence suggests that the
EGFR family members may be critical drivers in QNBC disease etiology and progression. AR
has been reported to regulate expression of members of the EGFR family and vice versa in
multiple cancer types(43-51). Researchers at Caris Research Institute recently observed
significantly higher EGFR expression among AR-negative compared to AR-positive TNBCs. In
contrast, HER4 mRNA expression levels have been reported to be significantly lower among
AR-negative compared to AR-positive TNBC patients(17). Thus, a lack of HER4 expression
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may be associated with QNBC disease and serve as a novel prognostic biomarker for QNBC
patients. Hence, we examined the prognostic and predictive role of the EGFR family members in
AA QNBC disease to explore the potential of these receptors to improve risk-prognostication
and/or be exploited for therapeutic intervention among this patient population. We
immunostained specimens from AA TNBC patients observed at Emory University Hospital (EH)
for AR and the EGFR family receptors and examined differences in their immunohistochemistry
(IHC) expression levels between AR-negative and AR-positive patients, as well as investigated
the prognostic role of this receptor family in AA QNBC.
10.3 Results
10.3.1 Clinico-pathological characteristics and biomarker expression among AR-negative and
AR-positive AA TNBC patients
We analyzed differences in associations with demographic and clinico-pathological
characteristics as well as treatment status between AR-negative (n=61) and AR-positive (n=16)
AA TNBC patients observed at EH (Table 1) We did not observe significant differences in
associations with demographic and clinico-pathological characteristics between AA QNBC and
TNBC patients. However, we did observe moderate significant differences associations with
nuclear grade, Nottingham grade, and lymph node status between the groups. A higher
percentage of AA QNBCs (76.6%) presented with a nuclear grade of 3 compared to AA TNBCs
(18.2%) (p=0.139). A higher proportion of AA QNBCs (72.7%) also presented with a
Nottingham grade of 3 compared to AA TNBC patients (15.6%) (p=0.062). Furthermore, a
greater percentage of AA QNBC patients (26%) exhibited lymph node involvement compared to
AA TNBC patients (2.6%) (p=0.110).
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10.3.2 AR-negatives exhibit lower combined immunohistochemical HER3-HER4 score than
AR-positives among AA TNBC patients
We examined differences in the IHC expression of the EGFR family members [EGFR
(membranous), HER3 (membranous), and HER4 (cytoplasmic)] between AR-negative and ARpositive AA TNBC patients. We also compared combinations of the scores between the groups
to determine differences in dimerization and cooperative signaling. We only observed significant
differences in combined IHC HER3 and HER4 expression (HER3-HER4 score) between QNBC
and TNBC AA patients, in which HER3-HER4 score was significantly lower in AR-negative
(n=61) compared to AR-positive (n=16) TNBC patients (p=0.014) (Figure 1). We further
investigated differences in HER3-HER4 score between the groups by comparing the scores
between chemotherapy treated and non-treated AA QNBC and TNBC patients, as well as among
early-stage treated patients (Figure 2). Representative microscopic images of HER3
(membranous) and HER4 (cytoplasmic) IHC staining can be found in Fig 2A. Interestingly, we
also observed significantly lower HER3-HER4 score among all (p=0.014) and chemotherapytreated (p=0.014) AR-negative (n=42) and AR-positive (n=12) AA TNBC patients (Fig 2B).
Furthermore, HER3-HER4 score was significantly lower among QNBCs (n=48) compared to
TNBCs (n=14) among early-stage AA patients (p=0.04) as well as among early-stage AA
patients treated with chemotherapy (p=0.03) (Fig 2C).
10.3.3 Lack of HER3-HER4 score is associated with more aggressive disease features among
early-stage AA QNBC patients
We investigated associations of HER3-HER4 score with clinico-pathological variables
(Table 2) and biomarkers (Table 3) among AA QNBC patients. Regarding clinico-pathological
characteristics, HER3-HER4 score negatively correlated with aggressive tumor features among
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AA patients. Among all AA patients, HER3-HER4 score negatively correlated with Ki67
percentage (ρ=-0.294; p=0.023) and Nottingham score (ρ=-0.275; p=0.033). Moreover, HER3HER4 score negatively correlated with Ki67 percentage among early-stage AA patients (ρ=0.307; p=0.034) and negatively correlated with Nottingham score among early-stage AA patients
administered chemotherapy (ρ=-0.366; p=0.040). However, among AA patients administered
chemotherapy, HER3-HER4 score positively correlated with sentinel lymph node (SLN)
involvement (ρ=0.325; p=0.036). Regarding clinical biomarkers, HER3-HER4 score also
negatively correlated with biomarkers associated with aggressive disease among AA QNBC
patients. Among all (ρ=-0.322; p=0.020) and early-stage (ρ=-0.315; p=0.040) AA patients,
HER3-HER4 score negatively correlated with nuclear forkhead box protein M1 (FOXM1)
expression. HER3-HER4 score also negatively correlated with nuclear retinoic acid receptor
alpha (RARα) expression among all (ρ=-0.326; p=0.014) and early-stage (ρ=-0.361; p=0.014)
AA patients. Furthermore, among early-stage AA patients, HER3-HER4 score negatively
correlated with BRCA1-associated protein 1 (BAP1) expression (ρ=-0.294; p=0.043).
10.3.4 Lack of combined IHC HER3-HER4 score predicts poorer survival among early-stage
AA QNBC patients
We investigated the prognostic and predictive power of HER3-HER4 score among AA
QNBC patients. HER3-HER4 scores were stratified into high (³6) and low (<6) subgroups using
a log-rank test among AA QNBC patients and Kaplan-Meier analyses were performed to
estimate the impact of HER3-HER4 score on survival over a 5- and 10- year period (Figure 2).
We observed that low HER3-HER4 score moderately predicted poorer 10-year (p=0.136) and 5year (p=0.0137) OS among all AA QNBC patients (Fig 2A-B). However, low HER3-HER4
score significantly predicted poorer 10-year OS among early-stage AA QNBC patients (p=0.047)
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(Fig 2C). Furthermore, low HER3-HER4 score weakly predicted poorer 10-year (p=0.108) OS
among early-stage radiation treated AA patients (Fig 2D). We also computed Cox proportional
hazard regression models to assess unadjusted and adjusted associations of HER3-HER4 score
with 5- and 10-year OS among AA QNBC patients (Table 4). Low HER3-HER4 score
moderately predicted shorter 10-year OS in adjusted analyses among all (p=0.057; HR: 0.310;
95% CI: 0.093-1.035) and early-stage (p=0.054; HR: 0.251; 95% CI: 0.062-1.025) AA QNBC
patients.
Downregulation of genes, pathways, and gene ontologies involved in HER4 signaling
among AA QNBC patients

We investigated differential expression of genes, pathways, and gene ontologies between
AR-low and AR-high AA patients isolated from TCGA breast dataset. We utilized the GAGE
package to analyze differences in biological pathways or experimentally-derived differential
expression sets between AR-low and AR-high AA TNBCs in TCGA breast dataset (Table 5).
We observed significantly more upregulation of cell proliferation and DNA damage repair
expression sets such as cell cycle, DNA replication, base-excision repair, mismatch repair, and
nucleotide excision repair (p<0.05) and significantly more downregulation of downstream
pathways of HER4 signaling such as MAPK, JAK/STAT, calcium signaling pathways, and
adenylate cyclase-modulating G-protein coupled receptor signaling pathway (p<0.05) among
AR-low compared to AR-high AA TNBCs. Furthermore, we discovered significantly more
downregulation of pro-inflammatory expression sets such as leukocyte transendothelial
migration and intestinal immune network for IgA production as well as chemokine, T cell, and B
cell signaling pathways among AR-low compared to AR-high AA patients (p<0.05). Moreover,
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we also found significantly more downregulation of cell-cell contact such as focal adhesion, cell
adhesion molecules (CAMs), and gap junction among AR-low compared to AR-high AAs
(p<0.05).
We utilized the Pathview package to analyze differences in gene ontologies between ARlow and AR-high AA TNBCs in TCGA breast dataset (Table 6). We also observed significantly
more upregulation of gene ontologies associated with cell cycle progression such as interphase, S
phase, mitosis, DNA replication, cell cycle checkpoint, M/G1 transition of mitotic cell cycle, and
G1/S transition of mitotic cell cycle as well as DNA damage response such as DNA repair,
response to DNA damage stimulus, DNA integrity checkpoint, and DNA damage checkpoint
(p<0.05). Gene ontologies associated with downstream signaling of HER4 such as MAPK
cascade, ERK1 and ERK2 cascade, phospholipase C activity, cAMP metabolic process,
phosphatidylinositol 3-kinase cascade, second-messenger-mediated signaling, and platelet
derived growth factor receptor signaling pathway were significantly more downregulated in ARlow compared to AR-high AA TNBC samples (p<0.05). Gene ontologies associated with
regulation of cell death, differentiation, and proliferation such as cell type specific apoptotic
processes, negative regulation of cell death, negative regulation of programmed cell death,
negative regulation of cell proliferation, and negative regulation of cell differentiation were also
significantly more downregulated among AR-low compared to AR-high AA samples (p<0.05).
In addition, gene ontologies indicative of cell-cell contact and tissue homeostasis such as cellcell adhesion, actin cytoskeleton organization, extracellular matrix organization, cell-substrate
adhesion, cell-matrix adhesion, cell adhesion mediated by integrin, positive regulation of cell
migration, and positive regulation of cell motility were significantly more downregulated among
AR-low compared to AR-high AA samples (p<0.05). Furthermore, gene ontologies reflective of
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a pro-inflammatory response such as T cell activation, lymphocyte activation, lymphocyte
differentiation, inflammatory response, B cell activation, leukocyte proliferation, leukocyte
migration, adaptive immune response, and humor immune response were significantly more
downregulated in AR-low compared to AR-high AA TNBC samples (p<0.05).
Utilizing the DESeq2 software tool, we analyzed differences in expression of 15,942
genes between AR-low and AR-high AA TNBC patients in the TCGA breast dataset. Log2 fold
changes can found in (Table 7). We observed the gene encoding HER4, ERBB4, was
significantly more downregulated among AR-low compared to AR-high AA TNBCs (p<0.05).
Furthermore, we discovered that the gene encoding the HER4 ligand that induces its proteolytic
cleavage, heparin-binding epidermal growth factor (HB-EGF), was significantly more
downregulated in AR-low compared to AR-high AA TNBC samples (p<0.05). We also
observed significantly more downregulation of genes encoding key signaling molecules in the
downstream pathways of HER4 signaling such as phosphodiesterase 1A (PTGER3),
phosphatidylinositol-3,4,5-triphosphate dependent Rac exchange factor 2 (PREX2), inositol-3phosphate synthase 1 (ISYNA1), phospholipase C like 1 (PLCL1), Ras guanyl releasing protein
2 (RASGRP2), mitogen-activated protein kinase binding protein 1 (MAPKBP1), Janus kinase 3
(JAK3), and signal transducer and activator of transcription 5B (STAT5B) among AR-low
compared to AR-high AA patients (p<0.05). We also observed significantly more
downregulation of genes encoding G-protein signaling such as G-protein-coupled receptor 4
(GPR4) and regulator of G-protein signaling 22 (p<0.05). Furthermore, we found that proapoptotic caspases such as caspase 10 (CASP10) and 12 (CASP12) were significantly more
downregulated among AR-low compared to AR-high AA TNBCs (p<0.05).
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10.4 Discussion
TNBC patients of African descent suffer the most aggressive clinical disease course, the
poorest prognosis, and have the least amount of targeted treatment options in comparison to
TNBC patients of other ethnicities. Thus, novel risk-predictive biomarkers and therapeutic
targets are urgently needed to circumvent a poor prognosis among this patient population. AR
has recently emerged as a promising alternative therapeutic target for TNBC patients, however,
AA TNBC patients have been reported to lack AR expression significantly more than EA TNBC
patients, leaving AAs less susceptible to AR-targeted therapy than EAs among TNBC patients.
Furthermore, a lack of AR expression has been associated with a poor prognosis among TNBC
patients of African descent. Thus, alternative actionable targets are needed for AA TNBC
patients lacking AR expression. The other EGFR family members (EGFR/HER1, HER3, and
HER4) have also emerged as promising alternative prognostic and/or pharmacologicallytargetable biomarkers in TNBC. Hence, in this study we investigated the potential of these EGFR
family members as novel, alternative biomarkers for AA TNBC patients absent of AR
expression.

We compared IHC expression of the three EGFR family members as well as combined
variations of the receptors between AR-negative and AR-positive AA TNBC patients and
observed that only HER3-HER4 score significantly differed between the patient groups.
Specifically, HER3-HER4 score was significantly lower among all and early-stage QNBC
compared to TNBC AA patients suggesting that a lack of HER3-HER4 signaling may be
underlying more aggressive TNBC among patients of African ancestry. Furthermore, HER3HER4 score was significantly lower among all and early-stage chemotherapy-treated QNBC
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compared to TNBC AA patients. As previously discussed, HER3 is catalytically inactive unless
it dimerizes with another EGFR family member and HER4 expression is the only family member
that is associated with a better prognosis in TNBC owing to its pro-apoptotic and
antiproliferative activity. Hence, lower HER3-HER4 expression among AR-absent compared to
AR-expressing AA TNBC patients may reflect reduced cell death and increased proliferation
among AA QNBC patients. Furthermore, these findings suggest less dimerization of HER3 with
HER4 and downstream signaling among AA QNBC compared to AA TNBC patients.
We also discovered that a lack of HER3-HER4 expression was associated with more
aggressive disease features among AA QNBC patients. Low IHC HER3-HER4 score was
associated with high Ki-67 percentage and Nottingham score among all and early-stage AA
QNBC patients. Low IHC HER3-HER4 score was also associated with high Ki-67 index among
early-stage AA QNBC patients administered chemotherapy. Thus, our observation of low IHC
HER3-HER4 score associated with high Ki-67 proliferation may be reflective of low HER4
signaling and consequently reduced modulation of cell proliferation among AA QNBC patients.
Furthermore, low HER3-HER4 score was associated with high FOXM1, RARα, and BAP1
expression among all and early-stage AA QNBC patients. FOXM1 is a transcription factor that
regulates cell cycle progression, particularly mitotic division, chromosome segregation and
genomic stability(57, 58). It has been found to be overexpressed in approximately 85% of
TNBCs and its upregulation has been suggested to play a critical role in carcinogenesis through
stimulating cell proliferation and tumor metastasis(59). Thus, our observation of low HER3HER4 score associated with high FOXM1 expression may be indicative of increased
deregulation of cell cycle progression, aberrant mitotic division, missegregation of
chromosomes, and genomic instability and subsequently tumorigenesis and progression among
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AA QNBC patients. Hence, FOXM1 may serve as a viable, alternative therapeutic target for AA
QNBC patients lacking HER3-HER4 expression. RARα is known to stimulate growth inhibition
of ER-positive but not, ER-negative BC cell lines as they tend to express RARα at lower
levels(60). The role of RARα in TNBC remains elusive however, our finding of low HER3HER4 score associated with increased RARα expression suggest that AA QNBC patients with
low HER3-HER4 signaling may also be sensitive to retinoid therapy. BAP1 acts a tumor
suppressor and plays a key role in the DNA damage response pathway. Hence, upregulation of
BAP1 among low HER3-HER4-expressing AA QNBC patients may be indicative of increased
DNA damage among this patient population suggesting they may be susceptible to DNA repair
targeted therapy.
We also discovered that low HER3-HER4 score significantly predicted poorer 10-year
OS among early-stage AA QNBC patients in Kaplan-Meier analysis. Furthermore, low HER3HER4 score predicted shorter 10-year OS among early-stage AA QNBC patients in multivariate
analyses. Thus, these findings suggest that a lack of HER3-HER4 expression may be associated
with more aggressive disease among early-stage AA TNBC patients lacking AR expression and
that HER3-HER4 score may serve as an alternative risk-prognostic biomarker for this patient
population.
Our gene expression analyses revealed that HER4 gene expression was significantly
more downregulated among AR-low compared to AR-high AA TNBC samples in TCGA
dataset, which corroborates our protein expression results. Furthermore, we observed
significantly more downregulation of signaling pathways and gene ontologies reflecting
downstream signaling of HER4 as well as genes encoding key downstream signaling molecules
in the HER4 pathway among AR-low compared to AR-high AA TNBC samples. We also
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observed significantly more downregulation of gene ontologies and genes encoding key
downstream proteins in processes modulated by HER4 signaling such as apoptosis, cell
proliferation, and cell differentiation among AR-low compared to AR-high AA TNBC samples.
This finding suggest that more downregulation of HER4 signaling may reflect less cell death as
well as more aberrant cell proliferation and differentiation among AR-low compared to AR-high
AA TNBC patients with low HER4 signaling. In addition, we observed significantly more
downregulation of biological pathways and gene ontologies reflecting pro-inflammatory activity
and cell-cell contact among AR-low compared to AR-high AA TNBC samples suggesting
suppressed antitumoral immune response and increased metastatic potential among AR-low AA
patients with low HER4 signaling. However, we discovered significantly more upregulation of
biological pathways and gene ontologies indicating increased cell cycle progression, cell
proliferation, and DNA damage response among AR-low compared to AR-high AA TNBC
patients. This finding also reflects our protein expression correlation results indicating that lack
of combined HER3-HER4 score was associated with high FOXM1 and BAP1 expression further
emphasizing that therapies targeting cell cycle progression and DNA damage response may be
selectively beneficial for AA QNBC patients with a low HER3-HER4 score.
Our study uncovers a valuable risk-prognostic biomarker for AA QNBC patients in earlystage disease. Our findings suggest that HER3-HER4 score should be assessed among AA
TNBC patients lacking AR expression in the clinic to guide clinical decision-making and
segment patients into optimal treatment paths. Furthermore, our results suggest alternative
therapeutic strategies for AA QNBC patients with low HER4 signaling such as FOXM1
inhibition, cytotoxic chemotherapy, and other cell-cycle progression-targeting therapies as well
as DNA damage response inhibition such as platinum-based agents. Thus, stratifying AA QNBC
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patients into high and low HER3-HER4 score may notably improve risk-prognostication and
prognosis among this patient population and subsequently help reduce the racial disparate burden
in TNBC. However, robust validation of our findings in additional cohorts is necessary in order
to successfully achieve these aims.
10.5 Methods
10.5.1 Study Cohort
We analyzed a cohort of 121 TNBC patients observed at EH in Atlanta, GA from 2002
(initial day of diagnosis) to 2016 (last day of contact). We isolated 77 AA TNBC patients from
this cohort and stratified them into AR-negative and AR-positive subgroups based on IHC AR
nuclear percentage. Negativity was determined as <1% expression and positivity was determined
as ≥1% expression. We obtained approval and permission from the institutional review board at
EH to gain access to patient information and samples used in this study. Patient demographic
characteristics, clinico-pathological variables, and breast cancer biomarker status were recorded
for each patient. This article referred to the 7th edition of the American Joint Committee on
Cancer)/Union for International Cancer Control TNM Classification and Stage groupings for
breast cancer (52). Demographic characteristics include self-reported race and age at the time of
diagnosis. Adjuvant chemotherapy treatment was recorded. No patients in this study underwent
neoadjuvant chemotherapy. Regarding adjuvant chemotherapy, 54 patients underwent treatment
and 9 patients did not.
10.5.2 Immunohistochemistry and scoring
Biomarker expression was evaluated through standard IHC staining and scored as Hscore (percentage x intensity), NH-score (nuclear percentage x intensity), and Nper (nuclear
percentage). Intensity of staining were scored as 0=none, 1=low, 2=moderate, and 3=high.
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Negativity was determined as <1% expression and positivity was determined as ≥1% expression
for all biomarkers. Antibody details and concentrations can be found in Table 8. The maximum
score for any given H-score is 300 and for combined (summed) H-scores is 600. Combined
biomarker scores were determined by summing the scores for each biomarker to yield a single
score. EH patient samples were stained, scored, and reviewed at EH. Scoring was performed by
two independent pathologists blinded to clinical annotation and individual scores were averaged.
10.5.3 Follow Up
Initial diagnosis and follow-up of patients occurred between 2002 and 2016. Initial dates
of diagnoses, treatment start and completion dates, and last dates of contact were recorded for
each patient. Survival status (alive/dead) was also recorded for each patient in addition to
survival time. The date of last follow-up for the last patient seen is March 3, 2016.
10.5.4 Gene Expression Dataset
We queried the publically available The Cancer Genome Atlas (TCGA) breast dataset
from the TCGA portal for all TNBC patients(53). Publically available ER/PR/HER2/AR IHC
data was used to determine TNBC and QNBC status. According to the available race data, we
selected AA patients out of the TNBC samples. We performed a log-rank test to identify the
optimal cut-off to stratify the AA TNBC patients into high- and low- AR expressing subgroups.
We performed differential gene expression analysis between AR-low and AR-high expressing
AA TNBC samples using the DESeq2 software tool(54). Differentially expressed genes with a p
value of <0.05 and log2fold change of above +1 and below -1 were selected in this study.
Differential expression analyses of Kyoto Encyclopedia of Genes and Genomes pathways and
gene ontologies between the patient groups were predicted by GAGE and Pathview packages,
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respectively(55, 56). A heat map was generated to depict the differentially expressed genes
among the patient groups of interest.
10.5.5 Statistical Analysis
The significance level for all analyses was p<0.05 with 95% confidence intervals (CIs).
SAS 9.4 program was used to generate test statistics and 2-tailed univariate p-values were
reported. Chi-square tests were performed to analyze differences in demographic characteristics,
breast clinico-pathological variables and biomarkers, as well as treatment information between
AR-negative and AR-positive AA TNBC patients. Wilcoxon rank-sum tests were performed to
determine differences in the means in expression of the EGFR family members between ARnegative and AR-positive AA TNBC patients. Spearman’s rank correlation coefficients (ρ) were
computed to determine associations of the EGFR family members with demographic and clinicopathological variables as well as biomarker expression among AR-negative AA TNBC patients.
Unadjusted and adjusted multivariate Cox proportional hazard models were computed to assess
the impact of combined IHC HER3-HER4 score on 10-year OS before and after controlling for
age, Nottingham grade, and stage. The Kaplan-Meier analysis was conducted using SAS 9.4
program to estimate survival function for AR-negative AA TNBC patients over a 10- year period
based on high and low combined IHC HER3-HER4 score. A log-rank test was used to stratify
combined IHC HER3-HER4 expression with better or worse survival in Kaplan-Meier analyses.
A log-rank test was also performed to identify the appropriate cut-off for low and high
expression of AR among AA TNBC patients in the TCGA dataset. The Wald test was used to
test for significance among differentially expressed genes between the patient groups using the
DESeq2 software tool.
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10.6 Tables and Figures
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Table 10.1 Clinico-pathological characteristics of AA QNBC and TNBC patients observed at
EH.
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Table 10.2 Correlation of combined HER3-HER4 score with clinico-pathological variables
among AA QNBC patients.
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Table 10.3 Correlation of combined HER3-HER4 score with clinico-pathological biomarkers
among AA QNBC patients.
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Table 10.4 Prediction of combined HER3-HER4 score for 5-year OS among AA QNBC
patients.
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Table 10.5 KEGG pathways upregulated and downregulated among AR-low compared to ARhigh expressing AA TNBC patients in TCGA breast dataset.
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Table 10.6 Gene ontologies upregulated among AR-low compared to AR-high AA TNBC
patients.
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Table 10.7 HER4 signaling-related differentially-expressed genes between AR-low and ARhigh expression among AA TNBC patients in TCGA breast dataset.
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Table 10.8 Antibodies and dilutions used for immunohistochemical biomarker staining at EH.
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Figure 10.1 IHC expression of the EGFR family members among AR-negative and ARpositive AA TNBC patients.
IHC expression of EGFR (membranous), HER3 (membranous), and HER4 (cytoplasmic) as well
as combinations of the receptors combined were compared between AR-negative and AR-positive
AA TNBC patients. H-score represent expression percentage x intensity. *p<0.05.

271

Figure 10.2 Combined IHC HER3-HER4 scores among AA QNBC and TNBC patients.
(A) Representative IHC staining of HER3 (membranous) and HER4 (cytoplasmic) images. (B)
IHC expression of combined HER3-HER4 scores were compared between all (overall),
chemotherapy treated (chemo), and non-chemotherapy treated (non-chemo) AR-negative and ARpositive AA TNBC patients. (C) Combined HER3-HER4 scores were also compared between
early-stage (I-II) (early overall) and early-stage chemotherapy-treated (early chemo) AR-negative
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and AR-positive AA TNBC patients. Sample size was too small to analyze early-stage nonchemotherapy treated patients. H-score represents expression percentage x intensity. *p<0.05.
Images taken at 200x magnification.

Figure 10.3 Combined IHC HER3-HER4 score predicts OS among early-stage AA QNBC
patients.
Combined IHC HER3-HER4 H-scores (percentage x intensity) were stratified into high (³6) and
low (<6) subgroups based on log-rank test. Kaplan-Meier curves were generated to estimate the
effect of high and low IHC HER3-HER4 score on survival over a 5- and 10- year period among
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AA QNBC patients. Prediction of high and low combined IHC HER3-HER4 score on 10-year OS
among (A) all, (B) early-stage, and (C) radiation treated early-stage AA QNBC patients. Prediction
of high and low combined IHC HER3-HER4 score on 5-year OS among radiation treated earlystage AA QNBC patients (D). p<0.05 was set as the level of significance.
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11 RETINOIC ACID RECEPTOR ALPHA AS A POSITIVE PROGNOSTIC
BIOMARKER IN TRIPLE NEGATIVE BREAST CANCER
11.1 Abstract
Triple negative breast cancers (TNBCs) lack conventional breast cancer targets, thus lack
risk-predictive biomarkers and targeted treatment options. RARa stimulates antiproliferative
activity in breast cancer by inhibiting cell growth, cell differentiation, and promoting apoptosis.
However, the role of RARα signaling in TNBC remains underexplored. We analyzed differences
in RARα gene expression between TNBC and non-TNBC patients in two independent publiclyavailable breast datasets and investigated the prognostic role of nuclear RARα
immunohistochemical (IHC) expression, which represents the transcriptionally active form of the
biomarker, in TNBC patients treated at Nottingham Hospital (NH) (n=166) and Emory
University Hospital (EH) (n=106). TNBCs expressed lower levels of RARα mRNA than nonTNBCs in the METABRIC (n=1,975) and TCGA (n=1,098) breast datasets (p<0.0001). High
nuclear RARα IHC expression was an independent predictor of good prognosis in multivariable
models in NH (HR=0.501, p<0.05 for BCSS and HR=0.394, p<0.01 for DMFS) and EH
(HR=0.223 for BCSS p<0.05) patients. Nuclear RARα IHC expression may provide valuable
risk-prognostic information and guide clinical decision making, specifically revealing a subset of
TNBC patients with good prognosis. Future studies are needed to evaluate whether this high
nuclear RARα group could benefit from RARα agonists or alternative therapeutic strategies and
be spared harsher chemotherapeutic regimens.
11.2 Introduction
Triple negative breast cancer (TNBC), a subtype of breast cancer (BC), remains a
formidable disease fraught with many challenges that elude successful clinical intervention. The
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disease accounts for approximately 20% of all reported BC cases and is defined by a lack of the
actionable targets, estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor (HER2) 1. Thus, this subgroup of BCs is excluded from receiving
traditional endocrine and HER2-targeted systemic therapies and lacks risk-predictive biomarkers.
Furthermore, TNBC is characterized by a more aggressive disease course typified by higher
nuclear grade, clinical stage, proliferation, and increased lymph node, cerebral, and visceral
metastases that all collude to result in poorer clinical outcomes compared with non-TNBCs 1-6.
Chemotherapy and radiation remain the standard of care for TNBC patients; however, TNBC
patients often relapse within the first 5 years after diagnosis, underscoring an unmet need for
alternative risk-predictive biomarkers and alternative therapeutic targets for this patient
population 3. Younger women and women of West African descent are disproportionately
diagnosed with TNBC and also exhibit more aggressive disease features, acquire more
aggressive TNBC subtypes, and experience poorer clinical outcomes compared to women of
European descent among TNBC patients 7-13,14-17.
Steroid or nuclear hormone receptors constitute a superfamily of transcription regulators
that play critical roles in embryonic development, cell growth, cell differentiation, and
homeostasis. These unique receptors dimerize in the nuclei to modulate transcription of target
genes upon ligand stimulation 18,19. They possess a C-terminal domain that binds to their ligand
as well as a highly-conserved N-terminal zinc-finger that facilitates specificity in target DNA
sequence or ligand-response element binding. The RAR and retinoic X receptor (RXR) families
represent subgroups of the steroid/nuclear receptor superfamily that also comprises receptors that
bind to steroid and thyroid hormones and harbor highly-conserved domains that mediate DNA
and ligand-binding activities20. RAR isoforms have been identified including RARα, RARβ, and
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RARγ as well as the RXR isoforms including RXRα, RXRβ, and RXRγ based on alternative
mRNA splicing. Retinoids are natural and synthetic vitamin A analogues that modulate cell
proliferation, differentiation, morphogenesis, metabolism, and apoptosis via RARs and RXRs21.
In the presence of retinoids, RAR heterodimerizes with RXR and the RAR/RXR dimer binds to
hormone response elements on DNA such as retinoic acid or retinoid X response elements
(RAREs and RXREs) to regulate transcription of target genes 22,23.
Retinoid signaling via RARs and RXRs have been shown to stimulate antiproliferative
activity, unlike ER, by inhibiting cell growth, cell differentiation, and promoting apoptosis in
mammary carcinoma cells24,25. Thus, loss of RARβ has been suggested to be an early event in
breast carcinogenesis 21. High levels of RARα have been observed in ER-positive BC cells, as
estrogens upregulate RARα, but not in ER-negative cells24,26. Retinoid signaling via RARα has
been demonstrated to mediate growth inhibition of ER-positive BC cell lines but not in ERnegative cell lines owing to low levels of RARα which are thus, considered to be retinoid
resistant 25. However, Fitzerald et. al showed that ER-negative BC cells with RARα expression
were sensitive to retinoid-stimulated growth inhibition suggesting that RARα expression
correlates with retinoid-induced growth inhibition irrespective of ER status27. However, the role
of RARα in TNBC remains elusive.
Given its seeming role in suppressing breast tumorigenesis, RARα may serve as a
positive prognostic biomarker in TNBC. While RARα levels are lower in TNBC than non-TNBC
cells, it is possible that a subset of TNBC patients have higher levels and a more favorable
prognosis, given how molecularly heterogeneous TNBCs are 28,29. Towards this end, we explored
the effect of nuclear RARα levels on survival outcomes in TNBC patients. Nuclear levels were
tested because they represent the transcriptionally active form of RARα 30. Ultimately, we found
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that high mRNA and protein nuclear RARα levels are associated with better survival among
TNBC patients in multivariate analyses. We also observed a racial disparity in nuclear RARα
levels among BC and TNBC patients. Furthermore, we identified differentially-expressed genes,
pathways, and gene ontologies between high and low nuclear RARα-expressing TNBC patients
which may be exploited therapeutically. Thus, a subset of TNBC patients with high intratumoral
RARα could potentially be spared harsher chemotherapy regimens and may benefit from RARα
agonism, whereas TNBC patients with low intratumoral RARα may require more aggressive
treatment.
11.3 Results
11.3.1 Nuclear RARα expression levels lower among TNBCs compared to non-TNBCs
Accumulating studies consistently suggest that RARα expression levels are lower among
hormone receptor (HR)-negative compared to HR-positive breast tumor phenotypes suggesting
that low levels of the protein could be conferring a more aggressive disease course. Hence, we
wanted to further explore differences in nuclear RARα expression levels between TNBC and
non-TNBC patients. We analyzed the METABRIC (discovery) and TCGA (validation) BC
datasets to compare normalized RARα expression levels between TNBC and non-TNBC
patients. As consistent with the literature, we observed significantly lower RARα expression
among TNBC compared to non-TNBC patients in both the discovery and validation cohorts
(Figure 1). In both the METABRIC (Fig 1A) and TCGA (Fig 1B) datasets, RARα expression
levels were approximately one third lower among TNBCs than non-TNBCs (p<0.0001 and
p<0.0001, respectively). Thus, our findings confirm literature evidence supporting reduced
RARα signaling among TNBCs compared to non-TNBCs in two independent breast cancer
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datasets and warrant further exploration of the role of RARα signaling in conferring aggressive
BC.
11.3.2 Nuclear RARα expression levels are lower among TNBC patients of African compared
to European descent
As previously mentioned, AA BC patients are significantly more likely to present with
TNBC compared to EA BC patients. Hence, we investigated whether racial disparities exist in
RARα signaling among BC and TNBC patients. Race information was unavailable for the
METABRIC dataset, so we compared RARα gene expression levels between AA and EA
patients only in TCGA dataset. We discovered significant differences in RARα expression
among AA compared to EA BC patients in the TCGA dataset (Figure 2). RARα gene expression
was significantly lower among AA (n=192) compared to EA (n=770) BC patients (p=0.003) (Fig
2A). Mean RARα gene expression was also lower in AAs (n=41) compared to EAs (n=87)
among TNBC patients but did not reach statistical significance (p=0.620) (Fig 2B).
We also compared nuclear RARα protein expression levels between racially distinct
TNBC patients in clinical datasets. We screened three ethnically-distinct patient populations
[European (n=166), EA (n=29), and AA (n=71)] from the NH and EH datasets, respectively, for
differences in expression of nuclear RARα IHC expression by performing a one-way ANOVA
test. We discovered significant differences in the marker between all three patient populations
suggesting a significant role for this marker in the racially disparate burden in TNBC (Figure 3)
(p<0.0001). Specifically, nuclear RARα IHC expression decreased with decreasing self-reported
European ancestry from European to AA samples in which Europeans exhibited the highest and
AA’s exhibited the lowest expression levels overall and among chemotherapy- and radiationtreated patients. Hence, our findings indicate that racial disparities in RARα signaling exists and
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reduce RARα signaling among patients of African descent could be contributing to the racial
disparate burden in BC and TNBC.
11.3.3 High nuclear RARα expression levels predict better prognosis among TNBC patients
Based on our observed significant differences in RARα gene and nuclear protein
expression levels between TNBC and non-TNBC patients, we investigated the impact of nuclear
RARα IHC expression on survival among TNBC patients in two independent clinical datasets
from NH (n=166) and EH (n=106). We assessed the influence of categorical nuclear RARα (low
vs. high) on overall survival 31, breast cancer specific survival (BCSS), disease-free survival
(DFS) and distant metastasis-free survival (DMFS) using the Kaplan-Meier method and Cox
proportional hazards regression in TNBC patients from both cohorts. High nuclear RARα Hscore was associated with significantly better OS (p<0.001) (Fig 4A), 5-, 10-, and 15- year BCSS
(p=0.006, p<0.001, and p=0.005, respectively) (Fig 4B-D), DFS (p<0.001) (Fig 4E), and DMFS
(p<0.0001) (Fig 4F) among TNBC patients treated at NH according to Kaplan-Meier analyses
(Figure 4). Representative micrograph of nuclear IHC staining can be found in Fig 5A. High
nuclear RARα percentage was also associated with better OS (p=0.040) (Fig 5B) and moderately
longer BCSS (p=0.090) (Fig 5C) among TNBC patients treated at EH according to the KaplanMeier method (Figure 5). We observed similar results using Cox proportional hazard regression
models. Nuclear RARα H-score was found to be an independent predictor of better OS, BCSS,
DFS, and DMFS among TNBC patients observed at NH in multivariable analysis, where the
covariates adjusted for included age at diagnosis, tumor size, Nottingham grade, lymph node
stage, and Ki67-labeling index (HR=0.483, p=0.001 for OS, HR=0.464, p=0.040 for 5-year
BCSS, HR=0.501, p=0.043 for 10-year BCSS, HR=0.045, p=0.006 for DFS and HR=0.394,
p=0.003 for DMFS) (Table 1). Furthermore, nuclear RARα H-score predicted better OS, DFS,
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and DMFS irrespective of the same covariates in addition to receipt of adjuvant chemotherapy
(HR=0.484, p=0.010 for OS, HR=0.457, p=0.008 for DFS and HR=0.412, p=0.005 for DMFS).
Nuclear RARα percentage was also found to be an independent predictor of better OS among
TNBC patients observed at EH in multivariate analysis, where the covariates adjusted for
included age at diagnosis, Nottingham grade, and Ki67-labeling index (HR=0.223, p=0.0498)
(Table 2). We also assessed associations of nuclear RARα expression levels with
clinicopathological characteristics among both cohorts. Interestingly, we found that nuclear
RARα H-score negatively correlated with lymphovascular invasion (r=-0.192; p=0.015) among
TNBC patients observed at NH (Table 3).
11.4 Methods
Publicly-available datasets
We queried the publicly available Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) (n=1975; patient characteristics described in 39) and The Cancer
Genome Atlas (TCGA) (n=1098; patient characteristics described in 31) gene expression breast
datasets from Oncomine for BC and TNBC patients40. Publicly-available ER/PR/HER2 IHC data
was used to determine TNBC status. We selected 167 and 145 TNBC samples from the
METABRIC and TCGA datasets, respectively.
Clinical datasets
We procured TNBC patient databases from Nottingham University Hospital (NH) in
Nottingham, UK and Emory University Hospital (EH) in Atlanta, GA. NH and EH cohorts were
comprised of 166 and 106 TNBC patients, respectively. NH patients were observed from 20072013 and EH patients were observed from 2002-2016. We obtained consent and permission from
the institutional review boards at each institution to obtain access to patient information used in
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this study. Patient demographic characteristics, clinicopathological variables, and treatment
information were recorded for NH (Table 4) and EH (Table 5) patients. This article referred to
the 7th edition of the American Joint Committee on Cancer/Union for International Cancer
Control TNM Classification and Stage groupings for BC 41. However, only lymph node staging
was available in the NH cohort and referred to in this study. Demographic characteristics include
self-reported race and age at the time of diagnosis. No EH patients received neoadjuvant
chemotherapy.
Immunohistochemistry and scoring
Nuclear RARα expression in TNBC patients observed at NH and EH was determined
through standard immunohistochemistry (IHC) staining. We immunolabeled primary TNBC
specimens for RARα and calculated H-scores as the product of the nuclear staining intensity (03) and the percentage of cells with any nuclear staining. Antibody details and concentration can
be found in Table 6. NH patient samples were stained, scored, and reviewed at NH. EH patient
samples were stained, scored, and reviewed at EH. Scoring was performed by two independent
pathologists blinded to clinical annotation and individual scores were averaged.
Follow up
Initial diagnosis occurred between 2002 and 2016 for EH patients and between 20072013 for NH patients. Median duration of follow-up for each cohort was approximately 6 and 5
years for EH and NH patients, respectively. Initial dates of diagnoses, treatment start and
completion dates, and last dates of contact were recorded for each patient. Survival status
(alive/dead) was also recorded for each patient in addition to survival time. The date of last
follow-up for the last patient seen at EH is March 3, 2016 and NH is August 22, 2011.
Statistical analyses
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The significance level for all analyses was set to p<0.05 with 95% confidence intervals 42.
Chi-square tests were performed to analyze differences association of demographic
characteristics, breast clinicopathological variables and treatment information with UK, EA, and
AA TNBC patients in the NH and EH datasets, respectively. SAS 9.4 program was used to
generate test statistics and 2-tailed univariate p-values were reported. Mann-Whitney U tests was
performed to determine differences in nuclear RARa normalized gene expression levels between
TNBC and non-TNBC patients in the METABRIC and TCGA dataset and between AA and EA
BC patients in TCGA dataset. One-way ANOVA tests were performed to determine differences
in mean IHC expression of nuclear RARa between UK, EA, and AA TNBC patients in the NH
and EH datasets, respectively. Unadjusted and adjusted multivariate Cox proportional hazard
regression models were also computed to assess the impact of nuclear RARα on survival among
TNBC patients in the clinical datasets. The Kaplan-Meier analysis was also conducted using
SAS 9.4 program to estimate survival function for TNBC patients observed at NH and EH based
on high and low expression levels of nuclear RARα. A log-rank test was used to stratify RARα
into high and low subgroups to evaluate associations of a high and low expression of nuclear
RARα with better or worse survival among TNBC patients. In the NH dataset, the optimal, mostsignificant cut point based on breast cancer specific survival (BCSS) was found using X-tile 43.
The proportional hazards assumption was found to be satisfied because plots of partial residuals
against rank time had nearly zero slope or y-intercept. Multivariable Cox models were fit using
backward stepwise elimination of covariates with a p-value >0.10.
11.5 Tables and Figures
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Table 11.1 Prediction of nuclear RARα Hscore on clinical outcomes among NH TNBC
patients.

Table 11.2 Prediction of nuclear RARα percentage on OS among EH TNBC patients.

Table 11.3 Correlation of nuclear RARα with clinico-pathological variables among NH
patients.
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Table 11.4 Clinico-pathological and treatment characteristics among NH TNBC patients.
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Table 11.5 Clinico-pathological and treatment characteristics among EH TNBC patients.
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Table 11.6 Antibodies and dilutions used for RARα immunohistochemistry biomarker
staining.
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Figure 11.1 Normalized gene expression levels of RARα differ between TNBCs and nonTNBCs.
Wilcoxon rank sum tests were performed to determine differences in normalized nuclear RARα
gene expression levels between TNBC and non-TNBC patients in the (A) METABRIC and (B)
TCGA BC datasets, represented in a box and whisker plot. Small circles represent outliers.

Figure 11.2 Normalized gene expression levels of RARα differ between AA vs. EA BC
patients.
Wilcoxon rank sum tests were performed to determine differences in normalized RARα gene
expression levels between AA and EA (A) BC and (B) TNBC patient in TCGA BC dataset,
represented in a box and whisker plot.
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Figure 11.3 Nuclear RARα IHC expression differs between biogeographically-distinct TNBC
patients.
Box and whisker plot comparing nuclear RARα IHC expression among between AA, EA, and
European patients treated at EH and NH, respectively. One-way Anova test was performed to
determine significant differences between the racial groups. p<0.05 was the level of significance.
Small circles represent outliers.

293

Figure 11.4 Nuclear RARα expression is associated with better prognosis among NH TNBC
patients.
Kaplan-Meier survival curves were generated to assess the impact of nuclear RARα Hscore on
clinical outcomes among NH TNBC patients (n=166). Log-rank tests were performed to identify
the optimal cutpoints to stratify patients into high and low nuclear RARα Hscore subgroups for
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each clinical outcome. Impact of nuclear RARα Hscore on (A) overall survival (optimal
cutpoint=180), 5-year breast cancer specific survival (BCSS) (optimal cutpoint=180), 10-year
BCSS (optimal cutpoint=180), (D) 15-year BCSS (optimal cutpoint=200), (E) disease-free
survival (optimal cutpoint=180), and distant metastasis-free survival (optimal cutpoint=180).

Figure 11.5 Nuclear RARα expression is associated with better prognosis among EH TNBC
patients.
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Kaplan-Meier survival curves were generated to assess the impact of nuclear RARα percentage on
clinical outcomes among EH TNBC patients (n=106). Log-rank tests were performed to identify
the optimal cutpoints to stratify patients into high and low nuclear RARα percentage subgroups
for each clinical outcome. Representative micrographs of nuclear RARα IHC staining (A). Impact
of nuclear RARα Hscore on (B) overall survival (optimal cutpoint=60) and (C) breast cancer
specific survival (optimal cutpoint=80).
11.6 References
1
2
3
4
5
6
7

8
9
10

11
12
13

Boyle, P. Triple-negative breast cancer: epidemiological considerations and
recommendations. Ann Oncol 23 Suppl 6, vi7-12, doi:10.1093/annonc/mds187 (2012).
Anders, C. & Carey, L. A. Understanding and treating triple-negative breast cancer.
Oncology (Williston Park) 22, 1233-1239; discussion 1239-1240, 1243 (2008).
Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence.
Clin Cancer Res 13, 4429-4434, doi:10.1158/1078-0432.CCR-06-3045 (2007).
Li, H., Han, X., Liu, Y., Liu, G. & Dong, G. Ki67 as a predictor of poor prognosis in
patients with triple-negative breast cancer. Oncol Lett 9, 149-152,
doi:10.3892/ol.2014.2618 (2015).
Trivers, K. F. et al. The epidemiology of triple-negative breast cancer, including race.
Cancer Causes Control 20, 1071-1082, doi:10.1007/s10552-009-9331-1 (2009).
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative
breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin
Oncol 13, 674-690, doi:10.1038/nrclinonc.2016.66 (2016).
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis
of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 109, 1721-1728,
doi:10.1002/cncr.22618 (2007).
Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast
Cancer Study. JAMA 295, 2492-2502, doi:10.1001/jama.295.21.2492 (2006).
Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O'Regan, R. & Seewaldt, V. L. Triplenegative breast cancer in African-American women: disparities versus biology. Nat Rev
Cancer 15, 248-254, doi:10.1038/nrc3896 (2015).
Keenan, T. et al. Comparison of the Genomic Landscape Between Primary Breast Cancer
in African American Versus White Women and the Association of Racial Differences
With Tumor Recurrence. J Clin Oncol 33, 3621-3627, doi:10.1200/JCO.2015.62.2126
(2015).
Lund, M. J. et al. Race and triple negative threats to breast cancer survival: a populationbased study in Atlanta, GA. Breast Cancer Res Treat 113, 357-370, doi:10.1007/s10549008-9926-3 (2009).
Sullivan, H. C. et al. Triple-negative breast carcinoma in African American and
Caucasian women: clinicopathology, immunomarkers, and outcome. Appl
Immunohistochem Mol Morphol 22, 17-23, doi:10.1097/PAI.0b013e318281148e (2014).
Gasparini, P. et al. Androgen receptor status is a prognostic marker in non-basal triple
negative breast cancers and determines novel therapeutic options. PLoS One 9, e88525,
doi:10.1371/journal.pone.0088525 (2014).

296

14
15
16
17
18
19
20
21
22
23
24
25
26
27

28
29

Adjei, E. K., Owusu-Afriyie, O., Awuah, B. & Stalsberg, H. Hormone receptors and Her2
expression in breast cancer in sub-Saharan Africa. A comparative study of biopsies from
Ghana and Norway. Breast J 20, 308-311, doi:10.1111/tbj.12261 (2014).
Luyeye Mvila, G. et al. Prognostic features of breast cancer differ between women in the
Democratic Republic of Congo and Belgium. Breast 24, 642-648,
doi:10.1016/j.breast.2015.07.031 (2015).
Bhikoo, R., Srinivasa, S., Yu, T. C., Moss, D. & Hill, A. G. Systematic review of breast
cancer biology in developing countries (part 2): asian subcontinent and South East Asia.
Cancers (Basel) 3, 2382-2401, doi:10.3390/cancers3022382 (2011).
Agboola, A. J. et al. Molecular characteristics and prognostic features of breast cancer in
Nigerian compared with UK women. Breast Cancer Res Treat 135, 555-569,
doi:10.1007/s10549-012-2173-7 (2012).
Nishikawa, J., Kitaura, M., Imagawa, M. & Nishihara, T. Vitamin D receptor contains
multiple dimerization interfaces that are functionally different. Nucleic Acids Res 23,
606-611 (1995).
De Vos, P., Schmitt, J., Verhoeven, G. & Stunnenberg, H. G. Human androgen receptor
expressed in HeLa cells activates transcription in vitro. Nucleic Acids Res 22, 1161-1166
(1994).
Lehmann, J. M., Hoffmann, B. & Pfahl, M. Genomic organization of the retinoic acid
receptor gamma gene. Nucleic Acids Res 19, 573-578 (1991).
Schneider, S. M., Offterdinger, M., Huber, H. & Grunt, T. W. Activation of retinoic acid
receptor alpha is sufficient for full induction of retinoid responses in SK-BR-3 and T47D
human breast cancer cells. Cancer Res 60, 5479-5487 (2000).
Germain, P. et al. International Union of Pharmacology. LXIII. Retinoid X receptors.
Pharmacol Rev 58, 760-772, doi:10.1124/pr.58.4.7 (2006).
Allenby, G. et al. Retinoic acid receptors and retinoid X receptors: interactions with
endogenous retinoic acids. Proc Natl Acad Sci U S A 90, 30-34 (1993).
Roman, S. D., Clarke, C. L., Hall, R. E., Alexander, I. E. & Sutherland, R. L. Expression
and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52,
2236-2242 (1992).
van der Burg, B. et al. Retinoic acid resistance of estradiol-independent breast cancer
cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol 91,
149-157 (1993).
Han, Q. X. et al. Elevated expression of retinoic acid receptor-alpha (RAR alpha) in
estrogen-receptor-positive breast carcinomas as detected by immunohistochemistry.
Diagn Mol Pathol 6, 42-48 (1997).
Fitzgerald, P., Teng, M., Chandraratna, R. A., Heyman, R. A. & Allegretto, E. A.
Retinoic acid receptor alpha expression correlates with retinoid-induced growth
inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res
57, 2642-2650 (1997).
Lehmann, B. D. et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes:
Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE 11, e0157368,
doi:10.1371/journal.pone.0157368 (2016).
Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and
targets of triple-negative breast cancer. Clin Cancer Res 21, 1688-1698,
doi:10.1158/1078-0432.ccr-14-0432 (2015).

297

30
31
32
33
34
35
36
37
38
39

40
41
42

43
44
45

Ablain, J. & de Thé, H. Retinoic acid signaling in cancer: The parable of acute
promyelocytic leukemia. International Journal of Cancer 135, 2262-2272,
doi:10.1002/ijc.29081 (2014).
Mao, J. H., Diest, P. J. V., Perez-Losada, J. & Snijders, A. M. Revisiting the impact of
age and molecular subtype on overall survival after radiotherapy in breast cancer patients.
Sci Rep 7, 12587, doi:10.1038/s41598-017-12949-5 (2017).
Bosch, A. et al. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in
RARα/RARγ expression during MMTV-Myc tumorigenesis. Breast Cancer Research :
BCR 14, R121-R121, doi:10.1186/bcr3247 (2012).
Centritto, F. et al. Cellular and molecular determinants of all-trans retinoic acid
sensitivity in breast cancer: Luminal phenotype and RARα expression. EMBO Molecular
Medicine 7, 950-972, doi:10.15252/emmm.201404670 (2015).
Conway, K. et al. DNA methylation profiling in the Carolina Breast Cancer Study
defines cancer subclasses differing in clinicopathologic characteristics and survival.
Breast cancer research : BCR 16, 450, doi:10.1186/s13058-014-0450-6 (2014).
Bryc, K., Durand, E. Y., Macpherson, J. M., Reich, D. & Mountain, J. L. The genetic
ancestry of African Americans, Latinos, and European Americans across the United
States. Am J Hum Genet 96, 37-53, doi:10.1016/j.ajhg.2014.11.010 (2015).
Stefflova, K. et al. Dissecting the within-Africa ancestry of populations of African
descent in the Americas. PLoS One 6, e14495, doi:10.1371/journal.pone.0014495 (2011).
Zakharia, F. et al. Characterizing the admixed African ancestry of African Americans.
Genome Biol 10, R141, doi:10.1186/gb-2009-10-12-r141 (2009).
Sheikh, M. S. et al. Retinoid-resistant estrogen receptor-negative human breast carcinoma
cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition
by retinoids. J Biol Chem 269, 21440-21447 (1994).
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours
reveals novel subgroups. Nature 486, 346-352,
doi:http://www.nature.com/nature/journal/v486/n7403/abs/nature10983.html supplementary-information (2012).
Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours.
Nature 490, 61-70, doi:10.1038/nature11412 (2012).
Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: the 7th edition
of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17, 14711474, doi:10.1245/s10434-010-0985-4 (2010).
Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase
III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the
addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J
Clin Oncol 31, 860-867, doi:10.1200/JCO.2011.41.0902 (2013).
Camp, R. L., Dolled-Filhart, M. & Rimm, D. L. X-Tile. A New Bio-Informatics Tool for
Biomarker Assessment and Outcome-Based Cut-Point Optimization 10, 7252-7259,
doi:10.1158/1078-0432.ccr-04-0713 (2004).
Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated datamining platform. Neoplasia 6, 1-6 (2004).
Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours
reveals novel subgroups. Nature 486, 346-352, doi:10.1038/nature10983 (2012).

298

12 DISCUSSION
Women of African descent continue to disproportionately suffer from BC compared to
women of other ethnic backgrounds worldwide. This global racially disparate burden in BC can
be largely attributed to distinctions in inherent tumor biology between patients of African
ancestry and other ethnicities. African and AA women are more likely to acquire aggressive
breast tumor phenotypes such as TNBC and QNBC, which lack expression of
pharmacologically-targetable biomarkers, leaving this patient population with no approved
targeted therapeutic options. My work seeks to address inherent tumor biological differences
between breast tumors of African and European descent to ascertain more aggressive tumor
biology among African patients. This work may also proffer alternative risk-predictive
biomarkers and therapeutic targets for this patient population to improve their clinical disease
course. My work proposes a three-pronged strategy to addressing inherent differences in breast
tumor biology between ethnically-distinct patient populations.
ITH has been widely reported to be the culprit of the acquisition of aggressive
phenotypes and drug resistance and has been shown to be more prevalent among BC and TNBC
patients of African descent. However, quantitating and therapeutically targeting ITH remains a
challenge in the clinic. My first approach involves investigating racial disparities in key drivers
of ITH, mitotic propensity and CA, among BC patients. Mitotic propensity captures the
frequency of actively dividing cells among the proliferating cell population. Increased mitotic
turnover can lead to increased erroneous mitosis and thus, the generation of diverse cellular
phenotypes or ITH. Our laboratory recently proposed a novel metric termed, M:P ratio, that can
potentially allow clinicians to quantitate mitotic propensity in a clinical setting. Hence, we

299

proposed analyzing differences in M:P ratio between breast tumors of African and European
descent and the role of M:P ratio in a more aggressive disease course among AA BC patients.
We discovered this metric to be higher among early-stage AA compared to EA BC patients and
that among several confounding variables (i.e. race, grade, stage, receptor status), race was the
only factor significantly associated with M:P ratio. CA is a hallmark of cancer cells and recently
reported to be associated with more aggressive BC such as high grade, stage, Ki67, and a TNBC
phenotype. CA has been suggested to be a key driver of ITH through inducing aberrant
multipolar mitosis and subsequently increased aneuploidy. Measuring centrosomal aberrations is
feasible in the clinic through non-invasive methods such as fine-needle aspirate cytology and
IHC. Furthermore, amplified centrosomes can be targeted therapeutically through cancer cellselective agents such as putative centrosome declustering drugs (i.e. griseofulvin and noscapine),
commercially available HSET inhibitors (i.e. CW069 and AZ82), and poly-ADP ribose
polymerase inhibitors (i.e. GF-15). Hence, we also compared centrosomal profiles between
breast tumors of African and European descent and investigated the role of CA in a more
aggressive disease course among AA patients. Our findings collectively suggest that women of
African descent may exhibit enhanced mitotic propensity and greater centrosomal aberrations
compared to women of European descent, which may underlie the acquisition of more aggressive
phenotypes among AA BC patients. Our work also demonstrated that QNBCs, more prevalent
among women of African descent, may exhibit greater centrosomal aberrations than TNBCs and
underlie a more aggressive disease course in this group of TNBCs. This work suggests that BC
patients of African descent may be selectively susceptible to CA-targeting agents and both CA
and M:P ratio may be able to improve risk-stratification of this patient population in the clinic for
optimal treatment paths.
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The tumor immune microenvironment has been implicated in disease progression and
drug resistance. Emerging evidence suggest that disparities in the presence of inflammatory
mediators exists among breast tumors of African and European descent and may be implicated in
the stark racial disparity in survival. Cancer immunotherapy has emerged as one of the leading
therapeutic strategies for cancer. TILs (i.e. T, B, and NK cells) are key mediators in the
antitumoral inflammatory response and have been harnessed for therapeutic purposes. The
presence of TILs have been associated with better clinical outcomes and pCR post neoadjuvant
chemotherapy but more aggressive disease, such as TNBC. Hence, we investigated differences in
the presence of lymphocytic infiltration among AA and EA TNBC patients. Our findings suggest
patients of African descent may exhibit a greater presence of TILs compared to patients of
European descent and that high TIL levels were associated with longer OS and DFS among AA
patients irrespective of confounding variables. This racial disparity and survival trend persisted
among QNBC patients. TIL levels were also discovered to be higher among AR-negative
compared AR-positive TNBCs and a greater presence of TILs were associated with more
favorable clinical outcomes among QNBCs patients. Thus, my work has uncovered a previously
unrecognized racial disparity in the breast tumor immune microenvironment that may be
exploited therapeutically to help reduce the racially disparate burden in breast cancer. Adoptive
T Cell therapy has emerged as a promising immunotherapeutic strategy to augment TIL levels to
improve patient outcomes. Thus, this work suggest patients of African descent with low TIL
levels may be selectively susceptible to TIL immunotherapy. Furthermore, TIL levels, which can
be easily assessed in the clinic via H&E staining and quantitated according to the International
TILs Working Group 2014 recommendations, may help risk-stratify TNBC patients of African
ancestry for ideal treatment paths.
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As previously mentioned, the greater incidence of triple and quadruple negative receptor
statuses among breast cancer patients of African descent has left this patient population with no
approved targeted therapies, underlying their more aggressive disease course and poorer
prognosis. This lack has increased my interest in investigating alternative growth receptors that
can be therapeutically targeted and potentially adapted for enhanced risk-prognostication among
this patient population. As TNBCs and QNBCs are characterized by a lack of HER2 expression,
I wanted to investigate racial disparities in the expression of the other three members in the HER
family including, EGFR, HER3, and HER4 and their potential as alternative risk-prognostic and
therapeutic targets among TNBC patients. Interestingly, in addition to HER2, the other three
HER family members, also showed lower expression among TNBC patients of African
compared to TNBC patients of European descent. Particularly, HER4, which has been
demonstrated to elicit antiproliferative activity, and EGFR-HER4 expression directly decreased
with increasing presumed African ancestry with Nigerian TNBC patients exhibiting the lowest
expression. EGFR and HER4 mRNA expression was also found to be expressed lower among
TNBC patients of African compared to European descent. Furthermore, lack of HER4 and
EGFR-HER4 expression was associated with a poor prognosis among TNBC patients of both
African and European ancestry suggesting that lack of HER4 signaling among Africans may be
underlying their more aggressive disease course compared to Europeans. Thus, in addition to ER,
PR, and HER2, lack of HER4 among TNBC patients may predict a poor prognosis suggesting it
may be useful to also assess HER4 expression among TNBC patients, particularly of African
descent, to guide clinical decision-making. Moreover, we discovered through gene expression
analysis, that PPAR signaling was more upregulated among TNBC patients low in EGFR-HER4
mRNA expression suggesting the PPAR pathway could be exploited for alternative therapeutic
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purposes among TNBC patients lacking HER4 signaling. We also investigated the role of an
additional receptor in the nuclear retinoid family, RARa, as another potential alternative
therapeutic target or prognostic biomarker among TNBC patients of African descent. As opposed
to most of the HER family members, RARa signaling has been reported to suppress tumor
growth and proliferation. Hence, we also observed significantly lower IHC expression of RARa
among TNBC patients of African compared to European descent suggesting lack of tumor
growth suppression via RARa signaling may also be contributing to disproportionately higher
mortality rates observed among African TNBCs. Furthermore, lack of nuclear RARa IHC
expression was able to predict poor prognosis among TNBC patients in two independent cohorts.
Thus, my findings also suggest that it may be beneficial to assess nuclear RARa expression
among TNBC patients, particularly of African descent, in the clinic to improve riskprognostication.
BC in Africans continues to be characterized by what it lacks making it challenging for
clinicians to manage this patient population. My work proposes a three-pronged approach in
identifying novel actionable biomarkers associated with African ancestry that can improve riskprognostication and treatment for this population. In addition to the lack of ER, PR, HER2, and
AR expression being disproportionately higher among BC patients of West African compared to
European descent, we discovered an additional biomarker, HER4, to previously unrecognized to
be expressed lower among Nigerian and AA TNBCs compared to European and EA TNBCs and
its lack of IHC expression associated with a poorer prognosis. Hence, we discovered another
novel biomarker disproportionately lacking in expression among TNBC patients of African
ancestry. However, owing to its antiproliferative activity as opposed to the other biomarkers,
HER4 may be exploited therapeutically among patients of African descent lacking HER4
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expression to improve their clinical outcomes. Future studies delineating mechanisms and
pathways upregulated among low HER4-expressing patients may also be exploited
therapeutically to improve outcomes in this TNBC patient population. Our multi-pronged
approach also uncovered a previously unrecognized racial disparity in levels of lymphocytic
infiltration between ethnically-distinct TNBC patients and revealed that TILs may also improve
risk-prognostication for TNBC of African descent in the clinic. Moreover, this work has
suggested a novel, cancer immunotherapeutic approach to treating TNBC in AA patients, such as
adoptive T cell therapy, which is currently being tested in clinical trials for BC. With ITH being
a major interference in the clinic in regards to treatment and being reported to be more prevalent
among BC patients of African compared to European descent, targeting ITH may be critical to
reducing disproportionate mortality rates among this patient population. However, measuring
and counteracting ITH in the clinic presents with many obstacles and challenges. Lastly, my
work has also revealed potential racial disparities in key drivers of ITH, mitotic propensity and
CA, that can more easily assess levels of ITH and be therapeutically targeted in a clinical setting,
suggesting a more clinically-facile strategy to reducing ITH and subsequently an aggressive
disease course among BC patients of African descent. Collectively, my findings proffer
alternative, actionable biomarkers that may circumvent obstacles in bridging the gap in survival
rates between BC patients of 4African and European descent and allow patients of West African
descent, disproportionately lacking in conventional actionable BC biomarkers, with alternative
treatment options. However, validation of our findings in additional cohorts and further
investigation into the mechanisms causing disparities in these novel biomarkers will be necessary
to achieving these aims.
Future Directions
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This work primarily seeks to augment clinical management and risk-prognostication of
breast cancer patients of African descent, however it has broader clinical implications. Discovery
of previously unrecognized racial distinctions in breast tumor biology may lead to the
identification of novel therapeutic strategies for aggressive breast cancer patients irrespective of
ethnicity, which may attenuate global breast cancer mortality. Furthermore, this work inspires
investigation into alternative avenues of addressing the global racially disparate burden in breast
cancer through -omic approaches such as metabolomics, proteomics, and epigenomics. These
novel technologies may uncover unique distinctions in breast tumor biology between raciallydistinct patients and spur the development of novel therapeutic strategies for disadvantaged
populations. Additionally, this work sparks interest into the investigation of the role of nongenetic risk factors in the global racial divide in mortality, such as lifestyle and environment, as
well as the interplay between these risk factors and alterations in the genetic landscape of
racially-distinct populations. Ultimately, our findings as well as other breakthroughs in cancer
health disparity research provide an incentive to increase personalization of patient care
according to each individual’s unique tumor genetic, epigenetic, and metabolic profiles to more
efficaciously reduce the global breast cancer burden.

